0001593034-22-000064 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-36326
Entity Registrant Name	Endo International plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	68-0683755
Entity Address, Address Line One	First Floor, Minerva House, Simmonscourt Road
Entity Address, City or Town	Ballsbridge, Dublin 4,
Entity Address, Country	IE
Entity Address, Postal Zip Code	Not Applicable
City Area Code	353
Local Phone Number	1-268-2000
Title of each class	Ordinary shares, nominal value $0.0001 per share
Trading symbol(s)	ENDPQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Ordinary Shares Outstanding (in shares)		235,199,746
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001593034
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 1,053,892	$ 1,507,196
Restricted cash and cash equivalents	145,486	124,114
Accounts receivable, net	423,460	592,019
Inventories, net	288,914	283,552
Prepaid expenses and other current assets	141,120	200,484
Income taxes receivable	1,290	7,221
Total current assets	2,054,162	2,714,586
PROPERTY, PLANT AND EQUIPMENT, NET	431,445	396,712
OPERATING LEASE ASSETS	31,342	34,832
GOODWILL	1,352,011	3,197,011
OTHER INTANGIBLES, NET	1,992,932	2,362,823
DEFERRED INCOME TAXES	0	1,138
OTHER ASSETS	144,565	60,313
TOTAL ASSETS	6,006,457	8,767,415
CURRENT LIABILITIES:
Accounts payable and accrued expenses	538,730	836,898
Current portion of legal settlement accrual	0	580,994
Current portion of operating lease liabilities	724	10,992
Current portion of long-term debt	0	200,342
Income taxes payable	3,599	736
Total current liabilities	543,053	1,629,962
DEFERRED INCOME TAXES	11,634	21,628
LONG-TERM DEBT, LESS CURRENT PORTION, NET	0	8,048,980
OPERATING LEASE LIABILITIES, LESS CURRENT PORTION	4,363	33,727
OTHER LIABILITIES	27,198	277,104
LIABILITIES SUBJECT TO COMPROMISE	9,345,250	0
COMMITMENTS AND CONTINGENCIES (NOTE 15)
SHAREHOLDERS’ DEFICIT:
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both September 30, 2022 and December 31, 2021	39	45
Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 235,199,746 and 233,690,816 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	24	23
Additional paid-in capital	8,965,514	8,953,906
Accumulated deficit	(12,661,085)	(9,981,515)
Accumulated other comprehensive loss	(229,533)	(216,445)
Total shareholders’ deficit	(3,925,041)	(1,243,986)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	$ 6,006,457	$ 8,767,415

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Euro deferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Euro deferred shares, shares authorized (in shares)	4,000,000	4,000,000
Euro deferred shares, shares issued (in shares)	4,000,000	4,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	235,199,746	233,690,816
Common stock, shares outstanding (in shares)	235,199,746	233,690,816

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
TOTAL REVENUES, NET	$ 541,690	$ 772,028	$ 1,763,063	$ 2,203,777
COSTS AND EXPENSES:
Cost of revenues	261,232	286,068	798,233	909,841
Selling, general and administrative	192,221	246,864	600,212	611,657
Research and development	31,885	25,616	97,803	85,024
Acquired in-process research and development charges	800	0	68,700	5,000
Litigation-related and other contingencies, net	419,376	83,495	444,738	119,327
Asset impairment charges	150,200	42,155	1,951,216	50,393
Acquisition-related and integration items, net	(1,399)	(1,432)	(951)	(6,357)
Interest expense, net	74,753	142,958	349,486	418,852
Loss on extinguishment of debt	0	0	0	13,753
Reorganization items, net	124,212	0	124,212	0
Other income, net	(3,998)	(5,955)	(22,147)	(4,671)
(LOSS) INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAX	(707,592)	(47,741)	(2,648,439)	958
INCOME TAX EXPENSE	10,680	1,548	16,016	13,372
LOSS FROM CONTINUING OPERATIONS	(718,272)	(49,289)	(2,664,455)	(12,414)
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 4)	(3,897)	(27,918)	(15,115)	(38,769)
Net loss	$ (722,169)	$ (77,207)	$ (2,679,570)	$ (51,183)
NET LOSS PER SHARE—BASIC:
Continuing operations (in dollars per share)	$ (3.05)	$ (0.21)	$ (11.35)	$ (0.05)
Discontinued operations (in dollars per share)	(0.02)	(0.12)	(0.07)	(0.17)
Basic (in dollars per share)	(3.07)	(0.33)	(11.42)	(0.22)
NET LOSS PER SHARE—DILUTED:
Continuing operations (in dollars per share)	(3.05)	(0.21)	(11.35)	(0.05)
Discontinued operations (in dollars per share)	(0.02)	(0.12)	(0.07)	(0.17)
Diluted (in dollars per share)	$ (3.07)	$ (0.33)	$ (11.42)	$ (0.22)
WEIGHTED AVERAGE SHARES:
Basic (in shares)	235,160	233,578	234,719	232,487
Diluted (in shares)	235,160	233,578	234,719	232,487

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
NET LOSS	$ (722,169)	$ (1,885,427)	$ (71,974)	$ (77,207)	$ (15,500)	$ 41,524	$ (2,679,570)	$ (51,183)
OTHER COMPREHENSIVE (LOSS) INCOME:
Net unrealized (loss) gain on foreign currency	(10,649)			(3,293)			(13,088)	637
Total other comprehensive (loss) income	(10,649)	$ (4,334)	$ 1,895	(3,293)	$ 2,238	$ 1,692	(13,088)	637
COMPREHENSIVE LOSS	$ (732,818)			$ (80,500)			$ (2,692,658)	$ (50,546)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
OPERATING ACTIVITIES:
Net Income (Loss)	$ (2,679,570)	$ (51,183)
Adjustments to reconcile Net loss to Net cash provided by operating activities:
Depreciation and amortization	302,338	350,455
Share-based compensation	13,506	22,237
Amortization of debt issuance costs and discount	9,406	10,755
Deferred income taxes	(8,337)	(3,633)
Change in fair value of contingent consideration	(951)	(6,771)
Loss on extinguishment of debt	0	13,753
Acquired in-process research and development charges	68,700	5,000
Asset impairments	1,951,216	50,393
Debt valuation adjustments	89,197	0
(Gain) loss on sale of business and other assets	(11,760)	198
Other	2,083	0
Changes in assets and liabilities which provided (used) cash:
Accounts receivable	154,645	(23,601)
Inventories	(31,100)	29,729
Prepaid and other assets	72,111	5,508
Accounts payable, accrued expenses and other liabilities	219,668	4,486
Income taxes payable/receivable, net	8,459	53,588
Net cash provided by operating activities	159,611	460,914
INVESTING ACTIVITIES:
Capital expenditures, excluding capitalized interest	(77,865)	(61,496)
Capitalized interest payments	(3,140)	(2,721)
Proceeds from the U.S. Government Agreement	13,601	0
Acquisitions, including in-process research and development, net of cash and restricted cash acquired	(89,520)	(5,000)
Product acquisition costs and license fees	0	(2,486)
Proceeds from sale of business and other assets, net	22,378	1,357
Net cash used in investing activities	(134,546)	(70,346)
FINANCING ACTIVITIES:
Proceeds from issuance of notes, net	0	1,279,978
Proceeds from issuance of term loans, net	0	1,980,000
Repayments of notes	(180,342)	0
Repayments of term loans	(10,000)	(3,305,475)
Adequate protection payments	(168,643)	0
Repayments of other indebtedness	(4,501)	(4,044)
Payments for debt issuance and extinguishment costs	0	(8,574)
Payments for contingent consideration	(1,939)	(3,355)
Payments of tax withholding for restricted shares	(1,898)	(14,688)
Proceeds from exercise of options	0	622
Net cash used in financing activities	(367,323)	(75,536)
Effect of foreign exchange rate	(4,674)	238
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	(346,932)	315,270
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	1,631,310	1,385,000
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	$ 1,284,378	$ 1,700,270

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 1. BASIS OF PRESENTATION Basis of Presentation Endo International plc is an Ireland-domiciled specialty pharmaceutical company that conducts business through its operating subsidiaries. Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our” or “us” refer to Endo International plc and its subsidiaries. The accompanying unaudited Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries, which are unaudited, include all normal and recurring adjustments necessary for a fair statement of the Company’s financial position as of September 30, 2022 and the results of its operations and its cash flows for the periods presented. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The year-end Condensed Consolidated Balance Sheet data as of December 31, 2021 was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying Notes included in the Annual Report. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassification adjustments primarily relate to changes to the presentation of certain costs and expenses in our Condensed Consolidated Statements of Operations. Specifically, effective with the first quarter of 2022, the Company has added a new financial statement line item labeled Acquired in-process research and development. Any prior period amounts of acquired in-process research and development charges presented in this report have been reclassified to this line item from the existing financial statement line item labeled Research and development. Going Concern As further discussed herein, thousands of governmental and private plaintiffs have filed suit against us and/or certain of our subsidiaries alleging opioid-related claims, most of which we have not been able to settle. As a result of the possibility or occurrence of an unfavorable outcome with respect to these proceedings, other legal proceedings and certain other risks and uncertainties, we have been exploring a wide array of potential actions as part of our contingency planning and, as further described in our Second Quarter 2022 Form 10-Q, we previously concluded that the related conditions and events gave rise to substantial doubt about our ability to continue as a going concern. Subsequent to the filing of the Second Quarter 2022 Form 10-Q, on August 16, 2022 (the Petition Date), Endo International plc, together with certain of its direct and indirect subsidiaries (the Debtors), filed voluntary petitions for relief under the Bankruptcy Code, which constituted an event of default that accelerated our obligations under substantially all of our then-outstanding debt instruments. However, section 362 of the Bankruptcy Code stays the creditors from taking any action to enforce the related financial obligations and the creditors’ rights of enforcement in respect of the debt instruments are subject to the applicable provisions of the Bankruptcy Code. Refer to Note 2. Bankruptcy Proceedings and Note 14. Debt for additional information. As a result of these conditions and events, management continues to believe there is substantial doubt about our ability to continue as a going concern within one year after the date of issuance of these Condensed Consolidated Financial Statements. The accompanying Condensed Consolidated Financial Statements have been prepared under the going concern basis of accounting as required by U.S. GAAP and do not include any adjustments that might be necessary should we be unable to continue as a going concern.

BANKRUPTCY PROCEEDINGS

9 Months Ended

Sep. 30, 2022

Reorganizations [Abstract]

BANKRUPTCY PROCEEDINGS

NOTE 2. BANKRUPTCY PROCEEDINGS

Chapter 11 Filing

As noted above, on the Petition Date, the Debtors filed voluntary petitions for relief under the Bankruptcy Code. The Debtors have received approval from the U.S. Bankruptcy Court for the Southern District of New York (the Bankruptcy Court) to jointly administer their chapter 11 cases (the Chapter 11 Cases) for administrative purposes only pursuant to Rule 1015(b) of the Federal Rules of Bankruptcy Procedure under the caption In re Endo International plc, et al. Certain entities consolidated by Endo International plc and included in these Condensed Consolidated Financial Statements are not party to the Chapter 11 Cases. These entities are collectively referred to herein as the Non-Debtor Affiliates.

The Debtors will continue to operate their businesses and manage their properties as debtors-in-possession pursuant to sections 1107 and 1108 of the Bankruptcy Code. As debtors-in-possession, the Debtors are generally permitted to continue to operate as ongoing businesses and pay debts and honor obligations arising in the ordinary course of their businesses after the Petition Date. However, the Debtors generally may not pay third-party claims or creditors on account of obligations arising before the Petition Date or engage in transactions outside the ordinary course of business without approval of the Bankruptcy Court. Under the Bankruptcy Code, third-party actions to collect pre-petition indebtedness owed by the Debtors, as well as most litigation pending against the Debtors as of the Petition Date, are generally subject to an automatic stay. However, under the Bankruptcy Code, certain legal proceedings, such as those involving the assertion of a governmental entity’s police or regulatory powers, may not be subject to the automatic stay and may continue unless otherwise ordered by the Bankruptcy Court.

Among other requirements, chapter 11 proceedings must comply with the priority scheme established by the Bankruptcy Code, under which certain post-petition and secured or “priority” pre-petition liabilities generally need to be satisfied before general unsecured creditors and shareholders are entitled to receive any distribution.

Under the Bankruptcy Code, the Debtors may assume, modify, assign or reject certain executory contracts and unexpired leases, including, without limitation, leases of real property and equipment, subject to the approval of the Bankruptcy Court and certain other conditions. Generally, the rejection of an executory contract or unexpired lease is treated as a pre-petition breach of such executory contract or unexpired lease and, subject to certain exceptions, relieves the Debtors from performing their future obligations under such executory contract or unexpired lease but entitles the contract counterparty or lessor to a pre-petition general unsecured claim for damages caused by such deemed breach. Generally, the assumption of an executory contract or unexpired lease requires the Debtors to cure existing monetary defaults under such executory contract or unexpired lease and provide adequate assurance of future performance. Accordingly, any description of an executory contract or unexpired lease in this report, including, where applicable, the express termination rights thereunder or a quantification of obligations, must be read in conjunction with, and is qualified by, any overriding rejection rights the Debtors have under the Bankruptcy Code.

To ensure their ability to continue operating in the ordinary course of business, the Debtors have filed with the Bankruptcy Court a variety of motions seeking “first day” relief, including the authority to access cash collateral, continue using their cash management system, pay employee wages and benefits and pay vendors in the ordinary course of business. At a hearing held on August 18, 2022, the Bankruptcy Court generally approved the relief sought in these motions on an interim basis. Following subsequent hearings held on September 28, 2022, October 13, 2022 and October 19, 2022, the Bankruptcy Court entered orders approving substantially all of the relief sought on a final basis.

Events of Default

The August 16, 2022 bankruptcy filings by the Debtors constituted an event of default that accelerated our obligations under substantially all of our then-outstanding debt instruments. However, section 362 of the Bankruptcy Code stays the creditors from taking any action to enforce the related financial obligations and the creditors’ rights of enforcement in respect of the debt instruments are subject to the applicable provisions of the Bankruptcy Code. Refer to Note 14. Debt for additional information.

Restructuring Support Agreement

On August 16, 2022, we entered into a Restructuring Support Agreement (the RSA) with an ad hoc group (the Ad Hoc First Lien Group) of certain creditors holding in excess of 50% of the aggregate outstanding principal amount of Secured Debt (as defined in that certain collateral trust agreement, dated as of April 27, 2017, among Endo International plc, certain subsidiaries of Endo International plc, the other grantors from time to time party thereto, JPMorgan Chase Bank, N.A., as administrative agent under the Credit Agreement (as defined below), and Wells Fargo Bank, National Association, as indenture trustee, and Wilmington Trust, National Association, as collateral trustee (the Collateral Trust Agreement)), pursuant to which, among other things, one or more entities formed in a manner acceptable to the Ad Hoc First Lien Group (the Stalking Horse Bidder or the Purchaser) will serve as stalking horse bidder as we seek to sell all or substantially all of our assets in a sale pursuant to section 363 of the Bankruptcy Code (the Sale).

The Stalking Horse Bidder’s bid (the Stalking Horse Bid), which is subject to higher or otherwise better bids from other parties, includes an offer to purchase substantially all of our assets for an aggregate purchase price including: (i) a credit bid in full satisfaction of the Prepetition First Lien Indebtedness (as defined in the RSA); (ii) $5 million in cash on account of certain unencumbered assets; (iii) $122 million to wind-down our operations following the Sale closing date (the Wind-Down Amount); (iv) pre-closing professional fees; and (v) the assumption of certain liabilities. As part of the Stalking Horse Bid, the Stalking Horse Bidder will also make offers of employment to all of our active employees. Pursuant to the RSA, the definitive purchase and sale agreement with respect to the Stalking Horse Bid will include customary representations and warranties and customary covenants by the parties thereto.

The RSA contemplates a marketing process and auction that will be conducted under the supervision of the Bankruptcy Court, during which interested parties will have an opportunity to conduct due diligence and determine whether to submit a bid to acquire the Debtors’ assets. If the Stalking Horse Bid is selected as the highest or otherwise best offer following said marketing process and auction, the Ad Hoc First Lien Group will direct the Collateral Trustee (as defined in the Collateral Trust Agreement) to assign its rights to credit bid, on behalf of the Secured Parties (as defined in the Collateral Trust Agreement), to the Stalking Horse Bidder, so as to enable the Stalking Horse Bidder to credit bid for all or substantially all of our assets in exchange for the extinguishment of the obligations to the Secured Parties. The RSA further contemplates that the Purchaser will fund one or more trusts for parties with opioid-related claims against us, as further discussed in Note 15. Commitments and Contingencies.

Pursuant to the RSA, each of the parties agreed to, among other things, take all actions as are necessary and appropriate to facilitate the implementation and consummation of the Restructuring (as defined in the RSA), negotiate in good faith certain definitive documents relating to the Restructuring and obtain required approvals. In addition, we agreed to conduct our business in the ordinary course, provide notice and certain materials relating to the Restructuring to the consenting creditors’ advisors and pay certain fees and expenses of the consenting creditors.

The RSA provides certain milestones for the Restructuring. If we fail to satisfy these milestones and such failure is not the result of a breach of the RSA by the Required Consenting First Lien Creditors (as defined in the RSA), the Required Consenting First Lien Creditors will have the right to terminate the RSA. These milestones, as modified since we entered into the RSA (and which may be further modified from time to time), include: (i) not later than 11:59 p.m. prevailing Eastern Time on October 25, 2022, the Bankruptcy Court shall have entered the Cash Collateral Order (as defined below) on a final basis; (ii) not later than 11:59 p.m. prevailing Eastern Time on the date that is one hundred (100) calendar days after the Petition Date, the Bankruptcy Court shall have entered an order approving the bidding procedures; (iii) not later than 11:59 p.m. prevailing Eastern Time on the date that is two hundred forty-five (245) calendar days after the Petition Date, the Bankruptcy Court shall have entered an order approving the Sale; and (iv) not later than 11:59 p.m. prevailing Eastern Time on the date that is three hundred thirty (330) calendar days after the Petition Date (the Outside Date), the closing of the Sale shall have occurred, subject to certain extensions of the Outside Date as set forth in the RSA, including: (a) for extensions of prior milestones; (b) to close the Sale transaction with a backup bidder; and (c) for delays in obtaining regulatory or third-party approvals or consents.

Each of the parties to the RSA may terminate the agreement (and thereby their support for the Sale) under certain limited circumstances, including for material breaches and materially untrue representations and warranties by their counterparties, if a governmental agency enjoins the Sale or if the purchase and sale agreement with respect to the Sale is terminated under certain circumstances.

Subsequent Developments

Cash Collateral

In October 2022, the Bankruptcy Court entered the Cash Collateral Order approving the Debtors’ consensual use of their secured creditors’ cash collateral. The Debtors intend to use the cash collateral to, among other things, permit the orderly continuation of their businesses, pay the costs of administration of their estates and satisfy other working capital and general corporate purposes. As described in additional detail elsewhere in this report, including in Note 14. Debt, the Cash Collateral Order obligates the Debtors to make certain adequate protection payments during the bankruptcy proceedings, establishes a budget for the Debtors’ use of cash collateral, establishes certain informational rights for the Debtors’ secured creditors and provides for the waiver of certain Bankruptcy Code provisions. The Cash Collateral Order also requires the Debtors to maintain at least $600.0 million of “liquidity,” calculated at the end of each week as unrestricted cash and cash equivalents plus certain specified amounts of restricted cash associated with the TLC Agreement (which is defined and further discussed below in Note 11. License, Collaboration and Asset Acquisition Agreements).

Asset Sale

As further discussed in Note 4. Discontinued Operations, during the second quarter of 2022, the Debtors entered into a definitive agreement to sell certain assets located in Chestnut Ridge, New York to Ram Ridge Partners (as defined below). In October 2022, the Bankruptcy Court approved the sale of the assets. The sale is currently expected to close in the fourth quarter of 2022.

Potential Claims

The Debtors intend to file with the Bankruptcy Court schedules and statements setting forth, among other things, the assets and liabilities of each of the Debtors, subject to the assumptions to be filed in connection therewith. The schedules and statements may be subject to further amendment or modification after filing. As part of the Chapter 11 Cases, persons and entities believing that they have claims or causes of action against the Debtors may file proofs of claim evidencing such claims. The Debtors have not yet set a bar date (deadline) for holders of claims to file proofs of claim.

The Debtors have received numerous claims as of the date of this report including, in certain cases, duplicate claims across multiple Debtors. We expect that the Debtors may continue to receive a significant number of claims in the future. As claims are filed, they are being evaluated for validity and compared to amounts recorded in our accounting records. As of the date of this report, the amounts of certain of the claims received exceed the amounts of the corresponding liabilities, if any, that we have recorded based on our assessments of the purported liabilities underlying such claims, and it is likely this will continue to be the case in future periods. We are not aware of any claims that we currently expect will require a material adjustment to the accounts and balances as reported as of September 30, 2022.

Differences in amounts recorded and claims filed by creditors will continue to be investigated and resolved, including through the filing of objections with the Bankruptcy Court, where appropriate. The Debtors may ask the Bankruptcy Court to disallow claims that the Debtors believe are duplicative, have been later amended or superseded, are without merit, are overstated or should be disallowed for other reasons. In addition, as a result of this process, the Debtors may identify additional liabilities that will need to be recorded or reclassified to Liabilities subject to compromise in the Condensed Consolidated Balance Sheets. In light of the substantial number of claims that may be filed, the claims resolution process may take considerable time to complete and may continue for the duration of the Debtors’ bankruptcy proceedings.

Bankruptcy Accounting

As a result of the Chapter 11 Cases, we have applied the provisions of Accounting Standards Codification Topic 852, Reorganizations (ASC 852) in preparing the accompanying Condensed Consolidated Financial Statements. ASC 852 requires that, for periods including and after the filing of a chapter 11 petition, the Condensed Consolidated Financial Statements distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business.

Accordingly, for periods beginning with the third quarter of 2022, pre-petition unsecured and undersecured claims related to the Debtors that may be impacted by the bankruptcy reorganization process have been classified as Liabilities subject to compromise in our Condensed Consolidated Balance Sheets. Liabilities subject to compromise include pre-petition liabilities for which there is uncertainty about whether such pre-petition liabilities could be impaired as a result of the Chapter 11 Cases. Liabilities subject to compromise are recorded at the expected amount of the total allowed claim, even if they may ultimately be settled for different amounts. The following table sets forth, as of September 30, 2022, information about the amounts presented as Liabilities subject to compromise in our Condensed Consolidated Balance Sheets (in thousands):


	September 30, 2022
Accounts payable	$	16,121
Accrued interest	160,097
Debt	7,979,183
Litigation accruals	794,578
Uncertain tax positions	232,920
Other (1)	162,351
Total	$	9,345,250

__________

(1)Amounts include operating and finance lease liabilities as further described in Note 9. Leases, acquisition-related contingent consideration liabilities as further described in Note 7. Fair Value Measurements, certain employee compensation-related liabilities and a variety of other miscellaneous liabilities.

The determination of how liabilities will ultimately be settled or treated cannot be made until approved by the Bankruptcy Court. Therefore, the amounts in the table above are preliminary and may be subject to future adjustments as a result of, among other things, the possibility or occurrence of certain Bankruptcy Court actions, further developments with respect to disputed claims, any rejection by us of executory contracts and/or any payments by us of amounts classified as Liabilities subject to compromise, which may be allowed in certain limited circumstances. Amounts are also subject to adjustments if we make changes to our assumptions or estimates related to claims as additional information becomes available to us including, without limitation, those related to the expected amounts of allowed claims, the value of any collateral securing claims and the secured status of claims. Such adjustments may be material. Additionally, as a result of our ongoing bankruptcy proceedings, we may sell or otherwise dispose of or liquidate assets or settle liabilities for amounts other than those reflected in the accompanying Condensed Consolidated Financial Statements. The possibility or occurrence of any such actions could materially impact the amounts and classifications of such assets and liabilities reported in our Condensed Consolidated Balance Sheets and could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Certain expenses, gains and losses resulting from and recognized during our bankruptcy proceedings are now being recorded in Reorganization items, net in our Condensed Consolidated Statements of Operations. The following table sets forth, for the three and nine months ended September 30, 2022, information about the amounts presented as Reorganization items, net in our Condensed Consolidated Statements of Operations (in thousands):


	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
Professional fees	$	35,015		$	35,015
Debt valuation adjustments	89,197			89,197

Total	$	124,212		$	124,212

Since the Petition Date, our operating cash flows included net cash outflows of $2.9 million related to amounts classified as Reorganization items, net, which primarily consisted of payments for professional fees.

Refer also to Note 14. Debt for information about how our bankruptcy proceedings and certain related developments have affected our debt service payments and how such payments are being reflected in our Condensed Consolidated Financial Statements.

Nasdaq Delisting

On August 17, 2022, we received a letter (the Notice) from The Nasdaq Stock Market LLC (Nasdaq) stating that, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that Endo’s ordinary shares would be delisted. In accordance with the Notice, trading of Endo’s ordinary shares was suspended at the opening of business on August 26, 2022. As a result, Endo’s ordinary shares began trading exclusively on the over-the-counter market on August 26, 2022. On the over-the-counter market, Endo’s ordinary shares, which previously traded on the Nasdaq Global Select Market under the symbol ENDP, began to trade under the symbol ENDPQ. On September 14, 2022, Nasdaq filed a Form 25-NSE with the SEC; Endo’s ordinary shares were subsequently delisted from the Nasdaq Global Select Market.

NOTE 21. CONDENSED COMBINED DEBTOR-IN-POSSESSION FINANCIAL INFORMATION

The financial statements included in this Note represent the unaudited Condensed Combined Financial Statements of the Debtors only, which include Endo International plc and most of its wholly-owned subsidiaries, except for its Indian subsidiaries and certain subsidiaries associated with the Company’s former Astora business. These statements reflect the results of operations, financial position and cash flows of the combined Debtors, including certain amounts and activities between Debtors and Non-Debtor Affiliates of the Company that are eliminated in the Condensed Consolidated Financial Statements.





CONDENSED COMBINED BALANCE SHEETS (UNAUDITED)
(Dollars in thousands)

	September 30, 2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	990,107
Restricted cash and cash equivalents	59,486
Accounts receivable, net	409,333
Inventories, net	254,206
Prepaid expenses and other current assets	126,613
Income taxes receivable	1,290

Receivables from Non-Debtor Affiliates	102,162
Total current assets	$	1,943,197

PROPERTY, PLANT AND EQUIPMENT, NET	236,755
OPERATING LEASE ASSETS	26,240
GOODWILL	1,352,011
OTHER INTANGIBLES, NET	1,992,932

INVESTMENTS IN NON-DEBTOR AFFILIATES	53,887
RECEIVABLES FROM NON-DEBTOR AFFILIATES	241,860
OTHER ASSETS	139,659
TOTAL ASSETS	$	5,986,541
LIABILITIES AND DEFICIT
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	517,978



Income taxes payable	3,459

Payables to Non-Debtor Affiliates	2,614
Total current liabilities	$	524,051
DEFERRED INCOME TAXES	11,536




OTHER LIABILITIES	21,792
LIABILITIES SUBJECT TO COMPROMISE	9,345,250
TOTAL DEFICIT	(3,916,088)
TOTAL LIABILITIES AND DEFICIT	$	5,986,541





CONDENSED COMBINED STATEMENTS OF OPERATIONS (UNAUDITED)
(Dollars in thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
TOTAL REVENUES, NET	$	541,889		$	1,765,228
COSTS AND EXPENSES:
Cost of revenues	266,811			807,013
Selling, general and administrative	189,689			592,139
Research and development	34,519			102,942
Acquired in-process research and development	800			68,700
Litigation-related and other contingencies, net	419,377			444,738
Asset impairment charges	150,200			1,951,216
Acquisition-related and integration items, net	(1,399)			(951)

Interest expense, net	71,874			347,862

Reorganization items, net	124,212			124,212
Other expense (income), net	9,052			(2,360)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX	$	(723,246)		$	(2,670,283)
INCOME TAX EXPENSE	10,535			15,032
LOSS FROM CONTINUING OPERATIONS	$	(733,781)		$	(2,685,315)
DISCONTINUED OPERATIONS, NET OF TAX	(3,896)			(15,096)
NET LOSS ATTRIBUTABLE TO DEBTOR ENTITIES	$	(737,677)		$	(2,700,411)
EQUITY IN INCOME OF NON-DEBTOR AFFILIATES, NET OF TAX	18,669			26,776
NET LOSS	$	(719,008)		$	(2,673,635)





CONDENSED COMBINED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
(Dollars in thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
NET LOSS	$	(719,008)		$	(2,673,635)
OTHER COMPREHENSIVE INCOME:
Net unrealized (loss) gain on foreign currency	$	(10,649)		$	(13,088)
Total other comprehensive (loss) income	$	(10,649)		$	(13,088)
COMPREHENSIVE LOSS	$	(729,657)		$	(2,686,723)





CONDENSED COMBINED STATEMENTS OF CASH FLOWS (UNAUDITED)
(Dollars in thousands)

	Nine Months Ended September 30,
	2022
OPERATING ACTIVITIES:
Net cash provided by operating activities (1)	$	75,349
INVESTING ACTIVITIES:
Capital expenditures, excluding capitalized interest	(35,018)

Proceeds from the U.S. Government Agreement	13,601

Acquisitions, including in-process research and development, net of cash and restricted cash acquired	(89,520)




Proceeds from sale of business and other assets, net	22,378
Disbursements for loans made to Non-Debtor Affiliates	(51,180)

Net cash used in investing activities	$	(139,739)
FINANCING ACTIVITIES:


Repayments of notes	(180,342)
Repayments of term loans	(10,000)


Adequate protection payments	(168,643)
Repayments of other indebtedness	(4,500)

Payments for contingent consideration	(1,939)
Payments of tax withholding for restricted shares	(1,898)


Net cash used in financing activities	$	(367,322)
Effect of foreign exchange rate	(2,393)

NET DECREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	$	(434,105)
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	1,568,698
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	$	1,134,593

__________

(1)The difference between the amount of Net cash provided by operating activities included in the table above and the amount of Net cash provided by operating activities included in the Condensed Consolidated Statements of Cash Flows for the same period primarily relates to the fact that the table above: (i) excludes the operating cash flows of our Non-Debtor Affiliates, which are included in the Condensed Consolidated Statements of Cash Flows, and (ii) includes the effects of the operating cash flows of the Debtors with the Non-Debtor Affiliates, which are eliminated in the Condensed Consolidated Statements of Cash Flows.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of our Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts and disclosures in our Condensed Consolidated Financial Statements, including the Notes thereto, and elsewhere in this report. For example, we are required to make significant estimates and assumptions related to revenue recognition, including sales deductions, long-lived assets, goodwill, other intangible assets, income taxes, contingencies, financial instruments, share-based compensation, Liabilities subject to compromise and Reorganization items, net, among others. Some of these estimates can be subjective and complex. Uncertainties related to the continued magnitude and duration of the COVID-19 pandemic, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending, health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic, including any possible re-initiation of shutdowns or renewed restrictions, have increased the complexity of developing these estimates, including the allowance for expected credit losses and the carrying amounts of long-lived assets, goodwill and other intangible assets. Additionally, as a result of our ongoing bankruptcy proceedings, we may sell or otherwise dispose of or liquidate assets or settle liabilities for amounts other than those reflected in the accompanying Condensed Consolidated Financial Statements. The possibility or occurrence of any such actions could materially impact the amounts and classifications of such assets and liabilities reported in our Condensed Consolidated Balance Sheets. Furthermore, our ongoing bankruptcy proceedings and planned sale process have resulted in and are likely to continue to result in significant changes to our business, which could ultimately result in, among other things, asset impairment charges that may be material. Although we believe that our estimates and assumptions are reasonable, there may be other reasonable estimates or assumptions that differ significantly from ours. Further, our estimates and assumptions are based upon information available at the time they were made. Actual results may differ significantly from our estimates, including as a result of the uncertainties described in this report, those described in our other reports filed with the SEC or other uncertainties. Significant Accounting Policies Added or Updated since December 31, 2021 Except as described in Note 2. Bankruptcy Proceedings, there have been no significant changes to our significant accounting policies since December 31, 2021. For additional discussion of the Company’s significant accounting policies, see Note 2. Summary of Significant Accounting Policies in the Consolidated Financial Statements included in Part IV, Item 15 of the Annual Report.

DISCONTINUED OPERATIONS

9 Months Ended

Sep. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS

NOTE 4. DISCONTINUED OPERATIONS

Astora

The operating results of the Company’s Astora business, which the Board of Directors (the Board) resolved to wind down in 2016, are reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for all periods presented. The following table provides the operating results of Astora Discontinued operations, net of tax, for the three and nine months ended September 30, 2022 and 2021 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Litigation-related and other contingencies, net	$	—	$	25,000	$	—	$	25,000
Loss from discontinued operations before income taxes	$	(3,897)	$	(31,306)	$	(15,115)	$	(43,400)
Income tax benefit	$	—	$	(3,388)	$	—	$	(4,631)
Discontinued operations, net of tax	$	(3,897)	$	(27,918)	$	(15,115)	$	(38,769)

Loss from discontinued operations before income taxes includes Litigation-related and other contingencies, net, mesh-related legal defense costs and certain other items.

The cash flows from discontinued operating activities related to Astora included the impact of net losses of $15.1 million and $38.8 million for the nine months ended September 30, 2022 and 2021, respectively, and the impact of cash activity related to vaginal mesh cases. During the periods presented above, there were no material net cash flows related to Astora discontinued investing activities and there was no depreciation or amortization expense related to Astora.

Certain Assets and Liabilities of Endo’s Retail Generics Business

In November 2020, we announced the initiation of several strategic actions to further optimize the Company’s operations and increase overall efficiency (the 2020 Restructuring Initiative), which are further discussed in Note 5. Restructuring. These actions include an initiative to exit certain of our manufacturing and other sites to optimize our retail generics business cost structure.

Certain of these sites were sold in 2021, resulting in the recognition of the following amounts during the third quarter of 2021: (i) an estimated expected pre-tax disposal loss of $42.2 million to write down the carrying amount of the disposal group to fair value, less cost to sell, which we recorded in Asset impairment charges in the Condensed Consolidated Statements of Operations and (ii) a net pre-tax reversal of $19.8 million of expense, primarily related to avoided severance costs for employees that transitioned to the purchasers in connection with these 2021 sales. The 2021 sales are further discussed in the Annual Report.

Additionally, during the second quarter of 2022, we entered into a definitive agreement to sell certain additional assets located in Chestnut Ridge, New York that supported our retail generics business to Ram Ridge Partners BH LLC (Ram Ridge Partners). We previously concluded that, as of June 30, 2022, these assets, which included property, plant and equipment with a carrying amount of approximately $11 million, met the criteria to be classified as held for sale in the Condensed Consolidated Balance Sheets. At September 30, 2022, as a result of the Chapter 11 Cases and the fact that the sale of these assets had become subject to approval by the Bankruptcy Court, we concluded these assets no longer met the criteria to be classified as held for sale. As a result, these assets were included in Property, plant and equipment, net in the Condensed Consolidated Balance Sheets as of September 30, 2022. In October 2022, the Bankruptcy Court approved the sale of the assets. The sale is currently expected to close in the fourth quarter of 2022. These assets, which primarily related to the Company’s Generic Pharmaceuticals segment, did not meet the requirements for treatment as a discontinued operation.

RESTRUCTURING

9 Months Ended

Sep. 30, 2022

Restructuring and Related Activities [Abstract]

RESTRUCTURING

NOTE 5. RESTRUCTURING

2020 Restructuring Initiative

As noted above, in November 2020, the Company announced the initiation of several strategic actions to further optimize the Company’s operations and increase overall efficiency. These actions were initiated with the expectation of generating significant cost savings to be reinvested, among other things, to support the Company’s key strategic priority to expand and enhance its product portfolio. These actions, which we have been progressing, include the following:

•Optimizing the Company’s retail generics business cost structure by exiting manufacturing and other sites in Irvine, California, Chestnut Ridge, New York and India. Certain sites have already been exited and certain products historically manufactured at these sites have been transferred to other internal and external sites within the Company’s manufacturing network.

•Improving operating flexibility and reducing general and administrative costs by transferring certain transaction processing activities to third-party global business process service providers.

•Increasing organizational effectiveness by further integrating the Company’s commercial, operations and research and development functions, respectively, to support the Company’s key strategic priorities.

As a result of the 2020 Restructuring Initiative, the Company’s global workforce was reduced by approximately 300 net full-time positions. The Company expects to realize annualized pre-tax cash savings (without giving effect to the costs described below) of approximately $85 million to $95 million by the first half of 2023, primarily related to reductions in Cost of revenues of approximately $65 million to $70 million and other expenses, including Selling, general and administrative and Research and development expenses, of approximately $20 million to $25 million. Future costs associated with the 2020 Restructuring Initiative are not expected to be material.

The following pre-tax net amounts related to the 2020 Restructuring Initiative are included in the Company’s Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2022 and 2021 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net restructuring charges (charge reversals) related to:
Accelerated depreciation	$	—	$	6,350	$	3,824	$	22,329
Asset impairments	—		42,155		—		42,155
Inventory adjustments	408		719		1,435		6,513
Employee separation, continuity and other benefit-related costs	(433)		(14,481)		1,290		(6,150)
Certain other restructuring costs	116		1,209		798		3,003
Total	$	91	$	35,952	$	7,347	$	67,850

These pre-tax net amounts were primarily attributable to our Generic Pharmaceuticals segment, which incurred $0.4 million and $5.5 million of pre-tax net charges during the three and nine months ended September 30, 2022, respectively, and $31.0 million and $53.5 million of pre-tax net charges during the three and nine months ended September 30, 2021, respectively. The remaining amounts related to our other segments and certain corporate unallocated costs.

As of September 30, 2022, cumulative amounts incurred to date include charges related to accelerated depreciation of approximately $51.0 million, asset impairments related to certain identifiable intangible assets, operating lease assets and disposal groups totaling approximately $49.5 million, inventory adjustments of approximately $11.5 million, employee separation, continuity and other benefit-related costs, net of approximately $53.9 million and certain other restructuring costs of approximately $3.5 million. Of these amounts, approximately $134.3 million was attributable to the Generic Pharmaceuticals segment, with the remaining amounts relating to our other segments and certain corporate unallocated costs.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net restructuring charges (charge reversals) included in:
Cost of revenues	$	375	$	(11,050)	$	4,025	$	9,294
Selling, general and administrative	(243)		4,946		201		15,174
Research and development	(41)		(99)		3,121		1,227
Asset impairment charges	—		42,155		—		42,155

Total	$	91	$	35,952	$	7,347	$	67,850

Changes to the liability for the 2020 Restructuring Initiative during the nine months ended September 30, 2022 were as follows (in thousands):


	Employee Separation, Continuity and Other Benefit-Related Costs		Certain Other Restructuring Costs		Total



Liability balance as of December 31, 2021	$	10,979	$	205	$	11,184
Net charges	1,290		798		2,088
Cash payments	(10,671)		(1,003)		(11,674)
Liability balance as of September 30, 2022	$	1,598	$	—	$	1,598

2022 Restructuring Initiative

In April 2022, the Company communicated the initiation of actions to streamline and simplify certain functions, including its commercial organization, to increase its overall organizational effectiveness and better align with current and future needs (the 2022 Restructuring Initiative). These actions were initiated with the expectation of generating cost savings, with a portion to be reinvested to support the Company’s key strategic priority to expand and enhance its product portfolio.

As a result of the 2022 Restructuring Initiative, the Company’s global workforce is ultimately expected to be reduced by up to approximately 100 net full-time positions. The Company expects to realize annualized pre-tax cash savings (without giving effect to the costs described below) of approximately $55 million to $65 million by the second quarter of 2023, primarily related to reductions in Selling, general and administrative expenses. Future costs associated with the 2022 Restructuring Initiative are not expected to be material.

The following pre-tax net amounts related to the 2022 Restructuring Initiative are included in the Company’s Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2022 (in thousands):


	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
Net restructuring (charge reversals) charges related to:


Inventory adjustments	$	—		$	2,462
Employee separation, continuity and other benefit-related costs	(1,681)			18,406
Certain other restructuring costs	1,102			8,657
Total	$	(579)		$	29,525

These pre-tax net amounts were primarily attributable to our Branded Pharmaceuticals segment, which incurred $0.1 million and $17.0 million of pre-tax net charges during the three and nine months ended September 30, 2022, respectively. The remaining amounts related to our Generic Pharmaceuticals segment and certain corporate unallocated costs.


	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
Net restructuring (charge reversals) charges included in:
Cost of revenues	$	68		$	13,352
Selling, general and administrative	(644)			12,075
Research and development	(3)			4,098


Total	$	(579)		$	29,525

Changes to the liability for the 2022 Restructuring Initiative during the nine months ended September 30, 2022 were as follows (in thousands):


	Employee Separation, Continuity and Other Benefit-Related Costs		Certain Other Restructuring Costs		Total



Liability balance as of December 31, 2021	$	—	$	—	$	—
Net charges	18,406		1,102		19,508
Cash payments	(12,871)		(551)		(13,422)
Liability balance as of September 30, 2022	$	5,535	$	551	$	6,086

Substantially all of the remaining liability at September 30, 2022 is classified as Liabilities subject to compromise in the Condensed Consolidated Balance Sheets.

SEGMENT RESULTS

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

SEGMENT RESULTS

NOTE 6. SEGMENT RESULTS

The Company’s four reportable business segments are Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. These segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.

We evaluate segment performance based on Segment adjusted income from continuing operations before income tax, which we define as (Loss) income from continuing operations before income tax and before acquired in-process research and development charges; acquisition-related and integration items, including transaction costs and changes in the fair value of contingent consideration; cost reduction and integration-related initiatives such as separation benefits, continuity payments, other exit costs and certain costs associated with integrating an acquired company’s operations; certain amounts related to strategic review initiatives; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; litigation-related and other contingent matters; certain legal costs; gains or losses from early termination of debt; debt modification costs; gains or losses from the sales of businesses and other assets; foreign currency gains or losses on intercompany financing arrangements; reorganization items, net; and certain other items.

Certain corporate expenses incurred by the Company are not directly attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as “Corporate unallocated costs.” Interest income and expense are also considered corporate items and not allocated to any of the Company’s segments. The Company’s Total segment adjusted income from continuing operations before income tax is equal to the combined results of each of its segments.

Branded Pharmaceuticals

Our Branded Pharmaceuticals segment includes a variety of branded products in the areas of urology, orthopedics, endocrinology, medical aesthetics and bariatrics, among others. Products in this segment include XIAFLEX®, SUPPRELIN® LA, AVEED®, NASCOBAL® Nasal Spray, QWO®, PERCOCET®, TESTOPEL® and EDEX®, among others.

Sterile Injectables

Our Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT®, ADRENALIN® and APLISOL®, among others, and certain generic sterile injectable products, including ertapenem for injection (the authorized generic of Merck Sharp & Dohme Corp.’s (Merck) Invanz®) and ephedrine sulfate injection, among others.

Generic Pharmaceuticals

Our Generic Pharmaceuticals segment consists of a product portfolio including solid oral extended-release products, solid oral immediate-release products, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products that treat and manage a wide variety of medical conditions.

International Pharmaceuticals

Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through our operating company Paladin Labs Inc. (Paladin). The key products of this segment serve various therapeutic areas, including attention deficit hyperactivity disorder, pain, women’s health, oncology and transplantation.

The following represents selected information for the Company’s reportable segments for the three and nine months ended September 30, 2022 and 2021 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenues from external customers:
Branded Pharmaceuticals	$	203,501	$	230,977	$	627,314	$	665,652
Sterile Injectables	118,693		343,653		481,892		946,998
Generic Pharmaceuticals	201,435		174,306		590,756		522,451
International Pharmaceuticals (1)	18,061		23,092		63,101		68,676
Total net revenues from external customers	$	541,690	$	772,028	$	1,763,063	$	2,203,777
Segment adjusted income from continuing operations before income tax:
Branded Pharmaceuticals	$	84,940	$	105,849	$	251,219	$	301,277
Sterile Injectables	58,633		282,300		318,284		751,922
Generic Pharmaceuticals	87,675		34,010		237,394		89,036
International Pharmaceuticals	4,296		6,764		17,149		24,337
Total segment adjusted income from continuing operations before income tax	$	235,544	$	428,923	$	824,046	$	1,166,572

__________

(1)Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada.

There were no material revenues from external customers attributed to an individual country outside of the U.S. during any of the periods presented.

The table below provides reconciliations of our Total consolidated (loss) income from continuing operations before income tax, which is determined in accordance with U.S. GAAP, to our Total segment adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2022 and 2021 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Total consolidated (loss) income from continuing operations before income tax	$	(707,592)	$	(47,741)	$	(2,648,439)	$	958
Interest expense, net	74,753		142,958		349,486		418,852
Corporate unallocated costs (1)	44,182		65,317		125,851		141,291
Amortization of intangible assets	84,042		91,901		261,844		281,101

Acquired in-process research and development charges	800		—		68,700		5,000
Amounts related to continuity and separation benefits, cost reductions and strategic review initiatives (2)	44,029		19,829		139,025		58,632
Certain litigation-related and other contingencies, net (3)	419,376		83,495		444,738		119,327
Certain legal costs (4)	8,052		38,842		31,322		82,961
Asset impairment charges (5)	150,200		42,155		1,951,216		50,393
Acquisition-related and integration items, net (6)	(1,399)		(1,432)		(951)		(6,357)
Loss on extinguishment of debt	—		—		—		13,753

Foreign currency impact related to the remeasurement of intercompany debt instruments	(6,220)		(2,036)		(7,114)		466
Reorganization items, net (7)	124,212		—		124,212		—
Other, net (8)	1,109		(4,365)		(15,844)		195
Total segment adjusted income from continuing operations before income tax	$	235,544	$	428,923	$	824,046	$	1,166,572

__________

(1)Amounts include certain corporate overhead costs, such as headcount, facility and corporate litigation expenses and certain other income and expenses.

(2)Amounts for the three months ended September 30, 2022 include net employee separation, continuity and other benefit-related charges of $14.1 million and other net charges, including those related to strategic review initiatives, of $30.0 million. Amounts for the nine months ended September 30, 2022 include net employee separation, continuity and other benefit-related charges of $58.1 million, accelerated depreciation charges of $3.8 million and other net charges, including those related to strategic review initiatives, of $77.1 million. Amounts for the three months ended September 30, 2021 include net employee separation, continuity and other benefit-related charge reversals of $11.3 million, accelerated depreciation charges of $6.4 million and other net charges, including those related to strategic review initiatives, of $24.8 million. Amounts for the nine months ended September 30, 2021 include net employee separation, continuity and other benefit-related charge reversals of $1.2 million, accelerated depreciation charges of $22.3 million and other net charges, including those related to strategic review initiatives, of $37.5 million. These amounts relate primarily to our restructuring activities as further described in Note 5. Restructuring, certain continuity and transitional compensation arrangements, certain other cost reduction initiatives and certain strategic review initiatives, including costs incurred in connection with our bankruptcy proceedings, which are included in this row until the Petition Date and in the Reorganization items, net row thereafter.

(3)Amounts include adjustments to our accruals for litigation-related settlement charges. Our material legal proceedings and other contingent matters are described in more detail in Note 15. Commitments and Contingencies.

(4)Amounts relate to opioid-related legal expenses. The amount during the nine months ended September 30, 2022 reflects the recovery of certain previously-incurred opioid-related legal expenses.

(5)Amounts primarily relate to charges to impair goodwill and intangible assets as further described in Note 10. Goodwill and Other Intangibles as well as certain disposal group impairment charges as further described in Note 4. Discontinued Operations.

(6)Amounts primarily relate to changes in the fair value of contingent consideration.

(7)Amounts relate to the net expense or income recognized during our bankruptcy proceedings required to be presented as Reorganization items, net under ASC 852. Refer to Note 2. Bankruptcy Proceedings for further details.

(8)Amounts for the three and nine months ended September 30, 2021 primarily relate to a gain of $4.9 million associated with the resolution of a prior contract dispute. For the nine months ended September 30, 2021, this gain was partially offset by $3.9 million of third-party fees incurred in connection with the March 2021 Refinancing Transactions, which were accounted for as debt modification costs. Refer to Note 14. Debt for additional information. Other amounts in this row relate to gains and losses on sales of businesses and other assets and certain other items.

Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.

During the three and nine months ended September 30, 2022 and 2021, the Company disaggregated its revenue from contracts with customers into the categories included in the table below (in thousands). The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Branded Pharmaceuticals:
Specialty Products:
XIAFLEX®	$	104,014	$	105,509	$	324,376	$	312,266
SUPPRELIN® LA	31,283		30,069		84,852		85,665
Other Specialty (1)	11,033		26,339		50,023		74,407
Total Specialty Products	$	146,330	$	161,917	$	459,251	$	472,338
Established Products:
PERCOCET®	$	25,052	$	26,914	$	77,483	$	78,695
TESTOPEL®	9,430		11,686		28,331		32,314

Other Established (2)	22,689		30,460		62,249		82,305
Total Established Products	$	57,171	$	69,060	$	168,063	$	193,314
Total Branded Pharmaceuticals (3)	$	203,501	$	230,977	$	627,314	$	665,652
Sterile Injectables:
VASOSTRICT®	$	33,697	$	255,697	$	225,217	$	676,764
ADRENALIN®	24,917		28,722		85,514		88,136


Other Sterile Injectables (4)	60,079		59,234		171,161		182,098
Total Sterile Injectables (3)	$	118,693	$	343,653	$	481,892	$	946,998
Total Generic Pharmaceuticals (5)	$	201,435	$	174,306	$	590,756	$	522,451
Total International Pharmaceuticals (6)	$	18,061	$	23,092	$	63,101	$	68,676
Total revenues, net	$	541,690	$	772,028	$	1,763,063	$	2,203,777

__________

(1)Products included within Other Specialty include AVEED®, NASCOBAL® Nasal Spray and QWO®.

(2)Products included within Other Established include, but are not limited to, EDEX®.

(3)Individual products presented above represent the top two performing products in each product category for either the three or nine months ended September 30, 2022, and/or any product having revenues in excess of $25 million during any completed quarterly period in 2022 or 2021.

(4)Products included within Other Sterile Injectables include ertapenem for injection, APLISOL® and others.

(5)The Generic Pharmaceuticals segment is comprised of a portfolio of products that are generic versions of branded products, are distributed primarily through the same wholesalers, generally have no intellectual property protection and are sold within the U.S. During the three and nine months ended September 30, 2022, varenicline tablets (Endo’s generic version of Pfizer Inc.’s Chantix®), which launched in September 2021, made up 15% and 13%, respectively, of consolidated total revenues. During the three months ended September 30, 2022, lubiprostone capsules (the authorized generic of Mallinckrodt plc’s Amitiza®), which launched in January 2021, made up 5% of consolidated total revenues. No other individual product within this segment has exceeded 5% of consolidated total revenues for the periods presented.

(6)The International Pharmaceuticals segment, which accounted for less than 5% of consolidated total revenues for each of the periods presented, includes a variety of specialty pharmaceutical products sold outside the U.S., primarily in Canada through Endo’s operating company Paladin.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 7. FAIR VALUE MEASUREMENTS

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

•Level 1—Quoted prices in active markets for identical assets or liabilities.

•Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Financial Instruments

The financial instruments recorded in our Condensed Consolidated Balance Sheets include cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds pay dividends that generally reflect short-term interest rates. Due to their initial maturities, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds), accounts receivable, accounts payable and accrued expenses approximate their fair values.

Restricted Cash and Cash Equivalents

The following table presents current and noncurrent restricted cash and cash equivalent balances at September 30, 2022 and December 31, 2021 (in thousands):


	Balance Sheet Line Items	September 30, 2022		December 31, 2021
Restricted cash and cash equivalents—current (1)	Restricted cash and cash equivalents	$	145,486	$	124,114
Restricted cash and cash equivalents—noncurrent (2)	Other assets	85,000		—
Total restricted cash and cash equivalents		$	230,486	$	124,114

__________

(1)Amounts at September 30, 2022 and December 31, 2021 include: (i) restricted cash and cash equivalents associated with litigation-related matters, including $58.5 million and $78.4 million, respectively, held in Qualified Settlement Funds (QSFs) for mesh- and/or opioid-related matters, and (ii) approximately $86.0 million and $45.0 million, respectively, of restricted cash and cash equivalents related to certain insurance-related matters. See Note 15. Commitments and Contingencies for further information about litigation-related matters.

(2)The amount at September 30, 2022 relates to the TLC Agreement. See Note 11. License, Collaboration and Asset Acquisition Agreements for further information about this amount.

Acquisition-Related Contingent Consideration

The fair value of contingent consideration liabilities is determined using unobservable inputs; hence, these instruments represent Level 3 measurements within the above-defined fair value hierarchy. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. The estimates of fair value are uncertain and changes in any of the estimated inputs used as of the date of this report could have resulted in significant adjustments to fair value. See the “Recurring Fair Value Measurements” section below for additional information on acquisition-related contingent consideration.

Recurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 were as follows (in thousands):


	Fair Value Measurements at September 30, 2022 using:
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total
Assets:
Money market funds (1)	$	14,539	$	—	$	—	$	14,539
Liabilities:



Acquisition-related contingent consideration (2)	$	—	$	—	$	15,812	$	15,812


	Fair Value Measurements at December 31, 2021 using:
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total
Assets:
Money market funds (1)	$	134,847	$	—	$	—	$	134,847
Liabilities:



Acquisition-related contingent consideration (2)	$	—	$	—	$	20,076	$	20,076

__________

(1)At September 30, 2022 and December 31, 2021, money market funds include $14.5 million and $16.2 million, respectively, in QSFs. Amounts in QSFs are considered restricted cash equivalents. See Note 15. Commitments and Contingencies for further discussion of our litigation. At September 30, 2022 and December 31, 2021, the differences between the amortized cost and the fair value of our money market funds were not material, individually or in the aggregate.

(2)At September 30, 2022, the balance of the Company’s liability for acquisition-related contingent consideration, which is governed by executory contracts and recorded at the expected amount of the total allowed claim, is classified within Liabilities subject to compromise in the Condensed Consolidated Balance Sheets. At December 31, 2021, this amount is classified in the Condensed Consolidated Balance Sheets as follows: $5.7 million is classified as a current liability and included within Accounts payable and accrued expenses and $14.3 million is classified as a noncurrent liability and included within Other liabilities.

Fair Value Measurements Using Significant Unobservable Inputs

The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which is measured at fair value on a recurring basis using significant unobservable inputs (Level 3), for the three and nine months ended September 30, 2022 and 2021 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Beginning of period	$	18,242	$	27,447	$	20,076	$	36,249
Amounts settled	(286)		(2,612)		(2,445)		(6,302)
Changes in fair value recorded in earnings	(1,399)		(1,435)		(951)		(6,771)
Effect of currency translation	(745)		(188)		(868)		36
End of period (1)	$	15,812	$	23,212	$	15,812	$	23,212

__________

(1)At September 30, 2022, the balance of the Company’s liability for acquisition-related contingent consideration, which is governed by executory contracts and recorded at the expected amount of the total allowed claim, is classified within Liabilities subject to compromise in the Condensed Consolidated Balance Sheets.

At September 30, 2022, the fair value measurements of the contingent consideration obligations were determined using risk-adjusted discount rates ranging from 10.0% to 15.0% (weighted average rate of approximately 10.8%, weighted based on relative fair value). Changes in fair value recorded in earnings related to acquisition-related contingent consideration are included in our Condensed Consolidated Statements of Operations as Acquisition-related and integration items, net.

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the nine months ended September 30, 2022 by acquisition (in thousands):


	Balance as of December 31, 2021		Changes in Fair Value Recorded in Earnings		Amounts Settled and Other		Balance as of September 30, 2022 (1)
Auxilium acquisition	$	9,038	$	422	$	(536)	$	8,924
Lehigh Valley Technologies, Inc. acquisitions	3,600		(694)		(506)		2,400

Other	7,438		(679)		(2,271)		4,488
Total	$	20,076	$	(951)	$	(3,313)	$	15,812

__________

Nonrecurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the nine months ended September 30, 2022 were as follows (in thousands):


	Fair Value Measurements during the Nine Months Ended September 30, 2022 (1) using:						Total Expense for the Nine Months Ended September 30, 2022
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs

Intangible assets, excluding goodwill (2)(3)	$	—	$	—	$	65,407	$	(103,153)
Certain property, plant and equipment	—		—		—		(3,063)


Total	$	—	$	—	$	65,407	$	(106,216)

__________

(1)The fair value amounts are presented as of the date of the fair value measurement as these assets are not measured at fair value on a recurring basis. Such measurements generally occur in connection with our quarter-end financial reporting close procedures.

(2)These fair value measurements were determined using risk-adjusted discount rates ranging from 9.5% to 12.0% (weighted average rate of approximately 11.7%, weighted based on relative fair value).

(3)The Company also performed fair value measurements in connection with its goodwill impairment tests. Refer to Note 10. Goodwill and Other Intangibles for additional information on goodwill and other intangible asset impairment tests, including information about the valuation methodologies used.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

INVENTORIES

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 8. INVENTORIES

Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):


	September 30, 2022		December 31, 2021
Raw materials (1)	$	101,407	$	90,453
Work-in-process (1)	59,630		82,728
Finished goods (1)	127,877		110,371
Total	$	288,914	$	283,552

__________

(1)The components of inventory shown in the table above are net of allowance for obsolescence.

Inventory in excess of the amount expected to be sold within one year is classified as noncurrent inventory and is not included in the table above. At September 30, 2022 and December 31, 2021, $35.3 million and $10.7 million, respectively, of noncurrent inventory was included in Other assets in the Condensed Consolidated Balance Sheets. As of September 30, 2022 and December 31, 2021, the Company’s Condensed Consolidated Balance Sheets included approximately $11.3 million and $12.2 million, respectively, of capitalized pre-launch inventories related to products that were not yet available to be sold.

LEASES

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

LEASES

NOTE 9. LEASES

The following table presents information about the Company’s right-of-use assets and lease liabilities at September 30, 2022 and December 31, 2021 (in thousands):


	Balance Sheet Line Items	September 30, 2022		December 31, 2021
Right-of-use assets:
Operating lease right-of-use assets	Operating lease assets	$	31,342	$	34,832
Finance lease right-of-use assets	Property, plant and equipment, net	28,819		38,365
Total right-of-use assets		$	60,161	$	73,197
Operating lease liabilities (1):
Current operating lease liabilities	Current portion of operating lease liabilities	$	724	$	10,992
Noncurrent operating lease liabilities	Operating lease liabilities, less current portion	4,363		33,727
Total operating lease liabilities		$	5,087	$	44,719
Finance lease liabilities (1):
Current finance lease liabilities	Accounts payable and accrued expenses	$	—	$	6,841
Noncurrent finance lease liabilities	Other liabilities	1,415		18,374
Total finance lease liabilities		$	1,415	$	25,215

__________

(1)Amounts at September 30, 2022 exclude operating lease liabilities of $33.6 million and finance lease liabilities of $18.8 million that are classified as Liabilities subject to compromise in the Condensed Consolidated Balance Sheets.

The following table presents information about lease costs and expenses and sublease income for the three and nine months ended September 30, 2022 and 2021 (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,
	Statement of Operations Line Items	2022		2021		2022		2021
Operating lease cost	Various (1)	$	3,415	$	3,612	$	8,452	$	10,869
Finance lease cost:
Amortization of right-of-use assets	Various (1)	$	2,024	$	2,311	$	6,455	$	6,933
Interest on lease liabilities	Interest expense, net	$	271	$	310	$	877	$	1,015
Other lease costs and income:
Variable lease costs (2)	Various (1)	$	3,525	$	3,035	$	8,220	$	9,099
Finance lease right-of-use asset impairment charges	Asset impairment charges	$	—	$	—	$	3,063	$	—

Sublease income	Various (1)	$	(1,560)	$	(957)	$	(4,810)	$	(2,837)

__________

(1)Amounts are included in the Condensed Consolidated Statements of Operations based on the function that the underlying leased asset supports. The following table presents the components of such aggregate amounts for the three and nine months ended September 30, 2022 and 2021 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Cost of revenues	$	1,539	$	2,988	$	4,668	$	9,032
Selling, general and administrative	$	5,812	$	4,959	$	13,488	$	14,870
Research and development	$	53	$	54	$	161	$	162

(2)Amounts represent variable lease costs incurred that were not included in the initial measurement of the lease liability such as common area maintenance and utilities costs associated with leased real estate and certain costs associated with our automobile leases.

The following table provides certain cash flow and supplemental noncash information related to our lease liabilities for the nine months ended September 30, 2022 and 2021 (in thousands):


	Nine Months Ended September 30,
	2022		2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$	9,746	$	10,010
Operating cash payments for finance leases	$	1,439	$	1,791
Financing cash payments for finance leases	$	4,501	$	4,044
Lease liabilities arising from obtaining right-of-use assets:
Operating leases (1)	$	1,296	$	4,985

__________

(1)The amount in 2022 primarily relates to a new lease agreement. The amount in 2021 primarily relates to an increase in lease liabilities and right-of-use assets related to a lease modification.

LEASES

NOTE 9. LEASES

The following table presents information about the Company’s right-of-use assets and lease liabilities at September 30, 2022 and December 31, 2021 (in thousands):


	Balance Sheet Line Items	September 30, 2022		December 31, 2021
Right-of-use assets:
Operating lease right-of-use assets	Operating lease assets	$	31,342	$	34,832
Finance lease right-of-use assets	Property, plant and equipment, net	28,819		38,365
Total right-of-use assets		$	60,161	$	73,197
Operating lease liabilities (1):
Current operating lease liabilities	Current portion of operating lease liabilities	$	724	$	10,992
Noncurrent operating lease liabilities	Operating lease liabilities, less current portion	4,363		33,727
Total operating lease liabilities		$	5,087	$	44,719
Finance lease liabilities (1):
Current finance lease liabilities	Accounts payable and accrued expenses	$	—	$	6,841
Noncurrent finance lease liabilities	Other liabilities	1,415		18,374
Total finance lease liabilities		$	1,415	$	25,215

__________

The following table presents information about lease costs and expenses and sublease income for the three and nine months ended September 30, 2022 and 2021 (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,
	Statement of Operations Line Items	2022		2021		2022		2021
Operating lease cost	Various (1)	$	3,415	$	3,612	$	8,452	$	10,869
Finance lease cost:
Amortization of right-of-use assets	Various (1)	$	2,024	$	2,311	$	6,455	$	6,933
Interest on lease liabilities	Interest expense, net	$	271	$	310	$	877	$	1,015
Other lease costs and income:
Variable lease costs (2)	Various (1)	$	3,525	$	3,035	$	8,220	$	9,099
Finance lease right-of-use asset impairment charges	Asset impairment charges	$	—	$	—	$	3,063	$	—

Sublease income	Various (1)	$	(1,560)	$	(957)	$	(4,810)	$	(2,837)

__________


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Cost of revenues	$	1,539	$	2,988	$	4,668	$	9,032
Selling, general and administrative	$	5,812	$	4,959	$	13,488	$	14,870
Research and development	$	53	$	54	$	161	$	162

The following table provides certain cash flow and supplemental noncash information related to our lease liabilities for the nine months ended September 30, 2022 and 2021 (in thousands):


	Nine Months Ended September 30,
	2022		2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$	9,746	$	10,010
Operating cash payments for finance leases	$	1,439	$	1,791
Financing cash payments for finance leases	$	4,501	$	4,044
Lease liabilities arising from obtaining right-of-use assets:
Operating leases (1)	$	1,296	$	4,985

__________

(1)The amount in 2022 primarily relates to a new lease agreement. The amount in 2021 primarily relates to an increase in lease liabilities and right-of-use assets related to a lease modification.

GOODWILL AND OTHER INTANGIBLES

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLES

NOTE 10. GOODWILL AND OTHER INTANGIBLES

Goodwill

Changes in the carrying amounts of our goodwill for the nine months ended September 30, 2022 were as follows (in thousands):


	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals		International Pharmaceuticals		Total





Goodwill as of December 31, 2021	$	828,818	$	2,368,193	$	—	$	—	$	3,197,011

Goodwill impairment charges	—		(1,845,000)		—		—		(1,845,000)

Goodwill as of September 30, 2022	$	828,818	$	523,193	$	—	$	—	$	1,352,011

The carrying amounts of goodwill at September 30, 2022 and December 31, 2021 are net of the following accumulated impairments (in thousands):


	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2021	$	855,810	$	363,000	$	3,142,657	$	550,355	$	4,911,822
Accumulated impairment losses as of September 30, 2022	$	855,810	$	2,208,000	$	3,142,657	$	502,985	$	6,709,452

Other Intangible Assets

Changes in the amounts of other intangible assets for the nine months ended September 30, 2022 are set forth in the table below (in thousands).


Cost basis:	Balance as of December 31, 2021		Acquisitions		Impairments		Effect of Currency Translation		Balance as of September 30, 2022




Licenses (weighted average life of 14 years)	$	442,107	$	—	$	—	$	—	$	442,107
Tradenames	6,409		—		—		—		6,409
Developed technology (weighted average life of 12 years)	6,226,139		—		(103,153)		(22,210)		6,100,776

Total other intangibles (weighted average life of 12 years years)	$	6,674,655	$	—	$	(103,153)	$	(22,210)	$	6,549,292

Accumulated amortization:	Balance as of December 31, 2021		Amortization		Impairments		Effect of Currency Translation		Balance as of September 30, 2022

Licenses	$	(419,932)	$	(3,432)	$	—	$	—	$	(423,364)
Tradenames	(6,409)		—		—		—		(6,409)
Developed technology	(3,885,491)		(258,412)		—		17,316		(4,126,587)
Total other intangibles	$	(4,311,832)	$	(261,844)	$	—	$	17,316	$	(4,556,360)
Net other intangibles	$	2,362,823							$	1,992,932

Amortization expense for the three and nine months ended September 30, 2022 totaled $84.0 million and $261.8 million, respectively. Amortization expense for the three and nine months ended September 30, 2021 totaled $91.9 million and $281.1 million, respectively. Amortization expense is included in Cost of revenues in the Condensed Consolidated Statements of Operations.

Impairments

Goodwill and, if applicable, indefinite-lived intangible assets are tested for impairment annually and when events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1.

As part of our goodwill and intangible asset impairment assessments, we estimate the fair values of our reporting units and our intangible assets using an income approach that utilizes a discounted cash flow model or, where appropriate, a market approach.

The discounted cash flow models are dependent upon our estimates of future cash flows and other factors including estimates of (i) future operating performance, including future sales, long-term growth rates, gross margins, operating expenses, discount rate and the probability of achieving the estimated cash flows and (ii) future economic conditions. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows are determined depending on the overall risk associated with the particular assets and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those a market participant would use. Any impairment charges resulting from annual or interim goodwill and intangible asset impairment assessments are recorded to Asset impairment charges in our Condensed Consolidated Statements of Operations.

Second-Quarter 2022 Goodwill Impairment Tests

Beginning in May 2022, our share price and the aggregate estimated fair value of our debt experienced significant declines. We believe these declines, which persisted through the end of the second quarter of 2022, were predominantly attributable to continuing and increasing investor and analyst uncertainty with respect to: (i) ongoing opioid and other litigation matters for which we had been unable to reach a broad-based resolution of outstanding claims and (ii) speculation surrounding the possibility of a bankruptcy filing. Further, rising inflation and interest rates unfavorably affected the cost of borrowing, which is one of several inputs used in the determination of the discount rates used in our discounted cash flow models. For example, the U.S. Federal Reserve raised its benchmark interest rate by 50 basis points in May 2022 and by an additional 75 basis points in June 2022. Taken together, we determined that these factors represented triggering events that required the performance of interim goodwill impairments tests for both our Sterile Injectables and Branded Pharmaceuticals reporting units as of June 30, 2022.

When performing these goodwill impairment tests, we estimated the fair values of our reporting units taking into consideration management’s continued commitment to Endo’s strategic plans and the corresponding projected cash flows, as well as the fact that management’s views on litigation risk had not materially changed since our annual goodwill impairment tests performed on October 1, 2021. However, when analyzing our aggregated estimated internal valuation of our reporting units as of June 30, 2022 compared to our market capitalization, we also considered the increased level of investor and analyst uncertainty described above, coupled with our belief that investors and analysts were unlikely to modify their projections or valuation models unless or until we could demonstrate significant progression on the resolution of outstanding litigation matters and/or demonstrate that the risks of potential future strategic alternatives, including the possibility of a future bankruptcy filing, were no longer applicable. After performing this analysis, we made certain adjustments to incorporate these factors into the valuations of our reporting units and determined that: (i) the estimated fair value of our Sterile Injectables reporting unit was less than its carrying amount, resulting in a pre-tax non-cash goodwill impairment charge of $1,748.0 million, and (ii) while the estimated fair value declined, there was no goodwill impairment for our Branded Pharmaceuticals reporting unit, for which the estimated fair value exceeded the carrying amount by more than 10%. The discount rates used in the June 30, 2022 goodwill tests were 13.5% and 18.5% for the Branded Pharmaceuticals and Sterile Injectables reporting units, respectively.

Third-Quarter 2022 Goodwill Impairment Tests

As further described in Note 2. Bankruptcy Proceedings, during the third quarter of 2022, we received the Stalking Horse Bid, which is subject to higher or otherwise better bids from other parties, in connection with the Sale. The value of the bid, as well as our market capitalization, was considered when determining whether it was more likely than not that the carrying amounts of one or more of our reporting units exceeds their respective fair values. Further, rising inflation and interest rates unfavorably affected the cost of borrowing, which is one of several inputs used in the determination of the discount rates used in our discounted cash flow models. For example, the U.S. Federal Reserve raised its benchmark interest rate by 75 basis points in July 2022 and by an additional 75 basis points in September 2022. Taken together, we determined that these factors represented triggering events that required the performance of interim goodwill impairments tests for both our Sterile Injectables and Branded Pharmaceuticals reporting units as of September 30, 2022.

When performing these goodwill impairment tests, we estimated the fair values of our reporting units taking into consideration management’s continued commitment to Endo’s strategic plans and the corresponding projected cash flows. However, when analyzing our aggregated estimated internal valuation of our reporting units as of September 30, 2022 compared to our market capitalization and the Stalking Horse Bid, we made adjustments to incorporate certain risks and uncertainties, including those related to the Chapter 11 Cases and the Sale, into the valuations of our reporting units and determined that: (i) the estimated fair value of our Sterile Injectables reporting unit was less than its carrying amount, resulting in a pre-tax non-cash goodwill impairment charge of $97.0 million, and (ii) the estimated fair value of our Branded Pharmaceuticals reporting unit exceeded the carrying amount by more than 10%. The discount rates used in the September 30, 2022 goodwill tests were 15.0% and 19.5% for the Branded Pharmaceuticals and Sterile Injectables reporting units, respectively.

Other Intangible Asset Impairments

With respect to other intangible assets, we recorded asset impairment charges of $53.2 million and $103.2 million during the three and nine months ended September 30, 2022, respectively, and $7.8 million during the nine months ended September 30, 2021. These pre-tax non-cash asset impairment charges related primarily to certain developed technology intangible assets that were tested for impairment following changes in market conditions and certain other factors impacting recoverability.

LICENSE, COLLABORATION AND ASSET ACQUISITION AGREEMENTS	9 Months Ended
LICENSE, COLLABORATION AND ASSET ACQUISITION AGREEMENTS	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LICENSE, COLLABORATION AND ASSET ACQUISITION AGREEMENTS	NOTE 11. LICENSE, COLLABORATION AND ASSET ACQUISITION AGREEMENTS We have entered into certain license, collaboration and discovery agreements with third parties for product development. Generally, these agreements require us to share in the development costs of such product candidates with third parties who in turn grant us marketing rights for such product candidates. Under these agreements we are generally required to: (i) make upfront payments and/or other payments upon successful completion of regulatory, sales and/or other milestones and/or (ii) pay royalties on sales of the products arising from these agreements. We have also, from time to time, entered into agreements to directly acquire certain assets from third parties. 2022 Nevakar Agreement In May 2022, we announced that our Endo Ventures Limited subsidiary had entered into an agreement to acquire six development-stage ready-to-use injectable product candidates from Nevakar Injectables, Inc., a subsidiary of Nevakar, Inc., for an upfront cash payment of $35.0 million (the 2022 Nevakar Agreement). The acquisition closed during the second quarter of 2022. The acquired set of assets and activities did not meet the definition of a business. As a result, we accounted for the transaction as an asset acquisition. Upon closing, the upfront payment was recorded as Acquired in-process research and development in the Condensed Consolidated Statements of Operations. The product candidates, which relate to our Sterile Injectables segment, are in various stages of development. The first commercial launch is expected in 2025; however, there can be no assurance this will occur within this timeframe or at all. With this acquisition, the Company will control all remaining development, regulatory, manufacturing and commercialization activities for the acquired product candidates. TLC Agreement In June 2022, we announced that our Endo Ventures Limited subsidiary had entered into an agreement with Taiwan Liposome Company, Ltd. (TLC) to commercialize TLC599 (the TLC Agreement). We are accounting for the agreement as an asset acquisition. TLC599 is an injectable compound in Phase 3 development for the treatment of osteoarthritis knee pain. The TLC Agreement provides us the opportunity to commercialize this differentiated nonsurgical product candidate to complement our Branded Pharmaceuticals segment’s current on-market and in-development orthopedic-focused opportunities. Under the terms of the TLC Agreement, TLC is primarily responsible for the development of the product and we are primarily responsible for obtaining regulatory approval and for commercialization of the product in the U.S. Upon receipt of regulatory approval, if obtained, we will have exclusive rights to manufacture, market, sell and distribute the product in the U.S. During the second quarter of 2022, we made an upfront payment of $30.0 million to TLC and recorded a corresponding charge to Acquired in-process research and development in the Condensed Consolidated Statements of Operations. TLC is also eligible to receive: (i) payments of up to an additional $110.0 million based on the achievement of certain development, regulatory and manufacturing milestones related to the initial indication for the treatment of osteoarthritis knee pain; (ii) payments of up to an additional $30.0 million based on the achievement of certain development and regulatory milestones related to certain potential future indications; (iii) payments of up to an additional $500.0 million based on the achievement of certain commercial milestones; and (iv) tiered royalties based on net sales of TLC599 in the U.S. Unless terminated earlier or extended, the term of the TLC Agreement generally extends until the 20-year anniversary of the first commercial sale of TLC599. Pursuant to the terms of the TLC Agreement, we have deposited approximately $85.0 million of cash into a bank account which may be used to fund certain future obligations under the TLC Agreement or returned to us upon satisfaction of certain conditions. As further described in Note 7. Fair Value Measurements, this amount is considered restricted cash as of September 30, 2022 and is included in our Condensed Consolidated Balance Sheets at September 30, 2022 as Other assets. In September 2022, we were informed by TLC of the top-line results from TLC’s Phase 3 clinical study to evaluate the efficacy and safety of TLC599 in patients with pain from osteoarthritis of the knee. While study participants treated with TLC599 showed improvement on the primary endpoint (change from baseline to week 12 on the WOMAC pain scale) consistent with the level of improvement reported in the previously conducted TLC599 Phase 2 clinical study, the difference compared to those receiving placebo was not statistically significant. Based on this data, we are evaluating options for TLC599 with TLC.

CONTRACT ASSETS AND LIABILITIES

9 Months Ended

Sep. 30, 2022

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]

CONTRACT ASSETS AND LIABILITIES

NOTE 12. CONTRACT ASSETS AND LIABILITIES

Our revenue consists almost entirely of sales of our products to customers, whereby we ship products to a customer pursuant to a purchase order. Revenue contracts such as these do not generally give rise to contract assets or contract liabilities because: (i) the underlying contracts generally have only a single performance obligation and (ii) we do not generally receive consideration until the performance obligation is fully satisfied. At September 30, 2022, the unfulfilled performance obligations for these types of contracts relate to ordered but undelivered products. We generally expect to fulfill the performance obligations and recognize revenue within one week of entering into the underlying contract. Based on the short-term initial contract duration, additional disclosure about the remaining performance obligations is not required.

Certain of our other revenue-generating contracts, including license and collaboration agreements, may result in contract assets and/or contract liabilities. For example, we may recognize contract liabilities upon receipt of certain upfront and milestone payments from customers when there are remaining performance obligations.

The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):


	September 30, 2022		December 31, 2021		$ Change		% Change
Contract assets (1)	$	2,737	$	13,005	$	(10,268)	(79)	%
Contract liabilities (2)	$	4,240	$	4,663	$	(423)	(9)	%

__________

(1)At September 30, 2022 and December 31, 2021, approximately $1.2 million and $2.8 million, respectively, of these contract asset amounts are classified as current and are included in Prepaid expenses and other current assets in the Company’s Condensed Consolidated Balance Sheets. The remaining amounts are classified as noncurrent and are included in Other assets. The decrease in contract assets during the nine months ended September 30, 2022 primarily relates to: (i) reclassifications of certain amounts to receivables as a result of rights to consideration becoming unconditional and (ii) changes in estimates with respect to amounts of consideration expected to be received from sales of certain intellectual property rights.

(2)At September 30, 2022 and December 31, 2021, approximately $0.6 million and $0.6 million, respectively, of these contract liability amounts are classified as current and are included in Accounts payable and accrued expenses in the Company’s Condensed Consolidated Balance Sheets. The remaining amounts are classified as noncurrent and are included in Other liabilities. During the nine months ended September 30, 2022, approximately $0.4 million of revenue was recognized that was included in the contract liability balance at December 31, 2021.

During the nine months ended September 30, 2022, we recognized revenue of $10.2 million relating to performance obligations satisfied, or partially satisfied, in prior periods. Such revenue generally relates to changes in estimates with respect to our variable consideration.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2022

Accounts Payable and Accrued Liabilities, Current [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 13. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses included the following at September 30, 2022 and December 31, 2021 (in thousands):


	September 30, 2022		December 31, 2021
Trade accounts payable	$	84,999	$	123,129
Returns and allowances	159,215		183,116
Rebates	148,165		150,039
Chargebacks	834		2,617
Other sales deductions	6,551		2,500
Accrued interest	43		106,735
Accrued payroll and related benefits	39,465		90,029
Accrued royalties and other distribution partner payables	15,934		58,422
Acquisition-related contingent consideration—current	—		5,748
Other (1)	83,524		114,563
Total	$	538,730	$	836,898

__________

(1)Amounts include a wide variety of accrued expenses, the most significant of which relate to accrued legal and other professional fees.

The amounts in the table above do not include amounts classified as Liabilities subject to compromise in our Condensed Consolidated Balance Sheets. Refer to Note 2. Bankruptcy Proceedings for additional information about Liabilities subject to compromise.

DEBT

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

DEBT

NOTE 14. DEBT

The following table presents information about the Company’s total indebtedness at September 30, 2022 and December 31, 2021 (dollars in thousands):


	September 30, 2022						December 31, 2021
	Effective Interest Rate (1)		Principal Amount (2)		Carrying Amount (2)		Effective Interest Rate		Principal Amount		Carrying Amount
7.25% Senior Notes due 2022			$	—	$	—	7.25	%	$	8,294	$	8,294
5.75% Senior Notes due 2022			—		—		5.75	%	172,048		172,048
5.375% Senior Notes due 2023	5.38	%	6,127		6,127		5.62	%	6,127		6,111
6.00% Senior Notes due 2023	6.00	%	56,436		56,436		6.28	%	56,436		56,203
5.875% Senior Secured Notes due 2024	6.88	%	300,000		291,531		6.14	%	300,000		297,928
6.00% Senior Notes due 2025	6.00	%	21,578		21,578		6.27	%	21,578		21,413
7.50% Senior Secured Notes due 2027	8.50	%	2,015,479		1,937,603		7.70	%	2,015,479		1,997,777
9.50% Senior Secured Second Lien Notes due 2027	9.50	%	940,590		940,590		9.68	%	940,590		933,330
6.00% Senior Notes due 2028	6.00	%	1,260,416		1,260,416		6.11	%	1,260,416		1,252,667
6.125% Senior Secured Notes due 2029	7.13	%	1,295,000		1,253,866		6.34	%	1,295,000		1,278,718
Term Loan Facility	12.25	%	1,975,000		1,937,854		6.12	%	1,985,000		1,947,633
Revolving Credit Facility	9.75	%	277,200		273,182		2.63	%	277,200		277,200

Total (3)			$	8,147,826	$	7,979,183			$	8,338,168	$	8,249,322

__________

(1)As noted below, beginning on the Petition Date, we ceased recognition of interest expense related to all of our debt instruments and began to incur “adequate protection payments” (further discussed below) related to our First Lien Debt Instruments (representing all of our debt instruments except for our senior unsecured notes and the 9.75% Senior Secured Second Lien Notes due 2027). The September 30, 2022 “effective interest rates” included in the table above represent the rates in effect on such date used to calculate: (i) future adequate protection payments related to our First Lien Debt Instruments and (ii) future contractual interest related to our other debt instruments, notwithstanding the fact that such interest is not currently being recognized. These rates are expressed as a percentage of the contractual principal amounts outstanding as of such date and, with respect to our First Lien Debt Instruments, without consideration of any reductions related to adequate protection payments made through such date.

(2)The September 30, 2022 principal amounts represent the amount of unpaid contractual principal owed on the respective instruments. During the third quarter of 2022, in accordance with ASC 852, we adjusted the carrying amounts of all unsecured and potentially undersecured debt instruments to equal the expected amount of the allowed claim by expensing (within Reorganization items, net in the Condensed Consolidated Statements of Operations) $89.2 million of previously-deferred and unamortized costs associated with these instruments. The September 30, 2022 carrying amounts of our First Lien Debt Instruments also reflect reductions for certain adequate protection payments made since the Petition Date, as further discussed herein.

(3)As of September 30, 2022, the entire carrying amount our debt, as well as any related remaining accrued and unpaid interest that existed as of the Petition Date, is included in the Liabilities subject to compromise line in the Condensed Consolidated Balance Sheets. As of December 31, 2021, $200.3 million of the carrying amount of our debt is classified as a current liability and is included in the Current portion of long-term debt line in the Condensed Consolidated Balance Sheets. The remaining carrying amount of our debt as of December 31, 2021 is included in the Long-term debt, less current portion, net line in the Condensed Consolidated Balance Sheets.

General Information

The Company and its subsidiaries, with certain customary exceptions, guarantee or serve as issuers or borrowers of the debt instruments representing substantially all of the Company’s indebtedness at September 30, 2022. The obligations under (i) the 5.875% Senior Secured Notes due 2024, (ii) the 7.50% Senior Secured Notes due 2027, (iii) the 6.125% Senior Secured Notes due 2029 and (iv) the Credit Agreement (as defined below) and related loan documents are secured on a pari passu basis by a first priority lien (subject to certain permitted liens) on the collateral securing such instruments, which collateral represents substantially all of the assets of the issuers or borrowers and guarantors party thereto (subject to customary exceptions). The obligations under the 9.50% Senior Secured Second Lien Notes due 2027 are secured by a second priority lien (subject to certain permitted liens) on, and on a junior basis with respect to, the collateral securing the obligations under the Credit Agreement, the 5.875% Senior Secured Notes due 2024, the 7.50% Senior Secured Notes due 2027 and the 6.125% Senior Secured Notes due 2029 and the related guarantees. Our senior unsecured notes are unsecured and effectively subordinated in right of priority to the obligations under the Credit Agreement, the 5.875% Senior Secured Notes due 2024, the 7.50% Senior Secured Notes due 2027, the 9.50% Senior Secured Second Lien Notes due 2027 and the 6.125% Senior Secured Notes due 2029, in each case to the extent of the value of the collateral securing such instruments.

The aggregate estimated fair value of the Company’s long-term debt, which was estimated using inputs based on quoted market prices for the same or similar debt issuances, was $5.1 billion and $8.0 billion at September 30, 2022 and December 31, 2021, respectively. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.

Credit Facilities

The Company and certain of its subsidiaries are party to the Credit Agreement, which immediately following the March 2021 Refinancing Transactions (as defined and further described below) provided for (i) a $1,000.0 million senior secured revolving credit facility (the Revolving Credit Facility) and (ii) a $2,000.0 million senior secured term loan facility (the Term Loan Facility and, together with the Revolving Credit Facility, the Credit Facilities). Current amounts outstanding as of September 30, 2022 under the Credit Facilities are set forth in the table above. As of September 30, 2022, $76.0 million of commitments under the Revolving Credit Facility have matured and $924.0 million of commitments have been terminated as a result of the Chapter 11 Cases.

Covenants, Events of Default and Bankruptcy-Related Matters

As further described below and in the Annual Report, the agreements relating to our outstanding indebtedness contain certain covenants and events of default.

Beginning during the second quarter of 2022, we elected to not make the following interest payments on or prior to their scheduled due dates: (i) approximately $38 million that was due on June 30, 2022 with respect to our outstanding 6.00% Senior Notes due 2028; (ii) approximately $2 million that was due on July 15, 2022 with respect to our outstanding 5.375% Senior Notes due 2023 and 6.00% Senior Notes due 2023; (iii) approximately $45 million that was due on July 31, 2022 with respect to our outstanding 9.50% Senior Secured Second Lien Notes due 2027; and (iv) approximately $1 million that was due on August 1, 2022 with respect to our outstanding 6.00% Senior Notes due 2025. Under each of the indentures governing these notes, we had a 30-day grace period from the respective due dates to make these interest payments before such non-payments constituted events of default with respect to such notes. We chose to enter these grace periods while continuing discussions with certain creditors in connection with our evaluation of strategic alternatives. Our decision to enter these grace periods was not driven by liquidity constraints. We made the interest payment of approximately $38 million that became due on June 30, 2022 with respect to our outstanding 6.00% Senior Notes due 2028 on July 28, 2022, which was prior to the end of the applicable grace period. We also made the interest payments totaling approximately $2 million that became due on July 15, 2022 with respect to our outstanding 5.375% Senior Notes due 2023 and 6.00% Senior Notes due 2023 on August 11, 2022, which was prior to the end of the applicable grace periods.

On the Petition Date, the Debtors filed voluntary petitions for relief under the Bankruptcy Code, which constituted an event of default that accelerated our obligations under substantially all of our then-outstanding debt instruments. However, section 362 of the Bankruptcy Code stays the creditors from taking any action to enforce the related financial obligations and the creditors’ rights of enforcement in respect of the debt instruments are subject to the applicable provisions of the Bankruptcy Code.

The transactions contemplated by the RSA are subject to approval by the Bankruptcy Court, among other conditions. Accordingly, no assurance can be given that the transactions described therein will be consummated. Because the Company has not yet obtained approval by the Bankruptcy Court regarding such transactions, there remains uncertainty with respect to the ability of our creditors, including our secured and unsecured debt holders, to recover the full amount of their claims against us. As a result, all secured and unsecured debt instruments have been classified as Liabilities subject to compromise in our Condensed Consolidated Balance Sheets as of September 30, 2022 and we ceased the recognition of interest expense related to these instruments as of the Petition Date. During the third quarter of 2022, we did not recognize approximately $77 million of contractual interest expense that would have been recognized if not for the Chapter 11 Cases.

As part of the RSA that is further discussed in Note 2. Bankruptcy Proceedings, the Company and the Ad Hoc First Lien Group agreed on the terms of a proposed order authorizing the Company’s use of cash collateral (as modified and entered by the Bankruptcy Court on a final (amended) basis in October 2022, the Cash Collateral Order) in connection with the Chapter 11 Cases on certain terms and conditions set forth therein.

Pursuant to the Cash Collateral Order, we are obligated to make certain adequate protection payments during our bankruptcy proceedings on each of our First Lien Debt Instruments. These adequate protection payments include the payment of amounts equal to any accrued and unpaid interest that existed as of the Petition Date by no later than eight business days after entry of the interim Cash Collateral Order, as well as the following payments, to be paid on the last business day of each calendar month, calculated based upon a rate of:

•with respect to the Revolving Credit Facility and the Term Loan Facility, 200 basis points plus: (i) if denominated in dollars, ABR plus the Applicable Rate (each as defined in the Credit Agreement), or (ii) if denominated in Canadian dollars, the Canadian Prime Rate plus the Applicable Rate (each as defined in the Credit Agreement); and

•with respect to the applicable senior secured notes, 100 basis points plus the applicable rate of interest set forth on the face of the applicable note.

The rates in the foregoing bullet points, which are used to calculate any applicable adequate protection payments, are expressed as a percentage of the contractual principal amounts outstanding without consideration of any reductions related to adequate protection payments. On a cumulative basis through September 30, 2022, we made the following adequate protection payments pursuant to the Cash Collateral Order:

•$4.0 million with respect to the Revolving Credit Facility;

•$37.1 million with respect to the Term Loan Facility; and

•$127.5 million with respect to the applicable senior secured notes.

As required by ASC 852, these adequate protection payments are recorded as a reduction of the carrying amount of the respective First Lien Debt Instruments, which are classified as Liabilities subject to compromise. This accounting treatment is due to the aforementioned uncertainties with respect to the ultimate outcome of the bankruptcy proceedings, including the proposed sale transaction, which in turn creates uncertainties surrounding the first lien debt holders’ ability to recover in full the amount of outstanding principal associated with those instruments. Some or all of the adequate protection payments may later be recharacterized as interest expense depending upon certain developments in the Chapter 11 Cases.

In addition to the terms described above, the Cash Collateral Order among other things establishes a budget for the Company’s use of cash collateral, establishes certain informational rights for the Company’s secured creditors and provides for the waiver of certain Bankruptcy Code provisions. The foregoing description of the Cash Collateral Order does not purport to be complete and is qualified in its entirety by reference to the Cash Collateral Order entered by the Bankruptcy Court in the Chapter 11 Cases.

Debt Financing Transactions

Set forth below are certain disclosures relating to debt financing transactions that occurred during the nine months ended September 30, 2022 or the year ended December 31, 2021. For additional disclosures relating to debt financing transactions that occurred during the year ended December 31, 2021, refer to Note 15. Debt in the Consolidated Financial Statements included in Part IV, Item 15 of the Annual Report.

March 2021 Refinancing

In March 2021, the Company executed certain transactions (the March 2021 Refinancing Transactions) that included:

•refinancing in full its previously-existing term loans, which had approximately $3,295.5 million of principal outstanding immediately before refinancing (the Existing Term Loans), with the proceeds from: (i) a new $2,000.0 million term loan (the Term Loan Facility) and (ii) $1,295.0 million of newly issued 6.125% Senior Secured Notes due 2029 (collectively, the Term Loan Refinancing);

•extending the maturity of approximately $675.3 million of existing revolving commitments under the Revolving Credit Facility to March 2026; and

•making certain other modifications to the credit agreement that was in effect immediately prior to the March 2021 Refinancing Transactions (the Prior Credit Agreement).

The changes to the Credit Facilities and the Prior Credit Agreement were effected pursuant to an amendment and restatement agreement entered into by the Company in March 2021 (the Restatement Agreement), which amended and restated the Prior Credit Agreement (as amended and restated by the Restatement Agreement, the Credit Agreement), among Endo International plc, certain of its subsidiaries, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, issuing bank and swingline lender.

The $2,000.0 million portion of the Term Loan Refinancing associated with the new term loan was accounted for as a debt modification, while the $1,295.0 million portion associated with the new notes issued was accounted for as an extinguishment. During the first quarter of 2021, in connection with the Term Loan Refinancing, $7.8 million of deferred and unamortized costs associated with the Existing Term Loans, representing the portion associated with the extinguishment, was charged to expense and is included in the Loss on extinguishment of debt line item in the Condensed Consolidated Statements of Operations. The Company also incurred an additional $56.7 million of new costs and fees, of which: (i) $29.2 million and $17.6 million were initially deferred to be amortized as interest expense over the terms of the Term Loan Facility and the newly issued 6.125% Senior Secured Notes due 2029, respectively; (ii) $6.0 million was considered debt extinguishment costs and was charged to expense in the first quarter of 2021 and is included in the Loss on extinguishment of debt line item in the Condensed Consolidated Statements of Operations; and (iii) $3.9 million was considered debt modification costs and was charged to expense in the first quarter of 2021 and is included in the Selling, general and administrative expense line item in the Condensed Consolidated Statements of Operations. The deferred amounts were being amortized as interest expense until the initiation of our bankruptcy proceedings during the third quarter of 2022, at which time the remaining unamortized costs were expensed as Reorganization items, net in the Condensed Consolidated Statements of Operations.

During the first quarter of 2021, the Company also incurred $2.1 million of new costs and fees associated with the extension of the Revolving Credit Facility, which have been deferred and are being amortized as interest expense over the new term of the Revolving Credit Facility.

October 2021 Revolving Credit Facility Repayment and January 2022 Senior Notes Repayments

In October 2021, commitments under the Revolving Credit Facility of approximately $76.0 million matured, thereby reducing the remaining commitments outstanding under the Revolving Credit Facility. This maturity, which reduced the remaining credit available under the Revolving Credit Facility, occurred because the 7.25% Senior Notes due 2022 and the 5.75% Senior Notes due 2022 were not refinanced or repaid in full prior to the date that was 91 days prior to their January 15, 2022 maturity dates. As a result of this maturity, the Company repaid approximately $22.8 million of borrowings in October 2021, representing the amount that had been borrowed pursuant to these matured commitments. The 7.25% Senior Notes due 2022 and the 5.75% Senior Notes due 2022 were repaid in January 2022.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 15. COMMITMENTS AND CONTINGENCIES

Legal Proceedings and Investigations

We and certain of our subsidiaries are involved in various claims, legal proceedings and internal and governmental investigations (collectively, proceedings) arising from time to time, including, among others, those relating to product liability, intellectual property, regulatory compliance, consumer protection, tax and commercial matters. An adverse outcome in any of these proceedings could have a material adverse effect on our business, financial condition, results of operations and cash flows. We are also subject to a number of matters that are not being disclosed herein because, in the opinion of our management, these matters are immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows.

As further discussed in Note 2. Bankruptcy Proceedings, on the Petition Date, the Debtors filed voluntary petitions for relief under the Bankruptcy Code. Under the Bankruptcy Code, third-party actions to collect pre-petition indebtedness owed by the Debtors, as well as most litigation pending against the Debtors as of the Petition Date, are generally subject to an automatic stay. However, under the Bankruptcy Code, certain legal proceedings, such as those involving the assertion of a governmental entity’s police or regulatory powers, may not be subject to the automatic stay and may continue unless otherwise ordered by the Bankruptcy Court. As a result, some proceedings may continue (or certain parties may attempt to argue that such proceedings should continue) notwithstanding the automatic stay. Where no stay is in place or expected, and in the event the stays in place were to be lifted, we intend to vigorously prosecute or defend our position as appropriate. We cannot predict the outcome of any proceeding, and there can be no assurance that we will be successful or obtain any requested relief.

We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability or other matters are or may be covered in whole or in part under our insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the realization of the potential claim for recovery is considered probable.

Notwithstanding the foregoing, amounts recovered under our insurance policies could be materially less than stated coverage limits and may not be adequate to cover damages, other relief and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims in the amounts we expect or that coverage will otherwise be available. We may not have and may be unable to obtain or maintain insurance on acceptable terms or with adequate coverage against potential liabilities or other losses, including costs, judgments, settlements and other liabilities incurred in connection with current or future legal proceedings, regardless of the success or failure of the claim. For example, we do not have insurance sufficient to satisfy all of the opioid claims that have been made against us and, should we suffer an adverse judgment, appeal and similar bonds may not be available in such amounts as may be necessary to further challenge all or part of such judgment. We also generally no longer have product liability insurance to cover claims in connection with the mesh-related litigation described herein. Additionally, we may be limited by the surviving insurance policies of acquired entities, which may not be adequate to cover potential liabilities or other losses. Even where claims are submitted to insurance carriers for defense and indemnity, there can be no assurance that the claims will be covered by insurance or that the indemnitors or insurers will remain financially viable or will not challenge our right to reimbursement in whole or in part. The failure to generate sufficient cash flow or to obtain other financing could affect our ability to pay amounts due under those liabilities not covered by insurance. Additionally, the nature of our business, the legal proceedings to which we are exposed and any losses we suffer may increase the cost of insurance, which could impact our decisions regarding our insurance programs.

As of September 30, 2022, our accrual for loss contingencies totaled $794.6 million, the most significant components of which relate to: (i) product liability and related matters associated with transvaginal surgical mesh products, which we have not sold since March 2016 and (ii) various opioid-related matters as further described herein. Although we believe there is a possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time. As of September 30, 2022, our entire accrual for loss contingencies is classified as Liabilities subject to compromise in the Condensed Consolidated Balance Sheets. As a result of the automatic stay under the Bankruptcy Code and the uncertain treatment of these liabilities pursuant to a chapter 11 plan or otherwise, the timing and amount of payment, if any, related to the amounts accrued for loss contingencies is uncertain.

As part of the Chapter 11 Cases, persons and entities believing that they have claims or causes of action against the Debtors, including litigants, may file proofs of claim evidencing such claims. The Debtors have not yet set a bar date (deadline) for holders of claims to file proofs of claim.

At the Company’s request, the Bankruptcy Court has appointed a future claims representative (FCR) in the Company’s Chapter 11 Cases. As further described in the applicable bankruptcy court filings, the FCR represents the rights of individuals who may in the future assert one or more claims against the Company or a successor of the Company’s businesses for personal injury based on the Company’s opioid, transvaginal mesh or ranitidine products, but who could not assert such claims in the Chapter 11 Cases because, among other reasons, the claimant was unaware of the alleged injury, had a latent manifestation of the alleged injury or was otherwise unable to assert or incapable of asserting the claims based on the alleged injury.

Vaginal Mesh Matters

Since 2008, we and certain of our subsidiaries, including American Medical Systems Holdings, Inc. (AMS) (subsequently converted to Astora Women’s Health Holding LLC and merged into Astora Women’s Health LLC and referred to herein as AMS and/or Astora), have been named as defendants in multiple lawsuits in various state and federal courts in the U.S., Canada, Australia and other countries, alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). We have not sold such products since March 2016. Plaintiffs claim a variety of personal injuries, including chronic pain, incontinence, inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.

At various times from June 2013 through the Petition Date, the Company and/or certain of its subsidiaries entered into various Master Settlement Agreements (MSAs) and other agreements intended to resolve approximately 71,000 filed and unfiled U.S. mesh claims. These MSAs and other agreements were solely by way of compromise and settlement and were not an admission of liability or fault by us or any of our subsidiaries. All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of QSFs into which the settlement funds are deposited, establish participation requirements and allow for a reduction of the total settlement payment in the event participation thresholds are not met. In certain circumstances, participation requirements or other conditions for payment were not satisfied prior to the Petition Date. Funds deposited in QSFs are considered restricted cash and/or restricted cash equivalents. Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating product use, the dismissal of any lawsuit and the release of the claim as to us and all affiliates. Prior to receiving funds, an individual claimant must represent and warrant that liens, assignment rights or other claims identified in the claims administration process have been or will be satisfied by the individual claimant. Confidentiality provisions apply to the settlement funds, amounts allocated to individual claimants and other terms of the agreements.

The following table presents the changes in the mesh-related QSFs and liability accrual balances during the nine months ended September 30, 2022 (in thousands):


	Mesh Qualified Settlement Funds		Mesh Liability Accrual
Balance as of December 31, 2021	$	78,402	$	258,137

Cash received for reversionary interests, net of cash contributions to Qualified Settlement Funds	(367)		—
Cash distributions to settle disputes from Qualified Settlement Funds	(20,089)		(20,089)
Other cash distributions to settle disputes	—		(6,499)
Other (1)	149		(820)
Balance as of September 30, 2022 (2)	$	58,095	$	230,729

__________

(1)Amounts deposited in the QSFs earn interest from time to time that is reflected in the table above as an increase to the QSF and Mesh Liability Accrual balances. Subject to any restrictions on making payments as a result of the Chapter 11 Cases, such interest is generally used to pay administrative costs of the funds and any interest remaining after all claims have been paid will generally be distributed to the claimants who participated in that settlement. Also included within this line are foreign currency adjustments for settlements not denominated in U.S. dollars.

(2)As of September 30, 2022, this balance is classified as Liabilities subject to compromise in the Condensed Consolidated Balance Sheets.

Charges related to vaginal mesh liability and associated legal fees and other expenses for all periods presented are reported in Discontinued operations, net of tax in our Condensed Consolidated Statements of Operations.

As of September 30, 2022, the Company has made total cumulative mesh liability payments of approximately $3.6 billion, $58.1 million of which remains in the QSFs as of September 30, 2022. In light of the filing of petitions for relief under the Bankruptcy Code, we do not expect to make new payments under previously executed mesh settlement agreements within the next 12 months. As funds are disbursed out of the QSFs from time to time, the liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents.

As of the Petition Date, mesh personal injury claims against AMS and Astora in the U.S. became subject to the automatic stay, and a similar cessation of litigation activity is in place in some other countries. In certain other countries where no stay is in place, and in the event the stays in place were to be lifted, we will continue to vigorously defend any unresolved claims and to explore other options as appropriate in our best interests.

We were contacted in October 2012 regarding a civil investigation initiated by various U.S. state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and we subsequently received additional subpoenas from California and other states. We are cooperating with the investigations.

Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any additional losses that could be incurred.

Although the Company believes it has appropriately estimated the probable total amount of loss associated with all mesh-related matters as of the date of this report, it is reasonably possible that adjustments to our overall liability accrual may be required. This could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Opioid-Related Matters

Since 2014, multiple U.S. states as well as other governmental persons or entities and private plaintiffs in the U.S. and Canada have filed suit against us and/or certain of our subsidiaries, including Endo Health Solutions Inc. (EHSI), Endo Pharmaceuticals Inc. (EPI), Par Pharmaceutical, Inc. (PPI), Par Pharmaceutical Companies, Inc. (PPCI), Endo Generics Holdings, Inc. (EGHI), Vintage Pharmaceuticals, LLC, Generics Bidco I, LLC, DAVA Pharmaceuticals, LLC, Par Sterile Products, LLC (PSP LLC) and in Canada, Paladin and Endo Ventures Limited, as well as various other manufacturers, distributors, pharmacies and/or others, asserting claims relating to the defendants’ alleged sales, marketing and/or distribution practices with respect to prescription opioid medications, including certain of our products. As of November 1, 2022, pending cases in the U.S. of which we were aware include, but are not limited to, approximately 15 cases filed by or on behalf of states; approximately 2,570 cases filed by counties, cities, Native American tribes and/or other government-related persons or entities; approximately 310 cases filed by hospitals, health systems, unions, health and welfare funds or other third-party payers and approximately 220 cases filed by individuals, including but not limited to legal guardians of children born with neonatal abstinence syndrome. Certain of the U.S. cases are putative class actions. The Canadian cases include an action filed by British Columbia on behalf of a proposed class of all federal, provincial and territorial governments and agencies in Canada that paid healthcare, pharmaceutical and treatment costs related to opioids; an action filed in Alberta by the City of Grand Prairie, Alberta, and The Corporation of the City of Brantford, Ontario, on behalf of a proposed class of all local or municipal governments in Canada; an action filed in Saskatchewan by the Peter Ballantyne Cree Nation and the Lac La Ronge Indian Band, on behalf of a proposed class of all First Nations communities and local or municipal governments in Canada; and three additional putative class actions, filed in British Columbia, Ontario and Quebec, seeking relief on behalf of Canadian residents who were prescribed and/or consumed opioid medications.

The complaints in the cases assert a variety of claims, including but not limited to statutory claims asserting violations of public nuisance, consumer protection, unfair trade practices, racketeering, Medicaid fraud and/or drug dealer liability laws and/or common law claims for public nuisance, fraud/misrepresentation, strict liability, negligence and/or unjust enrichment. The claims are generally based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications and/or alleged failures to take adequate steps to identify and report suspicious orders and to prevent abuse and diversion. Plaintiffs seek various remedies including, without limitation, declaratory and/or injunctive relief; compensatory, punitive and/or treble damages; restitution, disgorgement, civil penalties, abatement, attorneys’ fees, costs and/or other relief. The damages sought exceed our applicable insurance.

Many of the U.S. cases have been coordinated in a federal multidistrict litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio; however, in April 2022, the Judicial Panel on Multidistrict Litigation issued an order suggesting that, based on the progress of the MDL, it would no longer transfer new cases filed in or removed to federal court to the MDL. Other cases are pending in various federal or state courts. As of the Petition Date, litigation activity against the Company and its subsidiaries ceased in nearly all pending cases as a result of the automatic stay. A similar cessation of litigation activity is in place in Canada. One plaintiff, the State of Oregon, has taken the position that the automatic stay does not apply to its case, but has nevertheless agreed to suspend further litigation pending resolution of a motion for a preliminary injunction in the Bankruptcy Court that, if granted, would confirm that opioid cases brought by public plaintiffs may not proceed during the pendency of the bankruptcy proceedings.

In September 2019, EPI, EHSI, PPI and PPCI received subpoenas from the New York State Department of Financial Services (DFS) seeking documents and information regarding the marketing, sale and distribution of opioid medications in New York. In June 2020, DFS commenced an administrative action against the Company, EPI, EHSI, PPI and PPCI alleging violations of the New York Insurance Law and New York Financial Services Law. In July 2021, DFS filed an amended statement of charges. The amended statement of charges alleges that fraudulent or otherwise wrongful conduct in the marketing, sale and/or distribution of opioid medications caused false claims to be submitted to insurers. DFS seeks civil penalties for each allegedly fraudulent prescription as well as injunctive relief. In July 2021, EPI, EHSI, PPI and PPCI, among others, filed a petition in New York state court seeking to prohibit DFS from proceeding with its administrative enforcement action. In December 2021, DFS filed a motion to dismiss that petition, which the court granted in June 2022. The Company’s subsidiaries, among others, appealed that ruling in July 2022. Both the appeal and the DFS administrative matter were stayed following commencement of the Chapter 11 Cases.

Between 2019 and the Petition Date, the Company and/or certain of its subsidiaries executed a number of settlement agreements to resolve governmental opioid claims brought by certain states, counties, cities and/or other governmental entities. Certain related developments include but are not limited to the following:

•In September 2019, EPI, EHSI, PPI and PPCI executed a settlement agreement with two Ohio counties providing for payments totaling $10 million and up to $1 million of VASOSTRICT® and/or ADRENALIN®. The settlement amount was paid during the third quarter of 2019.

•In January 2020, EPI and PPI executed a settlement agreement with the state of Oklahoma providing for a payment of $8.75 million. The settlement amount was paid during the first quarter of 2020.

•In August 2021, EPI, EHSI, nine counties in eastern Tennessee, eighteen municipalities within those counties and a minor individual executed a settlement agreement providing for a payment of $35 million. The settlement amount was paid during the third quarter of 2021.

•In September 2021, Endo International plc, EPI, EHSI, PPI and PPCI executed a settlement agreement with the state of New York and two of its counties providing for a payment of $50 million. The settlement amount was paid during the third quarter of 2021.

•In October 2021, EPI and EHSI executed a settlement agreement with the Alabama Attorney General’s office intended to resolve opioid-related cases and claims of the state and other Alabama governmental persons and entities in exchange for a total payment of $25 million, subject to certain participation thresholds. The settlement amount was not paid as of the Petition Date and, as a result of the Chapter 11 Cases, it is not known when or if such amount will be paid.

•In December 2021, Endo International plc, EPI, EHSI, PPI and PPCI executed a settlement agreement with the Texas Attorney General’s office and four Texas counties intended to resolve opioid-related cases and claims of the state and other Texas governmental persons and entities in exchange for a total payment of $63 million, subject to certain participation thresholds. The settlement amount was deposited into a QSF during the first quarter of 2022.

•In January 2022, EPI and EHSI executed a settlement agreement with the Florida Attorney General’s office intended to resolve opioid-related cases and claims of the state and other Florida governmental persons and entities in exchange for a total payment of up to $65 million, subject to certain participation thresholds. The settlement amount was deposited into a QSF during the second quarter of 2022.

•In February 2022, EPI and EHSI executed a settlement agreement with the Louisiana Attorney General’s office intended to resolve opioid-related cases and claims of the state and other Louisiana governmental persons and entities in exchange for a total payment of $7.5 million, subject to certain participation thresholds. The settlement amount was not paid as of the Petition Date and, as a result of the Chapter 11 Cases, it is not known when or if such amount will be paid.

•In March 2022, EPI, EHSI and PPI executed a settlement agreement with the West Virginia Attorney General’s office intended to resolve opioid-related cases and claims of the state and other West Virginia governmental persons and entities in exchange for a total payment of $26 million, subject to certain participation thresholds. The settlement amount was not paid as of the Petition Date and, as a result of the Chapter 11 Cases, it is not known when or if such amount will be paid.

•In June 2022, EPI and EHSI executed a settlement agreement with the Arkansas Attorney General’s office and certain Arkansas local governments intended to resolve opioid-related cases and claims of the state and other Arkansas governmental persons and entities in exchange for a total payment of $9.75 million, subject to certain participation thresholds. With the exception of certain amounts held back pursuant to an MDL common benefit fund order, the settlement amount was paid during the third quarter of 2022.

•In July 2022, EPI and EHSI executed a settlement agreement with the Mississippi Attorney General’s office intended to resolve opioid-related cases and claims of the state and other Mississippi governmental persons and entities in exchange for a total payment of $9 million, subject to certain participation thresholds. The settlement amount was not paid as of the Petition Date and, as a result of the Chapter 11 Cases, it is not known when or if such amount will be paid.

•In July 2022, EPI, EHSI, PPI and PPCI executed a settlement agreement with the City and County of San Francisco providing for an initial payment of $5 million and subsequent payments of $500,000 a year over ten years. The settlement amount was not paid as of the Petition Date and, as a result of the Chapter 11 Cases, it is not known when or if such amount will be paid.

While the specific terms of the agreements vary, each agreement was solely by way of compromise and settlement and was not in any way an admission of wrongdoing, fault or liability of any kind by us or any of our subsidiaries. Certain settlement agreements provided for the creation of QSFs, the repayment of some or all of the settlement amount under certain conditions and/or additional payments in the event certain conditions were met. Depending on the terms of the respective agreements, funds deposited in QSFs have been and may continue to be considered restricted cash and/or restricted cash equivalents for a period of time subsequent to the initial funding. Distribution of funds from the QSFs is conditioned upon certain criteria that vary by agreement.

Certain of the settlement agreements described above provide for injunctive relief. The RSA also provides for certain voluntary injunctive terms that bind the Company during the course of the bankruptcy proceedings and would apply to any purchaser of our opioid business in conjunction with the bankruptcy proceedings.

The Stalking Horse Bid provides for the establishment by the Purchaser of voluntary opioid trusts for the benefit of certain public, tribal and private opioid claimants in exchange for releases to be provided to (among others) the Purchaser and Endo International plc, its subsidiaries and affiliated entities and persons. The trusts would distribute up to a total of $550 million over ten years to eligible claimants that opt into the trust agreements by specified participation deadlines. Under the proposed public claimant opioid trust, states which have previously reached settlement agreements and received payments from us may elect to participate in the trust. In doing so, those states would agree to return the amounts previously received, net of the amounts allocated to them in the trust agreement and would receive in return a release from any claim for the return of settlement funds under the applicable section of the Bankruptcy Code. The Company would have no obligation or liability with respect to the voluntary trusts, which would be funded exclusively by the Purchaser. As previously noted, the Stalking Horse Bid is subject to higher or otherwise better bids from other parties and therefore there is no certainty regarding whether the proposed sale transaction to the Purchaser, and the funding of the voluntary opioid trusts by the Purchaser, will actually occur.

Although the proposed voluntary opioid trusts would be funded by the Purchaser, and not by the Company or any of its subsidiaries, we believe the proposed funding amount represents the best estimate of liability relating to the contingencies associated with various opioid claims against the Company and its subsidiaries. We therefore recorded charges of approximately $419 million and $429 million during the three and nine months ended September 30, 2022, respectively, to adjust our aggregate opioid liability accrual to approximately $550 million as of September 30, 2022.

To the extent unresolved, and in the event stays in place were to be lifted, we will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests, which may include entering into settlement negotiations and settlements even in circumstances where we believe we have meritorious defenses. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

In addition to the lawsuits and administrative matters described above, the Company and/or its subsidiaries have received certain subpoenas, civil investigative demands (CIDs) and informal requests for information concerning the sale, marketing and/or distribution of prescription opioid medications, including but not limited to the following:

Various state attorneys general have served subpoenas and/or CIDs on EHSI and/or EPI. Some of these state attorneys general subsequently filed lawsuits against the Company and/or its subsidiaries; others have indicated their support for the opioid trusts described above. To the extent any state attorney general investigations are continuing, we are cooperating with them.

In January 2018, EPI received a federal grand jury subpoena from the U.S. District Court for the Southern District of Florida seeking documents and information related to OPANA® ER, other oxymorphone products and marketing of opioid medications. We are cooperating with the investigation.

In December 2020, the Company received a subpoena issued by the U.S. Attorney’s Office for the Western District of Virginia seeking documents related to McKinsey & Company. The Company received a related subpoena in May 2021, also issued by the U.S. Attorney’s Office for the Western District of Virginia. We are cooperating with the investigation.

Similar investigations may be brought by others or the foregoing matters may be expanded or result in litigation. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Ranitidine Matters

In June 2020, an MDL pending in the U.S. District Court for the Southern District of Florida, In re Zantac (Ranitidine) Products Liability Litigation, was expanded to add PPI and numerous other manufacturers and distributors of generic ranitidine as defendants. The claims are generally based on allegations that under certain conditions the active ingredient in ranitidine medications can break down to form an alleged carcinogen known as N-Nitrosodimethylamine (NDMA). The complaints assert a variety of claims, including but not limited to various product liability, breach of warranty, fraud, negligence, statutory and unjust enrichment claims. Plaintiffs generally seek various remedies including, without limitation, compensatory, punitive and/or treble damages; restitution, disgorgement, civil penalties, abatement, attorneys’ fees and costs as well as injunctive and/or other relief. Similar complaints against various defendants, in some instances including PPI, have also been filed in certain state courts, including but not limited to California, Illinois and Pennsylvania. Neither PPI nor its subsidiaries have manufactured or sold ranitidine since 2016.

The MDL court has issued various case management orders, including orders directing the filing of “master” and short-form complaints, establishing a census registry process for potential claimants and addressing various discovery issues. In December 2020, the court dismissed the master complaints as to PPI and other defendants with leave to amend certain claims. Certain plaintiffs, including third-party payers pursuing class action claims, appealed the dismissal orders to the U.S. Court of Appeals for the Eleventh Circuit. In February 2021, various other plaintiffs filed an amended master personal injury complaint, a consolidated amended consumer economic loss class action complaint and a consolidated medical monitoring class action complaint. PPI was not named as a defendant in the consumer economic loss complaint or the medical monitoring complaint. In July 2021, the MDL court dismissed all claims in the master complaints as to PPI and other generic defendants with prejudice on federal preemption grounds. In November 2021, the MDL court issued a final judgment as to PPI and other generic defendants. Certain MDL plaintiffs appealed the July 2021 dismissal order and/or the November 2021 judgment.

In July 2022, claimants who alleged certain types of injuries were “exited” from the MDL census registry. Some of these claimants subsequently filed lawsuits in various courts.

As of the Petition Date, the claims against PPI became subject to the automatic stay. Thereafter, PPI was voluntarily dismissed from several pending matters, including the appeal from the MDL court’s dismissal of the third-party payer class action complaint.

In the event the stays in place were to be lifted, we will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Generic Drug Pricing Matters

Since March 2016, various private plaintiffs, state attorneys general and other governmental entities have filed cases against our subsidiary PPI and/or, in some instances, the Company, Generics Bidco I, LLC, DAVA Pharmaceuticals, LLC, DAVA International, LLC, EPI, EHSI and/or PPCI, as well as other pharmaceutical manufacturers and, in some instances, other corporate and/or individual defendants, alleging price-fixing and other anticompetitive conduct with respect to generic pharmaceutical products. These cases, which include proposed class actions filed on behalf of direct purchasers, end-payers and indirect purchaser resellers, as well as non-class action suits, have generally been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Pennsylvania; three cases commenced by writ of summons in Pennsylvania state court are in deferred status. There is also a proposed class action filed in the Federal Court of Canada on behalf of a proposed class of Canadian purchasers.

The various complaints and amended complaints generally assert claims under federal and/or state antitrust law, state consumer protection statutes and/or state common law, and seek damages, treble damages, civil penalties, disgorgement, declaratory and injunctive relief, costs and attorneys’ fees. Some claims are based on alleged product-specific conspiracies; other claims allege broader, multiple-product conspiracies. Under these overarching conspiracy theories, plaintiffs generally seek to hold all alleged participants in a particular conspiracy jointly and severally liable for all harms caused by the alleged conspiracy, not just harms related to the products manufactured and/or sold by a particular defendant.

The MDL court has issued various case management and substantive orders, including orders denying certain motions to dismiss in whole or in part, and discovery is ongoing.

As of the Petition Date, the claims against the Company and its subsidiaries in the U.S. became subject to the automatic stay. A similar cessation of litigation activity is in place in Canada.

In December 2014, our subsidiary PPI received from the Antitrust Division of the U.S. Department of Justice (DOJ) a federal grand jury subpoena issued by the U.S. District Court for the Eastern District of Pennsylvania addressed to “Par Pharmaceuticals.” The subpoena requested documents and information focused primarily on product and pricing information relating to the authorized generic version of Lanoxin® (digoxin) oral tablets and generic doxycycline products, and on communications with competitors and others regarding those products. We are cooperating with the investigation.

In May 2018, we and our subsidiary PPCI each received a CID from the DOJ in relation to a False Claims Act investigation concerning whether generic pharmaceutical manufacturers engaged in price-fixing and market allocation agreements, paid illegal remuneration and caused the submission of false claims. We are cooperating with the investigation.

Other Antitrust Matters

Beginning in June 2014, multiple alleged purchasers of OPANA® ER sued our subsidiaries EHSI and EPI; Penwest Pharmaceuticals Co. (Penwest), which our subsidiary EPI had acquired; and Impax Laboratories, LLC (formerly Impax Laboratories, Inc. and referred to herein as Impax), alleging among other things violations of antitrust law arising out of an agreement between EPI and Impax to settle certain patent infringement litigation. Some cases were filed on behalf of putative classes of direct and indirect purchasers; others were non-class action suits. The cases were consolidated and/or coordinated in a federal MDL pending in the U.S. District Court for the Northern District of Illinois. The various complaints asserted claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally sought damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. In June 2021, the court certified a direct purchaser class and an end-payer class; in August 2021, following an appeal, the district court amended its class certification order to certify a narrower end-payer class. Trial on all plaintiffs’ claims began in June 2022. In July 2022, the jury returned a verdict in favor of EHSI, EPI and Penwest (Impax settled during trial). Later that month, plaintiffs filed a motion for judgment as a matter of law or in the alternative for a new trial. As of the Petition Date, the matter became subject to the automatic stay.

Beginning in February 2009, the U.S. Federal Trade Commission (FTC) and certain private plaintiffs sued our subsidiaries PPCI (since June 2016, EGHI) and/or PPI as well as other pharmaceutical companies alleging violations of antitrust law arising out of the settlement of certain patent litigation concerning the generic version of AndroGel® and seeking damages, treble damages, equitable relief and attorneys’ fees and costs. The cases were consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of Georgia. In May 2016, plaintiffs representing a putative class of indirect purchasers voluntarily dismissed their claims with prejudice. In February 2017, the FTC voluntarily dismissed its claims against EGHI with prejudice. In June 2018, the MDL court granted in part and denied in part various summary judgment and evidentiary motions filed by defendants. In particular, among other things, the court rejected two of the remaining plaintiffs’ causation theories and rejected damages claims related to AndroGel® 1.62%. In July 2018, the court denied certain plaintiffs’ motion for certification of a direct purchaser class. Between November 2019 and April 2021, PPI and PPCI entered into settlement agreements with all of the plaintiffs remaining in the MDL. The settlement agreements were solely by way of compromise and settlement and were not in any way an admission of wrongdoing, fault or liability of any kind. Separately, in August 2019, several alleged direct purchasers filed suit against PPI and other pharmaceutical companies in the U.S. District Court for the Eastern District of Pennsylvania asserting claims substantially similar to those asserted in the MDL, as well as additional claims against other defendants relating to other alleged conduct. As of the Petition Date, the claims against PPI became subject to the automatic stay.

Beginning in May 2018, multiple complaints were filed in the U.S. District Court for the Southern District of New York against PPI, EPI and/or us, as well as other pharmaceutical companies, alleging violations of antitrust law arising out of the settlement of certain patent litigation concerning the generic version of Exforge® (amlodipine/valsartan). Some cases were filed on behalf of putative classes of direct and indirect purchasers; others are non-class action suits. The various complaints assert claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, equitable relief and attorneys’ fees and costs. In September 2018, the putative class plaintiffs stipulated to the dismissal without prejudice of their claims against EPI and us, and the retailer plaintiffs later did the same. PPI filed a partial motion to dismiss certain claims in September 2018; the court granted the motion in August 2019. In March 2022, the putative class plaintiffs filed motions for class certification. In May 2022, defendants filed motions for summary judgment. As of the Petition Date, the claims against PPI became subject to the automatic stay.

Beginning in August 2019, multiple complaints were filed in the U.S. District Court for the Southern District of New York against PPI and other pharmaceutical companies alleging violations of antitrust law arising out the settlement of certain patent litigation concerning generic versions of Seroquel XR® (extended-release quetiapine fumarate). The claims against PPI are based on allegations that PPI entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals, LLC (Handa) in 2012 pursuant to which Handa assigned to PPI certain rights under a prior settlement agreement between Handa and AstraZeneca resolving certain patent litigation. Some cases were filed on behalf of putative classes of direct and indirect purchasers; others are non-class action suits. The various complaints assert claims under Sections 1 and 2 of the Sherman Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, equitable relief and attorneys’ fees and costs. In August 2020, the litigation was transferred to the U.S. District Court for the District of Delaware. In July 2022, the court dismissed certain claims asserted under state law but otherwise denied defendants’ motions to dismiss. As of the Petition Date, the claims against PPI became subject to the automatic stay.

Beginning in June 2020, multiple complaints were filed against Jazz Pharmaceuticals and other pharmaceutical companies, including PPI, alleging violations of state and/or federal antitrust laws in connection with the settlement of certain patent litigation concerning generic versions of Xyrem® (sodium oxybate). Some cases were filed on behalf of putative classes of indirect purchasers; others are non-class action suits. The cases have generally been consolidated and/or coordinated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Northern District of California; a case filed by Aetna Inc. in May 2022 is pending in California state court. The various complaints allege that Jazz entered into a series of “reverse-payment” settlements, including with PPI, to delay generic competition for Xyrem® and assert claims under Sections 1 and 2 of the Sherman Act, Section 16 of the Clayton Act, state antitrust and consumer protection statutes and/or state common law. Plaintiffs generally seek damages, treble damages, equitable relief and attorneys’ fees and costs. In April 2021, the defendants moved to dismiss the MDL complaints that had been filed as of that time. In August 2021, the MDL court issued an order dismissing certain aspects of the plaintiffs’ claims but otherwise denying the motions to dismiss. In July 2022, PPI, among others, filed a motion to quash the Aetna action for lack of personal jurisdiction; the defendants also filed a demurrer, motion to strike and motion to stay Aetna’s action. As of the Petition Date, the claims against PPI became subject to the automatic stay.

Beginning in June 2021, multiple complaints were filed on behalf of a putative class of direct purchasers in the U.S. District Court for the District of Massachusetts against Takeda Pharmaceuticals, PPI and us, alleging violations of federal antitrust law in connection with the settlement of certain patent litigation related to generic versions of Amitiza® (lubiprostone). The complaints alleged that Takeda and PPI entered into a settlement agreement that delayed the entry of generic Amitiza® and asserted claims under Section 1 and Section 2 of the Sherman Act. Plaintiffs sought damages, treble damages and attorneys’ fees and costs. In September 2021, the plaintiffs voluntarily dismissed all claims against Endo International plc without prejudice. As of the Petition Date, the claims against PPI became subject to the automatic stay. In August 2022, plaintiffs voluntarily dismissed all claims against PPI without prejudice.

In August 2021, a putative class action complaint was filed in the U.S. District Court for the Eastern District of Pennsylvania against Takeda Pharmaceuticals, EPI, PPI and others, alleging violations of federal antitrust law in connection with the settlement of certain patent litigation related to generic versions of Colcrys® (colchicine). In particular, the complaint alleged, among other things, that a distribution agreement between Takeda and PPI with respect to an authorized generic was in effect an output restriction conspiracy; the plaintiff asserted claims under Section 1 and Section 2 of the Sherman Act and sought damages, treble damages and attorneys’ fees and costs. In December 2021, the court dismissed the complaint for failure to state a claim (the plaintiff had already voluntarily dismissed all claims against EPI in November 2021). In January 2022, the plaintiff filed an amended complaint. In February 2022, the defendants filed a motion to dismiss the amended complaint, which the court granted in part and denied in part in March 2022. As of the Petition Date, the claims against PPI became subject to the automatic stay. In September 2022, plaintiffs voluntarily dismissed all claims against PPI with prejudice in exchange for PPI’s agreement to provide certain limited discovery as a non-party.

In January 2021, the FTC filed a lawsuit in the U.S. District Court for the District of Columbia against us, EPI, Impax Laboratories, LLC and Amneal Pharmaceuticals, Inc., generally alleging that the 2017 settlement of a contract dispute between EPI and Impax (now Amneal) constituted unfair competition in violation of Section 5(a) of the FTC Act. The complaint generally sought injunctive and equitable monetary relief. In April 2021, the defendants filed motions to dismiss, which the court granted in March 2022. The FTC filed a notice of appeal in May 2022. Briefing on the appeal has not been stayed and is expected to conclude in the first quarter of 2023.

To the extent unresolved, and in the event the stays in place were to be lifted, we will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Securities Litigation

In June 2020, a putative class action entitled Benoit Albiges v. Endo International plc, Paul V. Campanelli, Blaise Coleman, and Mark T. Bradley was filed in the U.S. District Court for the District of New Jersey by an individual shareholder on behalf of himself and all similarly situated shareholders. The lawsuit alleged violations of Section 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder relating to the marketing and sale of opioid medications and the New York Department of Financial Services’ administrative action against the Company, EPI, EHSI, PPI and PPCI. In September 2020, the court appointed Curtis Laakso lead plaintiff in the action. In November 2020, the plaintiffs filed an amended complaint that among other things added Matthew J. Maletta as a defendant. In January 2021, the defendants filed a motion to dismiss, which the court granted in August 2021. In November 2021, the plaintiffs filed a second amended complaint, which among other things added allegations about discovery issues in certain opioid-related lawsuits. In January 2022, the defendants moved to dismiss the second amended complaint. As of the Petition Date, the claims against the Company became subject to the automatic stay. In August 2022, the court granted the motion and dismissed the case with prejudice. The automatic stay does not apply to the individual defendants, and the plaintiffs’ time to appeal the ruling as to those defendants has run.

Similar matters may be brought by others. We are unable to predict the outcome of any such matters or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Nevakar Matter

In August 2022, Endo Ventures Limited (EVL) filed an adversary proceeding within the ongoing bankruptcy proceedings against Nevakar, Inc. and Nevakar Injectables Inc. (collectively Nevakar) to enforce a 2018 development, license and commercialization agreement (the 2018 Nevakar Agreement) and the 2022 Nevakar Agreement that is further described in Note 11. License, Collaboration and Asset Acquisition Agreements between EVL, on the one hand, and Nevakar, on the other. In this adversary proceeding, EVL alleges that Nevakar breached these agreements, financially harming EVL. EVL also seeks a declaratory judgment that its prior actions did not constitute any incurable material breach that might justify Nevakar’s purported termination of the 2018 Nevakar Agreement. In September 2022, Nevakar filed counterclaims against EVL, alleging that EVL breached the 2018 Nevakar Agreement and seeking a declaratory judgment that Nevakar’s termination of the 2018 Nevakar Agreement was effective. In September 2022, pursuant to a stipulation between the parties, the bankruptcy court entered a consent order preserving the status quo prior to Nevakar’s notice of termination pending a November 2022 trial on the issue of whether Nevakar’s purported termination of the 2018 Nevakar Agreement is effective. Depending on the result of that trial and subsequent litigation of any remaining disputes, adjustments to our overall liability accrual may be required, and there could be a material adverse effect on our business, financial condition, results of operations and cash flows.

Other Government Investigations

In March 2022, EPI received a CID from the Texas Attorney General’s office seeking documents and information related to hormone blocker products. This followed the Texas Attorney General’s December 2021 announcement of an investigation into whether EPI and AbbVie Inc. had advertised or promoted such products, including SUPPRELIN® LA and VANTAS®, for unapproved uses. We are cooperating with the investigation.

Similar investigations may be brought by others or the foregoing matter may be expanded or result in litigation. We are unable to predict the outcome of this matter or to estimate the possible range of any losses that could be incurred. Adjustments to our overall liability accrual may be required in the future, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Patent Matters

Beginning in April 2018, PSP LLC and PPI received notice letters from Eagle Pharmaceuticals, Inc. (Eagle) and other companies advising of the filing by such companies of Abbreviated New Drug Applications (ANDAs)/New Drug Applications (NDAs) for generic versions of VASOSTRICT® (vasopressin IV solution (infusion)) 20 units/ml and/or 200 units/10 ml. Beginning in May 2018, PSP LLC, PPI and Endo Par Innovation Company, LLC (EPIC) filed lawsuits against Eagle and other generic filers in the U.S. District Court for the District of Delaware or New Jersey. We reached settlements and voluntarily dismissed the suits against many of these filers. The remaining Delaware cases against Eagle and Amneal Pharmaceuticals LLC were consolidated and a trial was held in July 2021. In August 2021, the court issued an opinion holding that Eagle’s proposed generic product would not infringe PPI’s asserted patent claims. The court made no finding regarding the validity of the patents. We appealed the ruling. In August 2022, the Federal Circuit affirmed the District of Delaware’s decision (i) that Eagle’s proposed generic product would not infringe PPI’s asserted patent claims and (ii) denying the issuance of a declaratory judgment that Eagle’s planned sale of generic product would infringe under 35 U.S.C. § 271(a) and (b).

During the first quarter of 2022, multiple competitive generic alternatives to VASOSTRICT® 20 units/ml were launched, beginning with Eagle’s generic that was launched at risk and began shipping toward the end of January 2022. Since then, additional competitive alternatives have entered the market, including authorized generics. These launches began to significantly impact both Endo’s market share and product price toward the middle of the first quarter of 2022, and the effects of competition have since increased and are likely to continue to increase throughout 2022 and beyond. This competition could have a material adverse effect on our business, financial condition, results of operations and cash flows.

In March 2022, PSP LLC, PPI and EPIC received a notice letter from Cipla Limited (Cipla) advising of its filing of an ANDA for generic versions of VASOSTRICT® (vasopressin injection) for IV use 40 units/100 ml and 60 units/100 ml. In May 2022, PSP LLC and PPI filed a complaint against Cipla in the District Court of New Jersey, which triggered a 30-month stay of U.S. Food and Drug Administration (FDA) approval of Cipla’s ANDA; that stay expires in September 2024.

Other Proceedings and Investigations

Proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise in the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.

OTHER COMPREHENSIVE (LOSS) INCOME	9 Months Ended
OTHER COMPREHENSIVE (LOSS) INCOME	Sep. 30, 2022
Equity [Abstract]
OTHER COMPREHENSIVE (LOSS) INCOME	NOTE 16. OTHER COMPREHENSIVE (LOSS) INCOME During the three and nine months ended September 30, 2022 and 2021, there were no tax effects allocated to any component of Other comprehensive (loss) income and there were no reclassifications out of Accumulated other comprehensive loss. Substantially all of the Company’s Accumulated other comprehensive loss balances at September 30, 2022 and December 31, 2021 consist of Foreign currency translation loss.

SHAREHOLDERS' DEFICIT

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

SHAREHOLDERS' DEFICIT

NOTE 17. SHAREHOLDERS’ DEFICIT

The following table presents a reconciliation of the beginning and ending balances in Total shareholders’ deficit for the three and nine months ended September 30, 2022 (in thousands):


	Euro Deferred Shares		Ordinary Shares		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Shareholders’ Deficit


BALANCE, DECEMBER 31, 2021	$	45	$	23	$	8,953,906	$	(9,981,515)	$	(216,445)	$	(1,243,986)
Net loss	—		—		—		(71,974)		—		(71,974)
Other comprehensive income	—		—		—		—		1,895		1,895
Compensation related to share-based awards	—		—		4,929		—		—		4,929

Tax withholding for restricted shares	—		—		(1,863)		—		—		(1,863)
Other	(1)		1		1		—		—		1
BALANCE, MARCH 31, 2022	$	44	$	24	$	8,956,973	$	(10,053,489)	$	(214,550)	$	(1,310,998)
Net loss	—		—		—		(1,885,427)		—		(1,885,427)
Other comprehensive loss	—		—		—		—		(4,334)		(4,334)
Compensation related to share-based awards	—		—		2,721		—		—		2,721

Tax withholding for restricted shares	—		—		(31)		—		—		(31)
Other	(2)		—		(1)		—		—		(3)
BALANCE, JUNE 30, 2022	$	42	$	24	$	8,959,662	$	(11,938,916)	$	(218,884)	$	(3,198,072)
Net loss	—		—		—		(722,169)		—		(722,169)
Other comprehensive loss	—		—		—		—		(10,649)		(10,649)
Compensation related to share-based awards	—		—		5,856		—		—		5,856

Tax withholding for restricted shares	—		—		(4)		—		—		(4)
Other	(3)		—		—		—		—		(3)
BALANCE, SEPTEMBER 30, 2022	$	39	$	24	$	8,965,514	$	(12,661,085)	$	(229,533)	$	(3,925,041)

The following table presents a reconciliation of the beginning and ending balances in Total shareholders’ deficit for the three and nine months ended September 30, 2021 (in thousands):


	Euro Deferred Shares		Ordinary Shares		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Shareholders’ Deficit


BALANCE, DECEMBER 31, 2020	$	49	$	23	$	8,938,012	$	(9,368,270)	$	(217,753)	$	(647,939)
Net income	—		—		—		41,524		—		41,524
Other comprehensive income	—		—		—		—		1,692		1,692
Compensation related to share-based awards	—		—		9,993		—		—		9,993
Exercise of options	—		—		622		—		—		622
Tax withholding for restricted shares	—		—		(4,863)		—		—		(4,863)
Other	(2)		—		—		—		—		(2)
BALANCE, MARCH 31, 2021	$	47	$	23	$	8,943,764	$	(9,326,746)	$	(216,061)	$	(598,973)
Net loss	—		—		—		(15,500)		—		(15,500)
Other comprehensive income	—		—		—		—		2,238		2,238
Compensation related to share-based awards	—		—		4,444		—		—		4,444

Tax withholding for restricted shares	—		—		(9,251)		—		—		(9,251)

BALANCE, JUNE 30, 2021	$	47	$	23	$	8,938,957	$	(9,342,246)	$	(213,823)	$	(617,042)
Net loss	—		—		—		(77,207)		—		(77,207)
Other comprehensive loss	—		—		—		—		(3,293)		(3,293)
Compensation related to share-based awards	—		—		7,800		—		—		7,800

Tax withholding for restricted shares	—		—		(574)		—		—		(574)
Other	(1)		—		—		—		—		(1)
BALANCE, SEPTEMBER 30, 2021	$	46	$	23	$	8,946,183	$	(9,419,453)	$	(217,116)	$	(690,317)

Share-Based Compensation

The Company recognized share-based compensation expense of $6.5 million and $14.2 million during the three and nine months ended September 30, 2022, respectively, and $7.8 million and $22.2 million during the three and nine months ended September 30, 2021, respectively. As of September 30, 2022, the total remaining unrecognized compensation cost related to non-vested share-based compensation awards amounted to $12.8 million.

As of September 30, 2022, the weighted average remaining requisite service period for non-vested restricted stock units and performance share units was 1.0 years.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

OTHER INCOME, NET

9 Months Ended

Sep. 30, 2022

Component of Operating Income [Abstract]

OTHER INCOME, NET

NOTE 18. OTHER INCOME, NET

The components of Other income, net for the three and nine months ended September 30, 2022 and 2021 are as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net (gain) loss on sale of business and other assets (1)	$	(15)	$	107	$	(11,760)	$	198
Foreign currency (gain) loss, net (2)	(3,984)		(754)		(4,552)		1,507
Net loss from our investments in the equity of other companies (3)	71		89		297		399
Other miscellaneous, net	(70)		(5,397)		(6,132)		(6,775)
Other income, net	$	(3,998)	$	(5,955)	$	(22,147)	$	(4,671)

__________

(1)Amounts primarily relate to the sales of certain intellectual property rights and certain other assets.

(2)Amounts relate to the remeasurement of the Company’s foreign currency denominated assets and liabilities.

(3)Amounts relate to the income statement impacts of our investments in the equity of other companies, including investments accounted for under the equity method.

INCOME TAXES

9 Months Ended

Sep. 30, 2022

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 19. INCOME TAXES

The following table displays our (Loss) income from continuing operations before income tax, Income tax expense and Effective tax rate for the three and nine months ended September 30, 2022 and 2021 (dollars in thousands):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
(Loss) income from continuing operations before income tax	$	(707,592)		$	(47,741)		$	(2,648,439)		$	958
Income tax expense	$	10,680		$	1,548		$	16,016		$	13,372
Effective tax rate	(1.5)		%	(3.2)		%	(0.6)		%	1,395.8		%

The change in Income tax expense for the three months ended September 30, 2022 compared to the prior year period primarily relates to an increase in accrued interest on uncertain tax positions, changes in the geographic mix of pre-tax earnings and a discrete tax benefit primarily associated with the filing of the Company’s U.S. federal income tax return. The change in Income tax expense for the nine months ended September 30, 2022 compared to the prior year period primarily relates to the 2021 discrete tax expense related to Canadian uncertain tax positions and changes in the geographic mix of pre-tax earnings.

As previously disclosed, the Company concluded that there was substantial doubt about its ability to continue as a going concern within one year after the date of issuance of the Condensed Consolidated Financial Statements included in the Second Quarter 2022 Form 10-Q. The Company considered this in determining that certain net deferred tax assets were no longer more likely than not realizable. As a result, an immaterial increase in valuation allowance on the Company’s net deferred tax assets was recorded in various jurisdictions during the second quarter of 2022.

The Company maintains a full valuation allowance against the net deferred tax assets in the U.S., Luxembourg and certain other foreign tax jurisdictions as of September 30, 2022. It is possible that within the next 12 months there may be sufficient positive evidence to release a portion or all of the valuation allowance. Release of these valuation allowances would result in a benefit to income tax expense for the period the release is recorded, which could have a material impact on net earnings. The timing and amount of the potential valuation allowance release are subject to significant management judgment and prospective earnings.

On June 3, 2020, in connection with the IRS’s examination of our U.S. income tax return for the fiscal year ended December 31, 2015 (2015 Return), we received an acknowledgement of facts (AoF) from the IRS related to transfer pricing positions taken by Endo U.S., Inc. and its subsidiaries (Endo U.S.). The AoF asserted that Endo U.S. overpaid for certain pharmaceutical products that it purchased from certain non-U.S. related parties and proposed a specific adjustment to our 2015 U.S. income tax return position. On September 4, 2020, we received a Form 5701 Notice of Proposed Adjustment (NOPA) that is consistent with the previously disclosed AoF. We believe that the terms of the subject transactions are consistent with comparable transactions for similarly situated unrelated parties, and we intend to contest the proposed adjustment. While the NOPA is not material to our business, financial condition, results of operations or cash flows, the IRS could seek to apply its position to subsequent tax periods and propose similar adjustments. The aggregate impact of these adjustments, if sustained, could have a material adverse effect on our business, financial condition, results of operations and cash flows. Although the timing of the outcome of this matter is uncertain, it is possible any final resolution of the matter could take a number of years.

In connection with the IRS’s examination of our 2015 Return, on December 31, 2020, the IRS issued a Technical Advice Memorandum (TAM) regarding the portion of our 2015 NOL that we believe qualifies as a specified product liability loss (SLL). The TAM concurred in part with our positions on the 2015 Return but disagreed with our position that the AMS worthless stock loss qualifies as an SLL. In April 2021, we received draft NOPAs from the IRS consistent with the TAM. We continue to disagree with the IRS’s position and the draft NOPAs received and, if necessary, intend to contest any additional tax determined to be owed with respect to the NOPAs. However, if we were unsuccessful in contesting the IRS’s position, we have preliminarily estimated that we would have additional cash taxes payable to the IRS of between $70 million and $250 million excluding interest. We continue to discuss this position with the IRS and the actual amount that may be owed to the IRS if we are unsuccessful may be different than our preliminary estimate. Although the timing of the outcome of this matter is uncertain, it is possible any final resolution of the matter could take a number of years.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

NET LOSS PER SHARE

NOTE 20. NET LOSS PER SHARE

The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the three and nine months ended September 30, 2022 and 2021 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Numerator:
Loss from continuing operations	$	(718,272)	$	(49,289)	$	(2,664,455)	$	(12,414)


Loss from discontinued operations, net of tax	(3,897)		(27,918)		(15,115)		(38,769)
Net loss	$	(722,169)	$	(77,207)	$	(2,679,570)	$	(51,183)
Denominator:
For basic per share data—weighted average shares	235,160		233,578		234,719		232,487
Dilutive effect of ordinary share equivalents	—		—		—		—

For diluted per share data—weighted average shares	235,160		233,578		234,719		232,487

Basic per share amounts are computed based on the weighted average number of ordinary shares outstanding during the period. Diluted per share amounts are computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations during the period, the dilutive effect of ordinary share equivalents outstanding during the period.

The dilutive effect of ordinary share equivalents is measured using the treasury stock method. Any stock options and/or awards that have been issued but for which a grant date has not yet been established are not considered in the calculation of basic or diluted weighted average shares.

The following table presents, for the three and nine months ended September 30, 2022 and 2021, outstanding stock options and stock awards that could potentially dilute per share amounts in the future that were not included in the computation of diluted per share amounts for the periods presented because to do so would have been antidilutive (in thousands):


	Three Months Ended September 30,		Nine Months Ended September 30,
	2022	2021	2022	2021
Stock options	5,274	6,532	5,558	6,626
Stock awards	5,151	8,668	6,066	9,570

CONDENSED COMBINED DEBTOR-IN-POSSESSION FINANCIAL INFORMATION

9 Months Ended

Sep. 30, 2022

Reorganizations [Abstract]

CONDENSED COMBINED DEBTOR-IN-POSSESSION FINANCIAL INFORMATION

NOTE 2. BANKRUPTCY PROCEEDINGS

Chapter 11 Filing

Events of Default

Restructuring Support Agreement

Subsequent Developments

Cash Collateral

Asset Sale

Potential Claims

Bankruptcy Accounting


	September 30, 2022
Accounts payable	$	16,121
Accrued interest	160,097
Debt	7,979,183
Litigation accruals	794,578
Uncertain tax positions	232,920
Other (1)	162,351
Total	$	9,345,250

__________


	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
Professional fees	$	35,015		$	35,015
Debt valuation adjustments	89,197			89,197

Total	$	124,212		$	124,212

Nasdaq Delisting

NOTE 21. CONDENSED COMBINED DEBTOR-IN-POSSESSION FINANCIAL INFORMATION





CONDENSED COMBINED BALANCE SHEETS (UNAUDITED)
(Dollars in thousands)

	September 30, 2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	990,107
Restricted cash and cash equivalents	59,486
Accounts receivable, net	409,333
Inventories, net	254,206
Prepaid expenses and other current assets	126,613
Income taxes receivable	1,290

Receivables from Non-Debtor Affiliates	102,162
Total current assets	$	1,943,197

PROPERTY, PLANT AND EQUIPMENT, NET	236,755
OPERATING LEASE ASSETS	26,240
GOODWILL	1,352,011
OTHER INTANGIBLES, NET	1,992,932

INVESTMENTS IN NON-DEBTOR AFFILIATES	53,887
RECEIVABLES FROM NON-DEBTOR AFFILIATES	241,860
OTHER ASSETS	139,659
TOTAL ASSETS	$	5,986,541
LIABILITIES AND DEFICIT
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	517,978



Income taxes payable	3,459

Payables to Non-Debtor Affiliates	2,614
Total current liabilities	$	524,051
DEFERRED INCOME TAXES	11,536




OTHER LIABILITIES	21,792
LIABILITIES SUBJECT TO COMPROMISE	9,345,250
TOTAL DEFICIT	(3,916,088)
TOTAL LIABILITIES AND DEFICIT	$	5,986,541





CONDENSED COMBINED STATEMENTS OF OPERATIONS (UNAUDITED)
(Dollars in thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
TOTAL REVENUES, NET	$	541,889		$	1,765,228
COSTS AND EXPENSES:
Cost of revenues	266,811			807,013
Selling, general and administrative	189,689			592,139
Research and development	34,519			102,942
Acquired in-process research and development	800			68,700
Litigation-related and other contingencies, net	419,377			444,738
Asset impairment charges	150,200			1,951,216
Acquisition-related and integration items, net	(1,399)			(951)

Interest expense, net	71,874			347,862

Reorganization items, net	124,212			124,212
Other expense (income), net	9,052			(2,360)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX	$	(723,246)		$	(2,670,283)
INCOME TAX EXPENSE	10,535			15,032
LOSS FROM CONTINUING OPERATIONS	$	(733,781)		$	(2,685,315)
DISCONTINUED OPERATIONS, NET OF TAX	(3,896)			(15,096)
NET LOSS ATTRIBUTABLE TO DEBTOR ENTITIES	$	(737,677)		$	(2,700,411)
EQUITY IN INCOME OF NON-DEBTOR AFFILIATES, NET OF TAX	18,669			26,776
NET LOSS	$	(719,008)		$	(2,673,635)





CONDENSED COMBINED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
(Dollars in thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
NET LOSS	$	(719,008)		$	(2,673,635)
OTHER COMPREHENSIVE INCOME:
Net unrealized (loss) gain on foreign currency	$	(10,649)		$	(13,088)
Total other comprehensive (loss) income	$	(10,649)		$	(13,088)
COMPREHENSIVE LOSS	$	(729,657)		$	(2,686,723)





CONDENSED COMBINED STATEMENTS OF CASH FLOWS (UNAUDITED)
(Dollars in thousands)

	Nine Months Ended September 30,
	2022
OPERATING ACTIVITIES:
Net cash provided by operating activities (1)	$	75,349
INVESTING ACTIVITIES:
Capital expenditures, excluding capitalized interest	(35,018)

Proceeds from the U.S. Government Agreement	13,601

Acquisitions, including in-process research and development, net of cash and restricted cash acquired	(89,520)




Proceeds from sale of business and other assets, net	22,378
Disbursements for loans made to Non-Debtor Affiliates	(51,180)

Net cash used in investing activities	$	(139,739)
FINANCING ACTIVITIES:


Repayments of notes	(180,342)
Repayments of term loans	(10,000)


Adequate protection payments	(168,643)
Repayments of other indebtedness	(4,500)

Payments for contingent consideration	(1,939)
Payments of tax withholding for restricted shares	(1,898)


Net cash used in financing activities	$	(367,322)
Effect of foreign exchange rate	(2,393)

NET DECREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	$	(434,105)
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	1,568,698
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	$	1,134,593

__________

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2022
Accounting Policies [Abstract]
Going Concern	Going Concern As further discussed herein, thousands of governmental and private plaintiffs have filed suit against us and/or certain of our subsidiaries alleging opioid-related claims, most of which we have not been able to settle. As a result of the possibility or occurrence of an unfavorable outcome with respect to these proceedings, other legal proceedings and certain other risks and uncertainties, we have been exploring a wide array of potential actions as part of our contingency planning and, as further described in our Second Quarter 2022 Form 10-Q, we previously concluded that the related conditions and events gave rise to substantial doubt about our ability to continue as a going concern. Subsequent to the filing of the Second Quarter 2022 Form 10-Q, on August 16, 2022 (the Petition Date), Endo International plc, together with certain of its direct and indirect subsidiaries (the Debtors), filed voluntary petitions for relief under the Bankruptcy Code, which constituted an event of default that accelerated our obligations under substantially all of our then-outstanding debt instruments. However, section 362 of the Bankruptcy Code stays the creditors from taking any action to enforce the related financial obligations and the creditors’ rights of enforcement in respect of the debt instruments are subject to the applicable provisions of the Bankruptcy Code. Refer to Note 2. Bankruptcy Proceedings and Note 14. Debt for additional information. As a result of these conditions and events, management continues to believe there is substantial doubt about our ability to continue as a going concern within one year after the date of issuance of these Condensed Consolidated Financial Statements. The accompanying Condensed Consolidated Financial Statements have been prepared under the going concern basis of accounting as required by U.S. GAAP and do not include any adjustments that might be necessary should we be unable to continue as a going concern.
Use of Estimates	Use of Estimates The preparation of our Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts and disclosures in our Condensed Consolidated Financial Statements, including the Notes thereto, and elsewhere in this report. For example, we are required to make significant estimates and assumptions related to revenue recognition, including sales deductions, long-lived assets, goodwill, other intangible assets, income taxes, contingencies, financial instruments, share-based compensation, Liabilities subject to compromise and Reorganization items, net, among others. Some of these estimates can be subjective and complex. Uncertainties related to the continued magnitude and duration of the COVID-19 pandemic, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending, health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic, including any possible re-initiation of shutdowns or renewed restrictions, have increased the complexity of developing these estimates, including the allowance for expected credit losses and the carrying amounts of long-lived assets, goodwill and other intangible assets. Additionally, as a result of our ongoing bankruptcy proceedings, we may sell or otherwise dispose of or liquidate assets or settle liabilities for amounts other than those reflected in the accompanying Condensed Consolidated Financial Statements. The possibility or occurrence of any such actions could materially impact the amounts and classifications of such assets and liabilities reported in our Condensed Consolidated Balance Sheets. Furthermore, our ongoing bankruptcy proceedings and planned sale process have resulted in and are likely to continue to result in significant changes to our business, which could ultimately result in, among other things, asset impairment charges that may be material. Although we believe that our estimates and assumptions are reasonable, there may be other reasonable estimates or assumptions that differ significantly from ours. Further, our estimates and assumptions are based upon information available at the time they were made. Actual results may differ significantly from our estimates, including as a result of the uncertainties described in this report, those described in our other reports filed with the SEC or other uncertainties.
Significant Accounting Policies Added or Updated	Significant Accounting Policies Added or Updated since December 31, 2021 Except as described in Note 2. Bankruptcy Proceedings, there have been no significant changes to our significant accounting policies since December 31, 2021. For additional discussion of the Company’s significant accounting policies, see Note 2. Summary of Significant Accounting Policies in the Consolidated Financial Statements included in Part IV, Item 15 of the Annual Report.

BANKRUPTCY PROCEEDINGS (Tables)

9 Months Ended

Sep. 30, 2022

Reorganizations [Abstract]

Schedule of Liabilities Subject to Compromise

The following table sets forth, as of September 30, 2022, information about the amounts presented as Liabilities subject to compromise in our Condensed Consolidated Balance Sheets (in thousands):


	September 30, 2022
Accounts payable	$	16,121
Accrued interest	160,097
Debt	7,979,183
Litigation accruals	794,578
Uncertain tax positions	232,920
Other (1)	162,351
Total	$	9,345,250

__________

Schedule of Reorganisation Item in Consolidated Condensed Statements of Operations

The following table sets forth, for the three and nine months ended September 30, 2022, information about the amounts presented as Reorganization items, net in our Condensed Consolidated Statements of Operations (in thousands):


	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
Professional fees	$	35,015		$	35,015
Debt valuation adjustments	89,197			89,197

Total	$	124,212		$	124,212

DISCONTINUED OPERATIONS (Tables)

9 Months Ended

Sep. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Disposal Groups, including Discontinued Operations, Operations Results of Astora

The following table provides the operating results of Astora Discontinued operations, net of tax, for the three and nine months ended September 30, 2022 and 2021 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Litigation-related and other contingencies, net	$	—	$	25,000	$	—	$	25,000
Loss from discontinued operations before income taxes	$	(3,897)	$	(31,306)	$	(15,115)	$	(43,400)
Income tax benefit	$	—	$	(3,388)	$	—	$	(4,631)
Discontinued operations, net of tax	$	(3,897)	$	(27,918)	$	(15,115)	$	(38,769)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

RESTRUCTURING (Tables)

9 Months Ended

Sep. 30, 2022

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net restructuring charges (charge reversals) related to:
Accelerated depreciation	$	—	$	6,350	$	3,824	$	22,329
Asset impairments	—		42,155		—		42,155
Inventory adjustments	408		719		1,435		6,513
Employee separation, continuity and other benefit-related costs	(433)		(14,481)		1,290		(6,150)
Certain other restructuring costs	116		1,209		798		3,003
Total	$	91	$	35,952	$	7,347	$	67,850


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net restructuring charges (charge reversals) included in:
Cost of revenues	$	375	$	(11,050)	$	4,025	$	9,294
Selling, general and administrative	(243)		4,946		201		15,174
Research and development	(41)		(99)		3,121		1,227
Asset impairment charges	—		42,155		—		42,155

Total	$	91	$	35,952	$	7,347	$	67,850


	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
Net restructuring (charge reversals) charges related to:


Inventory adjustments	$	—		$	2,462
Employee separation, continuity and other benefit-related costs	(1,681)			18,406
Certain other restructuring costs	1,102			8,657
Total	$	(579)		$	29,525


	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
Net restructuring (charge reversals) charges included in:
Cost of revenues	$	68		$	13,352
Selling, general and administrative	(644)			12,075
Research and development	(3)			4,098


Total	$	(579)		$	29,525

Schedule of Restructuring Reserve by Type of Cost

Changes to the liability for the 2020 Restructuring Initiative during the nine months ended September 30, 2022 were as follows (in thousands):


	Employee Separation, Continuity and Other Benefit-Related Costs		Certain Other Restructuring Costs		Total



Liability balance as of December 31, 2021	$	10,979	$	205	$	11,184
Net charges	1,290		798		2,088
Cash payments	(10,671)		(1,003)		(11,674)
Liability balance as of September 30, 2022	$	1,598	$	—	$	1,598

Changes to the liability for the 2022 Restructuring Initiative during the nine months ended September 30, 2022 were as follows (in thousands):


	Employee Separation, Continuity and Other Benefit-Related Costs		Certain Other Restructuring Costs		Total



Liability balance as of December 31, 2021	$	—	$	—	$	—
Net charges	18,406		1,102		19,508
Cash payments	(12,871)		(551)		(13,422)
Liability balance as of September 30, 2022	$	5,535	$	551	$	6,086

SEGMENT RESULTS (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of Reportable Segments Information

The following represents selected information for the Company’s reportable segments for the three and nine months ended September 30, 2022 and 2021 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenues from external customers:
Branded Pharmaceuticals	$	203,501	$	230,977	$	627,314	$	665,652
Sterile Injectables	118,693		343,653		481,892		946,998
Generic Pharmaceuticals	201,435		174,306		590,756		522,451
International Pharmaceuticals (1)	18,061		23,092		63,101		68,676
Total net revenues from external customers	$	541,690	$	772,028	$	1,763,063	$	2,203,777
Segment adjusted income from continuing operations before income tax:
Branded Pharmaceuticals	$	84,940	$	105,849	$	251,219	$	301,277
Sterile Injectables	58,633		282,300		318,284		751,922
Generic Pharmaceuticals	87,675		34,010		237,394		89,036
International Pharmaceuticals	4,296		6,764		17,149		24,337
Total segment adjusted income from continuing operations before income tax	$	235,544	$	428,923	$	824,046	$	1,166,572

__________

(1)Revenues generated by our International Pharmaceuticals segment are primarily attributable to external customers located in Canada.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Total consolidated (loss) income from continuing operations before income tax	$	(707,592)	$	(47,741)	$	(2,648,439)	$	958
Interest expense, net	74,753		142,958		349,486		418,852
Corporate unallocated costs (1)	44,182		65,317		125,851		141,291
Amortization of intangible assets	84,042		91,901		261,844		281,101

Acquired in-process research and development charges	800		—		68,700		5,000
Amounts related to continuity and separation benefits, cost reductions and strategic review initiatives (2)	44,029		19,829		139,025		58,632
Certain litigation-related and other contingencies, net (3)	419,376		83,495		444,738		119,327
Certain legal costs (4)	8,052		38,842		31,322		82,961
Asset impairment charges (5)	150,200		42,155		1,951,216		50,393
Acquisition-related and integration items, net (6)	(1,399)		(1,432)		(951)		(6,357)
Loss on extinguishment of debt	—		—		—		13,753

Foreign currency impact related to the remeasurement of intercompany debt instruments	(6,220)		(2,036)		(7,114)		466
Reorganization items, net (7)	124,212		—		124,212		—
Other, net (8)	1,109		(4,365)		(15,844)		195
Total segment adjusted income from continuing operations before income tax	$	235,544	$	428,923	$	824,046	$	1,166,572

__________

(1)Amounts include certain corporate overhead costs, such as headcount, facility and corporate litigation expenses and certain other income and expenses.

(4)Amounts relate to opioid-related legal expenses. The amount during the nine months ended September 30, 2022 reflects the recovery of certain previously-incurred opioid-related legal expenses.

(6)Amounts primarily relate to changes in the fair value of contingent consideration.

Schedule of Disaggregation of Revenue

The Company believes these categories depict how the nature, timing and uncertainty of revenue and cash flows are affected by economic factors.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Branded Pharmaceuticals:
Specialty Products:
XIAFLEX®	$	104,014	$	105,509	$	324,376	$	312,266
SUPPRELIN® LA	31,283		30,069		84,852		85,665
Other Specialty (1)	11,033		26,339		50,023		74,407
Total Specialty Products	$	146,330	$	161,917	$	459,251	$	472,338
Established Products:
PERCOCET®	$	25,052	$	26,914	$	77,483	$	78,695
TESTOPEL®	9,430		11,686		28,331		32,314

Other Established (2)	22,689		30,460		62,249		82,305
Total Established Products	$	57,171	$	69,060	$	168,063	$	193,314
Total Branded Pharmaceuticals (3)	$	203,501	$	230,977	$	627,314	$	665,652
Sterile Injectables:
VASOSTRICT®	$	33,697	$	255,697	$	225,217	$	676,764
ADRENALIN®	24,917		28,722		85,514		88,136


Other Sterile Injectables (4)	60,079		59,234		171,161		182,098
Total Sterile Injectables (3)	$	118,693	$	343,653	$	481,892	$	946,998
Total Generic Pharmaceuticals (5)	$	201,435	$	174,306	$	590,756	$	522,451
Total International Pharmaceuticals (6)	$	18,061	$	23,092	$	63,101	$	68,676
Total revenues, net	$	541,690	$	772,028	$	1,763,063	$	2,203,777

__________

(1)Products included within Other Specialty include AVEED®, NASCOBAL® Nasal Spray and QWO®.

(2)Products included within Other Established include, but are not limited to, EDEX®.

(4)Products included within Other Sterile Injectables include ertapenem for injection, APLISOL® and others.

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Schedule of Cash and Cash Equivalents

The following table presents current and noncurrent restricted cash and cash equivalent balances at September 30, 2022 and December 31, 2021 (in thousands):


	Balance Sheet Line Items	September 30, 2022		December 31, 2021
Restricted cash and cash equivalents—current (1)	Restricted cash and cash equivalents	$	145,486	$	124,114
Restricted cash and cash equivalents—noncurrent (2)	Other assets	85,000		—
Total restricted cash and cash equivalents		$	230,486	$	124,114

__________

(2)The amount at September 30, 2022 relates to the TLC Agreement. See Note 11. License, Collaboration and Asset Acquisition Agreements for further information about this amount.

Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 were as follows (in thousands):


	Fair Value Measurements at September 30, 2022 using:
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total
Assets:
Money market funds (1)	$	14,539	$	—	$	—	$	14,539
Liabilities:



Acquisition-related contingent consideration (2)	$	—	$	—	$	15,812	$	15,812


	Fair Value Measurements at December 31, 2021 using:
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs		Total
Assets:
Money market funds (1)	$	134,847	$	—	$	—	$	134,847
Liabilities:



Acquisition-related contingent consideration (2)	$	—	$	—	$	20,076	$	20,076

__________

Schedule of Changes to Liability for Acquisition-Related Contingent Consideration


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Beginning of period	$	18,242	$	27,447	$	20,076	$	36,249
Amounts settled	(286)		(2,612)		(2,445)		(6,302)
Changes in fair value recorded in earnings	(1,399)		(1,435)		(951)		(6,771)
Effect of currency translation	(745)		(188)		(868)		36
End of period (1)	$	15,812	$	23,212	$	15,812	$	23,212

__________

The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the nine months ended September 30, 2022 by acquisition (in thousands):


	Balance as of December 31, 2021		Changes in Fair Value Recorded in Earnings		Amounts Settled and Other		Balance as of September 30, 2022 (1)
Auxilium acquisition	$	9,038	$	422	$	(536)	$	8,924
Lehigh Valley Technologies, Inc. acquisitions	3,600		(694)		(506)		2,400

Other	7,438		(679)		(2,271)		4,488
Total	$	20,076	$	(951)	$	(3,313)	$	15,812

__________

Schedule of Nonrecurring Fair Value Measurements

The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis during the nine months ended September 30, 2022 were as follows (in thousands):


	Fair Value Measurements during the Nine Months Ended September 30, 2022 (1) using:						Total Expense for the Nine Months Ended September 30, 2022
	Level 1 Inputs		Level 2 Inputs		Level 3 Inputs

Intangible assets, excluding goodwill (2)(3)	$	—	$	—	$	65,407	$	(103,153)
Certain property, plant and equipment	—		—		—		(3,063)


Total	$	—	$	—	$	65,407	$	(106,216)

__________

(2)These fair value measurements were determined using risk-adjusted discount rates ranging from 9.5% to 12.0% (weighted average rate of approximately 11.7%, weighted based on relative fair value).

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):


	September 30, 2022		December 31, 2021
Raw materials (1)	$	101,407	$	90,453
Work-in-process (1)	59,630		82,728
Finished goods (1)	127,877		110,371
Total	$	288,914	$	283,552

__________

(1)The components of inventory shown in the table above are net of allowance for obsolescence.

LEASES (Tables)

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Schedule of Assets and Liabilities, Lessee

The following table presents information about the Company’s right-of-use assets and lease liabilities at September 30, 2022 and December 31, 2021 (in thousands):


	Balance Sheet Line Items	September 30, 2022		December 31, 2021
Right-of-use assets:
Operating lease right-of-use assets	Operating lease assets	$	31,342	$	34,832
Finance lease right-of-use assets	Property, plant and equipment, net	28,819		38,365
Total right-of-use assets		$	60,161	$	73,197
Operating lease liabilities (1):
Current operating lease liabilities	Current portion of operating lease liabilities	$	724	$	10,992
Noncurrent operating lease liabilities	Operating lease liabilities, less current portion	4,363		33,727
Total operating lease liabilities		$	5,087	$	44,719
Finance lease liabilities (1):
Current finance lease liabilities	Accounts payable and accrued expenses	$	—	$	6,841
Noncurrent finance lease liabilities	Other liabilities	1,415		18,374
Total finance lease liabilities		$	1,415	$	25,215

__________

Schedule of Lease, Cost

The following table presents information about lease costs and expenses and sublease income for the three and nine months ended September 30, 2022 and 2021 (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,
	Statement of Operations Line Items	2022		2021		2022		2021
Operating lease cost	Various (1)	$	3,415	$	3,612	$	8,452	$	10,869
Finance lease cost:
Amortization of right-of-use assets	Various (1)	$	2,024	$	2,311	$	6,455	$	6,933
Interest on lease liabilities	Interest expense, net	$	271	$	310	$	877	$	1,015
Other lease costs and income:
Variable lease costs (2)	Various (1)	$	3,525	$	3,035	$	8,220	$	9,099
Finance lease right-of-use asset impairment charges	Asset impairment charges	$	—	$	—	$	3,063	$	—

Sublease income	Various (1)	$	(1,560)	$	(957)	$	(4,810)	$	(2,837)

__________


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Cost of revenues	$	1,539	$	2,988	$	4,668	$	9,032
Selling, general and administrative	$	5,812	$	4,959	$	13,488	$	14,870
Research and development	$	53	$	54	$	161	$	162

The following table provides certain cash flow and supplemental noncash information related to our lease liabilities for the nine months ended September 30, 2022 and 2021 (in thousands):


	Nine Months Ended September 30,
	2022		2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$	9,746	$	10,010
Operating cash payments for finance leases	$	1,439	$	1,791
Financing cash payments for finance leases	$	4,501	$	4,044
Lease liabilities arising from obtaining right-of-use assets:
Operating leases (1)	$	1,296	$	4,985

__________

(1)The amount in 2022 primarily relates to a new lease agreement. The amount in 2021 primarily relates to an increase in lease liabilities and right-of-use assets related to a lease modification.

GOODWILL AND OTHER INTANGIBLES (Tables)

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in the Carrying Amount of Goodwill

Changes in the carrying amounts of our goodwill for the nine months ended September 30, 2022 were as follows (in thousands):


	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals		International Pharmaceuticals		Total





Goodwill as of December 31, 2021	$	828,818	$	2,368,193	$	—	$	—	$	3,197,011

Goodwill impairment charges	—		(1,845,000)		—		—		(1,845,000)

Goodwill as of September 30, 2022	$	828,818	$	523,193	$	—	$	—	$	1,352,011

The carrying amounts of goodwill at September 30, 2022 and December 31, 2021 are net of the following accumulated impairments (in thousands):


	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2021	$	855,810	$	363,000	$	3,142,657	$	550,355	$	4,911,822
Accumulated impairment losses as of September 30, 2022	$	855,810	$	2,208,000	$	3,142,657	$	502,985	$	6,709,452

Schedule of Other Intangible Assets

Changes in the amounts of other intangible assets for the nine months ended September 30, 2022 are set forth in the table below (in thousands).


Cost basis:	Balance as of December 31, 2021		Acquisitions		Impairments		Effect of Currency Translation		Balance as of September 30, 2022




Licenses (weighted average life of 14 years)	$	442,107	$	—	$	—	$	—	$	442,107
Tradenames	6,409		—		—		—		6,409
Developed technology (weighted average life of 12 years)	6,226,139		—		(103,153)		(22,210)		6,100,776

Total other intangibles (weighted average life of 12 years years)	$	6,674,655	$	—	$	(103,153)	$	(22,210)	$	6,549,292

Accumulated amortization:	Balance as of December 31, 2021		Amortization		Impairments		Effect of Currency Translation		Balance as of September 30, 2022

Licenses	$	(419,932)	$	(3,432)	$	—	$	—	$	(423,364)
Tradenames	(6,409)		—		—		—		(6,409)
Developed technology	(3,885,491)		(258,412)		—		17,316		(4,126,587)
Total other intangibles	$	(4,311,832)	$	(261,844)	$	—	$	17,316	$	(4,556,360)
Net other intangibles	$	2,362,823							$	1,992,932

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

CONTRACT ASSETS AND LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2022

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]

Schedule of Contract Assets and Liabilities

The following table shows the opening and closing balances of contract assets and contract liabilities from contracts with customers (dollars in thousands):


	September 30, 2022		December 31, 2021		$ Change		% Change
Contract assets (1)	$	2,737	$	13,005	$	(10,268)	(79)	%
Contract liabilities (2)	$	4,240	$	4,663	$	(423)	(9)	%

__________

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

9 Months Ended

Sep. 30, 2022

Accounts Payable and Accrued Liabilities, Current [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued expenses included the following at September 30, 2022 and December 31, 2021 (in thousands):


	September 30, 2022		December 31, 2021
Trade accounts payable	$	84,999	$	123,129
Returns and allowances	159,215		183,116
Rebates	148,165		150,039
Chargebacks	834		2,617
Other sales deductions	6,551		2,500
Accrued interest	43		106,735
Accrued payroll and related benefits	39,465		90,029
Accrued royalties and other distribution partner payables	15,934		58,422
Acquisition-related contingent consideration—current	—		5,748
Other (1)	83,524		114,563
Total	$	538,730	$	836,898

__________

(1)Amounts include a wide variety of accrued expenses, the most significant of which relate to accrued legal and other professional fees.

DEBT (Tables)

9 Months Ended

Sep. 30, 2022

Debt Disclosure [Abstract]

Schedule of Long-Term Debt Instruments

The following table presents information about the Company’s total indebtedness at September 30, 2022 and December 31, 2021 (dollars in thousands):


	September 30, 2022						December 31, 2021
	Effective Interest Rate (1)		Principal Amount (2)		Carrying Amount (2)		Effective Interest Rate		Principal Amount		Carrying Amount
7.25% Senior Notes due 2022			$	—	$	—	7.25	%	$	8,294	$	8,294
5.75% Senior Notes due 2022			—		—		5.75	%	172,048		172,048
5.375% Senior Notes due 2023	5.38	%	6,127		6,127		5.62	%	6,127		6,111
6.00% Senior Notes due 2023	6.00	%	56,436		56,436		6.28	%	56,436		56,203
5.875% Senior Secured Notes due 2024	6.88	%	300,000		291,531		6.14	%	300,000		297,928
6.00% Senior Notes due 2025	6.00	%	21,578		21,578		6.27	%	21,578		21,413
7.50% Senior Secured Notes due 2027	8.50	%	2,015,479		1,937,603		7.70	%	2,015,479		1,997,777
9.50% Senior Secured Second Lien Notes due 2027	9.50	%	940,590		940,590		9.68	%	940,590		933,330
6.00% Senior Notes due 2028	6.00	%	1,260,416		1,260,416		6.11	%	1,260,416		1,252,667
6.125% Senior Secured Notes due 2029	7.13	%	1,295,000		1,253,866		6.34	%	1,295,000		1,278,718
Term Loan Facility	12.25	%	1,975,000		1,937,854		6.12	%	1,985,000		1,947,633
Revolving Credit Facility	9.75	%	277,200		273,182		2.63	%	277,200		277,200

Total (3)			$	8,147,826	$	7,979,183			$	8,338,168	$	8,249,322

__________

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Schedule of Changes in Qualified Settlement Funds Accounts and Product Liability Balance

The following table presents the changes in the mesh-related QSFs and liability accrual balances during the nine months ended September 30, 2022 (in thousands):


	Mesh Qualified Settlement Funds		Mesh Liability Accrual
Balance as of December 31, 2021	$	78,402	$	258,137

Cash received for reversionary interests, net of cash contributions to Qualified Settlement Funds	(367)		—
Cash distributions to settle disputes from Qualified Settlement Funds	(20,089)		(20,089)
Other cash distributions to settle disputes	—		(6,499)
Other (1)	149		(820)
Balance as of September 30, 2022 (2)	$	58,095	$	230,729

__________

(2)As of September 30, 2022, this balance is classified as Liabilities subject to compromise in the Condensed Consolidated Balance Sheets.

SHAREHOLDERS' DEFICIT (Tables)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Schedule of Shareholders' Equity

The following table presents a reconciliation of the beginning and ending balances in Total shareholders’ deficit for the three and nine months ended September 30, 2022 (in thousands):


	Euro Deferred Shares		Ordinary Shares		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Shareholders’ Deficit


BALANCE, DECEMBER 31, 2021	$	45	$	23	$	8,953,906	$	(9,981,515)	$	(216,445)	$	(1,243,986)
Net loss	—		—		—		(71,974)		—		(71,974)
Other comprehensive income	—		—		—		—		1,895		1,895
Compensation related to share-based awards	—		—		4,929		—		—		4,929

Tax withholding for restricted shares	—		—		(1,863)		—		—		(1,863)
Other	(1)		1		1		—		—		1
BALANCE, MARCH 31, 2022	$	44	$	24	$	8,956,973	$	(10,053,489)	$	(214,550)	$	(1,310,998)
Net loss	—		—		—		(1,885,427)		—		(1,885,427)
Other comprehensive loss	—		—		—		—		(4,334)		(4,334)
Compensation related to share-based awards	—		—		2,721		—		—		2,721

Tax withholding for restricted shares	—		—		(31)		—		—		(31)
Other	(2)		—		(1)		—		—		(3)
BALANCE, JUNE 30, 2022	$	42	$	24	$	8,959,662	$	(11,938,916)	$	(218,884)	$	(3,198,072)
Net loss	—		—		—		(722,169)		—		(722,169)
Other comprehensive loss	—		—		—		—		(10,649)		(10,649)
Compensation related to share-based awards	—		—		5,856		—		—		5,856

Tax withholding for restricted shares	—		—		(4)		—		—		(4)
Other	(3)		—		—		—		—		(3)
BALANCE, SEPTEMBER 30, 2022	$	39	$	24	$	8,965,514	$	(12,661,085)	$	(229,533)	$	(3,925,041)

The following table presents a reconciliation of the beginning and ending balances in Total shareholders’ deficit for the three and nine months ended September 30, 2021 (in thousands):


	Euro Deferred Shares		Ordinary Shares		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Shareholders’ Deficit


BALANCE, DECEMBER 31, 2020	$	49	$	23	$	8,938,012	$	(9,368,270)	$	(217,753)	$	(647,939)
Net income	—		—		—		41,524		—		41,524
Other comprehensive income	—		—		—		—		1,692		1,692
Compensation related to share-based awards	—		—		9,993		—		—		9,993
Exercise of options	—		—		622		—		—		622
Tax withholding for restricted shares	—		—		(4,863)		—		—		(4,863)
Other	(2)		—		—		—		—		(2)
BALANCE, MARCH 31, 2021	$	47	$	23	$	8,943,764	$	(9,326,746)	$	(216,061)	$	(598,973)
Net loss	—		—		—		(15,500)		—		(15,500)
Other comprehensive income	—		—		—		—		2,238		2,238
Compensation related to share-based awards	—		—		4,444		—		—		4,444

Tax withholding for restricted shares	—		—		(9,251)		—		—		(9,251)

BALANCE, JUNE 30, 2021	$	47	$	23	$	8,938,957	$	(9,342,246)	$	(213,823)	$	(617,042)
Net loss	—		—		—		(77,207)		—		(77,207)
Other comprehensive loss	—		—		—		—		(3,293)		(3,293)
Compensation related to share-based awards	—		—		7,800		—		—		7,800

Tax withholding for restricted shares	—		—		(574)		—		—		(574)
Other	(1)		—		—		—		—		(1)
BALANCE, SEPTEMBER 30, 2021	$	46	$	23	$	8,946,183	$	(9,419,453)	$	(217,116)	$	(690,317)

OTHER INCOME, NET (Tables)

9 Months Ended

Sep. 30, 2022

Component of Operating Income [Abstract]

Schedule of components of other expense, net

The components of Other income, net for the three and nine months ended September 30, 2022 and 2021 are as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net (gain) loss on sale of business and other assets (1)	$	(15)	$	107	$	(11,760)	$	198
Foreign currency (gain) loss, net (2)	(3,984)		(754)		(4,552)		1,507
Net loss from our investments in the equity of other companies (3)	71		89		297		399
Other miscellaneous, net	(70)		(5,397)		(6,132)		(6,775)
Other income, net	$	(3,998)	$	(5,955)	$	(22,147)	$	(4,671)

__________

(1)Amounts primarily relate to the sales of certain intellectual property rights and certain other assets.

(2)Amounts relate to the remeasurement of the Company’s foreign currency denominated assets and liabilities.

(3)Amounts relate to the income statement impacts of our investments in the equity of other companies, including investments accounted for under the equity method.

INCOME TAXES (Tables)

9 Months Ended

Sep. 30, 2022

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
(Loss) income from continuing operations before income tax	$	(707,592)		$	(47,741)		$	(2,648,439)		$	958
Income tax expense	$	10,680		$	1,548		$	16,016		$	13,372
Effective tax rate	(1.5)		%	(3.2)		%	(0.6)		%	1,395.8		%

NET LOSS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Schedule of Reconciliation of the Numerator and Denominator of Basic and Diluted Net (Loss) Income Per Share

The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the three and nine months ended September 30, 2022 and 2021 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Numerator:
Loss from continuing operations	$	(718,272)	$	(49,289)	$	(2,664,455)	$	(12,414)


Loss from discontinued operations, net of tax	(3,897)		(27,918)		(15,115)		(38,769)
Net loss	$	(722,169)	$	(77,207)	$	(2,679,570)	$	(51,183)
Denominator:
For basic per share data—weighted average shares	235,160		233,578		234,719		232,487
Dilutive effect of ordinary share equivalents	—		—		—		—

For diluted per share data—weighted average shares	235,160		233,578		234,719		232,487

Schedule of Computation of Diluted Income Per Share Amount


	Three Months Ended September 30,		Nine Months Ended September 30,
	2022	2021	2022	2021
Stock options	5,274	6,532	5,558	6,626
Stock awards	5,151	8,668	6,066	9,570

CONDENSED COMBINED DEBTOR-IN-POSSESSION FINANCIAL INFORMATION (Tables)

9 Months Ended

Sep. 30, 2022

Reorganizations [Abstract]

Schedule of Condensed Combined Financial Statements of the Debtors





CONDENSED COMBINED BALANCE SHEETS (UNAUDITED)
(Dollars in thousands)

	September 30, 2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	990,107
Restricted cash and cash equivalents	59,486
Accounts receivable, net	409,333
Inventories, net	254,206
Prepaid expenses and other current assets	126,613
Income taxes receivable	1,290

Receivables from Non-Debtor Affiliates	102,162
Total current assets	$	1,943,197

PROPERTY, PLANT AND EQUIPMENT, NET	236,755
OPERATING LEASE ASSETS	26,240
GOODWILL	1,352,011
OTHER INTANGIBLES, NET	1,992,932

INVESTMENTS IN NON-DEBTOR AFFILIATES	53,887
RECEIVABLES FROM NON-DEBTOR AFFILIATES	241,860
OTHER ASSETS	139,659
TOTAL ASSETS	$	5,986,541
LIABILITIES AND DEFICIT
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	517,978



Income taxes payable	3,459

Payables to Non-Debtor Affiliates	2,614
Total current liabilities	$	524,051
DEFERRED INCOME TAXES	11,536




OTHER LIABILITIES	21,792
LIABILITIES SUBJECT TO COMPROMISE	9,345,250
TOTAL DEFICIT	(3,916,088)
TOTAL LIABILITIES AND DEFICIT	$	5,986,541





CONDENSED COMBINED STATEMENTS OF OPERATIONS (UNAUDITED)
(Dollars in thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
TOTAL REVENUES, NET	$	541,889		$	1,765,228
COSTS AND EXPENSES:
Cost of revenues	266,811			807,013
Selling, general and administrative	189,689			592,139
Research and development	34,519			102,942
Acquired in-process research and development	800			68,700
Litigation-related and other contingencies, net	419,377			444,738
Asset impairment charges	150,200			1,951,216
Acquisition-related and integration items, net	(1,399)			(951)

Interest expense, net	71,874			347,862

Reorganization items, net	124,212			124,212
Other expense (income), net	9,052			(2,360)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX	$	(723,246)		$	(2,670,283)
INCOME TAX EXPENSE	10,535			15,032
LOSS FROM CONTINUING OPERATIONS	$	(733,781)		$	(2,685,315)
DISCONTINUED OPERATIONS, NET OF TAX	(3,896)			(15,096)
NET LOSS ATTRIBUTABLE TO DEBTOR ENTITIES	$	(737,677)		$	(2,700,411)
EQUITY IN INCOME OF NON-DEBTOR AFFILIATES, NET OF TAX	18,669			26,776
NET LOSS	$	(719,008)		$	(2,673,635)





CONDENSED COMBINED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
(Dollars in thousands)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2022			2022
NET LOSS	$	(719,008)		$	(2,673,635)
OTHER COMPREHENSIVE INCOME:
Net unrealized (loss) gain on foreign currency	$	(10,649)		$	(13,088)
Total other comprehensive (loss) income	$	(10,649)		$	(13,088)
COMPREHENSIVE LOSS	$	(729,657)		$	(2,686,723)





CONDENSED COMBINED STATEMENTS OF CASH FLOWS (UNAUDITED)
(Dollars in thousands)

	Nine Months Ended September 30,
	2022
OPERATING ACTIVITIES:
Net cash provided by operating activities (1)	$	75,349
INVESTING ACTIVITIES:
Capital expenditures, excluding capitalized interest	(35,018)

Proceeds from the U.S. Government Agreement	13,601

Acquisitions, including in-process research and development, net of cash and restricted cash acquired	(89,520)




Proceeds from sale of business and other assets, net	22,378
Disbursements for loans made to Non-Debtor Affiliates	(51,180)

Net cash used in investing activities	$	(139,739)
FINANCING ACTIVITIES:


Repayments of notes	(180,342)
Repayments of term loans	(10,000)


Adequate protection payments	(168,643)
Repayments of other indebtedness	(4,500)

Payments for contingent consideration	(1,939)
Payments of tax withholding for restricted shares	(1,898)


Net cash used in financing activities	$	(367,322)
Effect of foreign exchange rate	(2,393)

NET DECREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	$	(434,105)
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	1,568,698
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	$	1,134,593

__________

BANKRUPTCY PROCEEDINGS (Details) - USD ($) $ in Millions		1 Months Ended
BANKRUPTCY PROCEEDINGS (Details) - USD ($) $ in Millions	Aug. 16, 2022	Sep. 30, 2022	Oct. 31, 2022
Reorganization
Reorganisation items, net		$ 2.9
Subsequent event
Reorganization
Liquidity requirement			$ 600.0
Staling Horse Bid
Reorganization
Potential proceeds from settlement of unencumbered assets	$ 5.0
Potential reimbursement closing cost	$ 122.0
Restructuring Support Agreement
Reorganization
Outstanding principal amount of secured debt, percentage	50.00%

BANKRUPTCY PROCEEDINGS - Liabilities Subject to Compromise (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Reorganizations [Abstract]
Accounts payable	$ 16,121
Accrued interest	160,097
Debt	7,979,183
Litigation accruals	794,578
Uncertain tax positions	232,920
Other	162,351
Total	$ 9,345,250	$ 0

BANKRUPTCY PROCEEDINGS - Reorganization Items (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Reorganizations [Abstract]
Professional fees	$ 35,015		$ 35,015
Debt valuation adjustments	89,197		89,197	$ 0
Total	$ 124,212	$ 0	$ 124,212	$ 0

DISCONTINUED OPERATIONS - Astora - Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operations, net of tax	$ (3,897)	$ (27,918)	$ (15,115)	$ (38,769)
Discontinued operations, disposed of by means other than sale, abandonment \| Astora
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Litigation-related and other contingencies, net	0	25,000	0	25,000
Loss from discontinued operations before income taxes	(3,897)	(31,306)	(15,115)	(43,400)
Income tax benefit	0	(3,388)	0	(4,631)
Discontinued operations, net of tax	$ (3,897)	$ (27,918)	$ (15,115)	$ (38,769)

- Definition

Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

+ Details

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

DISCONTINUED OPERATIONS - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
DISCONTINUED OPERATIONS - Narrative (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022
Restructuring Cost and Reserve [Line Items]
Loss from discontinued operations, net of tax	$ (3,897,000)	$ (27,918,000)	$ (15,115,000)	$ (38,769,000)
Asset impairments	150,200,000	42,155,000	1,951,216,000	50,393,000
Chestnut Ridge, New York
Restructuring Cost and Reserve [Line Items]
Assets held for sale					$ 11,000,000
Discontinued operations, disposed of by means other than sale, abandonment \| Astora
Restructuring Cost and Reserve [Line Items]
Loss from discontinued operations, net of tax	$ (3,897,000)	(27,918,000)	(15,115,000)	(38,769,000)
Cash used in investing activities			0	0
Depreciation and amortization			$ 0	$ 0
Disposal group, disposed of by sale, not discontinued operations \| Endo International PLC
Restructuring Cost and Reserve [Line Items]
Asset impairments		42,200,000
Pre-tax reversal of severance costs		$ 19,800,000

RESTRUCTURING - Narrative (Details) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
RESTRUCTURING - Narrative (Details) $ in Thousands	Nov. 05, 2020 USD ($) position	Apr. 30, 2022 USD ($) position	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Other restructuring charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 30,000	$ 24,800	$ 77,100	$ 37,500
2020 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected number of positions eliminated \| position	300
Restructuring charges			91	35,952	7,347	67,850
2020 Restructuring Initiative \| Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, cost incurred to date			51,000		51,000
2020 Restructuring Initiative \| Asset impairments
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, cost incurred to date			49,500		49,500
2020 Restructuring Initiative \| Inventory adjustments
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, cost incurred to date			11,500		11,500
2020 Restructuring Initiative \| Employee Separation, Continuity and Other Benefit-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges					1,290
Restructuring and related cost, cost incurred to date			53,900		53,900
2020 Restructuring Initiative \| Other restructuring charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges					798
Restructuring and related cost, cost incurred to date			3,500		3,500
2020 Restructuring Initiative \| Operating segments \| Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring charges			400	31,000	5,500	53,500
Restructuring and related cost, cost incurred to date			134,300		134,300
2020 Restructuring Initiative \| Cost of revenues
Restructuring Cost and Reserve [Line Items]
Restructuring charges			375	$ (11,050)	4,025	$ 9,294
2020 Restructuring Initiative \| Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring and related costs, expected cost savings	$ 85,000
2020 Restructuring Initiative \| Minimum \| Cost of revenues
Restructuring Cost and Reserve [Line Items]
Restructuring and related costs, expected cost savings	65,000
2020 Restructuring Initiative \| Minimum \| Other expenses
Restructuring Cost and Reserve [Line Items]
Restructuring and related costs, expected cost savings	20,000
2020 Restructuring Initiative \| Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring and related costs, expected cost savings	95,000
2020 Restructuring Initiative \| Maximum \| Cost of revenues
Restructuring Cost and Reserve [Line Items]
Restructuring and related costs, expected cost savings	70,000
2020 Restructuring Initiative \| Maximum \| Other expenses
Restructuring Cost and Reserve [Line Items]
Restructuring and related costs, expected cost savings	$ 25,000
2022 Restructuring Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected number of positions eliminated \| position		100
Restructuring charges			(579)		29,525
2022 Restructuring Initiative \| Employee Separation, Continuity and Other Benefit-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges					18,406
2022 Restructuring Initiative \| Other restructuring charges
Restructuring Cost and Reserve [Line Items]
Restructuring charges					1,102
2022 Restructuring Initiative \| Operating segments \| Generic Pharmaceuticals
Restructuring Cost and Reserve [Line Items]
Restructuring charges			100		17,000
2022 Restructuring Initiative \| Cost of revenues
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 68		$ 13,352
2022 Restructuring Initiative \| Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring and related costs, expected cost savings		$ 55,000
2022 Restructuring Initiative \| Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring and related costs, expected cost savings		$ 65,000

RESTRUCTURING - Pre-tax Net Charges (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net restructuring charges (charge reversals) related to:
Accelerated depreciation		$ 6,400	$ 3,800	$ 22,300
Asset impairments	$ 150,200	42,155	1,951,216	50,393
2020 Restructuring Initiative
Net restructuring charges (charge reversals) related to:
Accelerated depreciation	0	6,350	3,824	22,329
Asset impairments	0	42,155	0	42,155
Inventory adjustments	408	719	1,435	6,513
Employee separation, continuity and other benefit-related costs	(433)	(14,481)	1,290	(6,150)
Certain other restructuring costs	116	1,209	798	3,003
Total	91	$ 35,952	7,347	$ 67,850
2022 Restructuring Initiative
Net restructuring charges (charge reversals) related to:
Inventory adjustments	0		2,462
Employee separation, continuity and other benefit-related costs	(1,681)		18,406
Certain other restructuring costs	1,102		8,657
Total	$ (579)		$ 29,525

RESTRUCTURING - Pre-tax Net Charges Included in the Condensed Consolidated Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
2020 Restructuring Initiative
Net restructuring charges (charge reversals) included in:
Restructuring charges	$ 91	$ 35,952	$ 7,347	$ 67,850
2022 Restructuring Initiative
Net restructuring charges (charge reversals) included in:
Restructuring charges	(579)		29,525
Cost of revenues \| 2020 Restructuring Initiative
Net restructuring charges (charge reversals) included in:
Restructuring charges	375	(11,050)	4,025	9,294
Cost of revenues \| 2022 Restructuring Initiative
Net restructuring charges (charge reversals) included in:
Restructuring charges	68		13,352
Selling, general and administrative \| 2020 Restructuring Initiative
Net restructuring charges (charge reversals) included in:
Restructuring charges	(243)	4,946	201	15,174
Selling, general and administrative \| 2022 Restructuring Initiative
Net restructuring charges (charge reversals) included in:
Restructuring charges	(644)		12,075
Research and development \| 2020 Restructuring Initiative
Net restructuring charges (charge reversals) included in:
Restructuring charges	(41)	(99)	3,121	1,227
Research and development \| 2022 Restructuring Initiative
Net restructuring charges (charge reversals) included in:
Restructuring charges	(3)		4,098
Asset impairments \| 2020 Restructuring Initiative
Net restructuring charges (charge reversals) included in:
Restructuring charges	$ 0	$ 42,155	$ 0	$ 42,155

RESTRUCTURING - Changes to the Liability (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
2020 Restructuring Initiative
Restructuring Reserve
Net charges	$ 91	$ 35,952	$ 7,347	$ 67,850
2022 Restructuring Initiative
Restructuring Reserve
Net charges	(579)		29,525
Total \| 2020 Restructuring Initiative
Restructuring Reserve
Beginning liability balance			11,184
Net charges			2,088
Cash payments			(11,674)
Ending liability balance	1,598		1,598
Total \| 2022 Restructuring Initiative
Restructuring Reserve
Beginning liability balance			0
Net charges			19,508
Cash payments			(13,422)
Ending liability balance	6,086		6,086
Employee Separation, Continuity and Other Benefit-Related Costs \| 2020 Restructuring Initiative
Restructuring Reserve
Beginning liability balance			10,979
Net charges			1,290
Cash payments			(10,671)
Ending liability balance	1,598		1,598
Employee Separation, Continuity and Other Benefit-Related Costs \| 2022 Restructuring Initiative
Restructuring Reserve
Beginning liability balance			0
Net charges			18,406
Cash payments			(12,871)
Ending liability balance	5,535		5,535
Certain Other Restructuring Costs
Restructuring Reserve
Net charges	30,000	$ 24,800	77,100	$ 37,500
Certain Other Restructuring Costs \| 2020 Restructuring Initiative
Restructuring Reserve
Beginning liability balance			205
Net charges			798
Cash payments			(1,003)
Ending liability balance	0		0
Certain Other Restructuring Costs \| 2022 Restructuring Initiative
Restructuring Reserve
Beginning liability balance			0
Net charges			1,102
Cash payments			(551)
Ending liability balance	$ 551		$ 551

SEGMENT RESULTS - Schedule of Reportable Segments Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)
Segment Reporting Information
Number of reportable segments \| segment			4
Total net revenues from external customers	$ 541,690	$ 772,028	$ 1,763,063	$ 2,203,777
Total segment adjusted income from continuing operations before income tax	235,544	428,923	824,046	1,166,572
Branded Pharmaceuticals
Segment Reporting Information
Total net revenues from external customers	203,501	230,977	627,314	665,652
Total segment adjusted income from continuing operations before income tax	84,940	105,849	251,219	301,277
Sterile Injectables
Segment Reporting Information
Total net revenues from external customers	118,693	343,653	481,892	946,998
Total segment adjusted income from continuing operations before income tax	58,633	282,300	318,284	751,922
Generic Pharmaceuticals
Segment Reporting Information
Total net revenues from external customers	201,435	174,306	590,756	522,451
Total segment adjusted income from continuing operations before income tax	87,675	34,010	237,394	89,036
International Pharmaceuticals
Segment Reporting Information
Total net revenues from external customers	18,061	23,092	63,101	68,676
Total segment adjusted income from continuing operations before income tax	$ 4,296	$ 6,764	$ 17,149	$ 24,337

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

SEGMENT RESULTS - Schedule of Reconciliations of Consolidated Adjusted Income (Loss) Before Income Tax (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information
Total consolidated (loss) income from continuing operations before income tax	$ (707,592)	$ (47,741)		$ (2,648,439)	$ 958
Amortization of intangible assets				261,844
Acquired in-process research and development charges	800	0		68,700	5,000
Asset impairment charges	150,200	42,155		1,951,216	50,393
Acquisition-related and integration items, net	(1,399)	(1,432)		(951)	(6,357)
Loss on extinguishment of debt	0	0		0	13,753
Reorganization items, net	124,212	0		124,212	0
Total segment adjusted income from continuing operations before income tax	235,544	428,923		824,046	1,166,572
Accelerated depreciation		6,400		3,800	22,300
Gain (loss) from prior contract dispute		4,900			4,900
6.125% Senior Secured Notes due 2029
Segment Reporting Information
Loss on extinguishment of debt			$ 6,000
6.125% Senior Secured Notes due 2029 \| Selling, general and administrative
Segment Reporting Information
Loss on extinguishment of debt			$ 3,900
Debt modification costs					3,900
Employee severance
Segment Reporting Information
Restructuring charges	14,100	(11,300)		58,100	(1,200)
Other restructuring charges
Segment Reporting Information
Restructuring charges	30,000	24,800		77,100	37,500
Segment reconciling items
Segment Reporting Information
Interest expense, net	74,753	142,958		349,486	418,852
Corporate unallocated costs	44,182	65,317		125,851	141,291
Amortization of intangible assets	84,042	91,901		261,844	281,101
Acquired in-process research and development charges	800	0		68,700	5,000
Amounts related to continuity and separation benefits, cost reductions and strategic review initiatives	44,029	19,829		139,025	58,632
Certain litigation-related and other contingencies, net	419,376	83,495		444,738	119,327
Certain legal costs	8,052	38,842		31,322	82,961
Asset impairment charges	150,200	42,155		1,951,216	50,393
Acquisition-related and integration items, net	(1,399)	(1,432)		(951)	(6,357)
Loss on extinguishment of debt	0	0		0	13,753
Foreign currency impact related to the remeasurement of intercompany debt instruments	(6,220)	(2,036)		(7,114)	466
Reorganization items, net	124,212	0		124,212	0
Other, net	1,109	(4,365)		(15,844)	195
Operating segments
Segment Reporting Information
Total segment adjusted income from continuing operations before income tax	$ 235,544	$ 428,923		$ 824,046	$ 1,166,572

SEGMENT RESULTS - Schedule of Disaggregation of Revenues (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue
TOTAL REVENUES, NET	$ 541,690,000	$ 772,028,000	$ 1,763,063,000	$ 2,203,777,000
Product line revenue reporting threshold			$ 25,000,000
Varenicline Tablets \| Revenue from Contract with Customer Benchmark \| Product Concentration Risk \| Maximum
Disaggregation of Revenue
Concentration risk, percentage	15.00%		13.00%
Lubiprostone Capsules \| Revenue from Contract with Customer Benchmark \| Product Concentration Risk \| Maximum
Disaggregation of Revenue
Concentration risk, percentage	5.00%
Branded Pharmaceuticals
Disaggregation of Revenue
TOTAL REVENUES, NET	$ 203,501,000	230,977,000	$ 627,314,000	665,652,000
Branded Pharmaceuticals \| Specialty Products
Disaggregation of Revenue
TOTAL REVENUES, NET	146,330,000	161,917,000	459,251,000	472,338,000
Branded Pharmaceuticals \| XIAFLEX®
Disaggregation of Revenue
TOTAL REVENUES, NET	104,014,000	105,509,000	324,376,000	312,266,000
Branded Pharmaceuticals \| SUPPRELIN® LA
Disaggregation of Revenue
TOTAL REVENUES, NET	31,283,000	30,069,000	84,852,000	85,665,000
Branded Pharmaceuticals \| Other Specialty
Disaggregation of Revenue
TOTAL REVENUES, NET	11,033,000	26,339,000	50,023,000	74,407,000
Branded Pharmaceuticals \| Established Products
Disaggregation of Revenue
TOTAL REVENUES, NET	57,171,000	69,060,000	168,063,000	193,314,000
Branded Pharmaceuticals \| PERCOCET®
Disaggregation of Revenue
TOTAL REVENUES, NET	25,052,000	26,914,000	77,483,000	78,695,000
Branded Pharmaceuticals \| TESTOPEL®
Disaggregation of Revenue
TOTAL REVENUES, NET	9,430,000	11,686,000	28,331,000	32,314,000
Branded Pharmaceuticals \| Other Established
Disaggregation of Revenue
TOTAL REVENUES, NET	22,689,000	30,460,000	62,249,000	82,305,000
Sterile Injectables
Disaggregation of Revenue
TOTAL REVENUES, NET	118,693,000	343,653,000	481,892,000	946,998,000
Sterile Injectables \| VASOSTRICT®
Disaggregation of Revenue
TOTAL REVENUES, NET	33,697,000	255,697,000	225,217,000	676,764,000
Sterile Injectables \| ADRENALIN®
Disaggregation of Revenue
TOTAL REVENUES, NET	24,917,000	28,722,000	85,514,000	88,136,000
Sterile Injectables \| Other Sterile Injectables
Disaggregation of Revenue
TOTAL REVENUES, NET	60,079,000	59,234,000	171,161,000	182,098,000
Generic Pharmaceuticals
Disaggregation of Revenue
TOTAL REVENUES, NET	201,435,000	174,306,000	590,756,000	522,451,000
International Pharmaceuticals
Disaggregation of Revenue
TOTAL REVENUES, NET	$ 18,061,000	$ 23,092,000	$ 63,101,000	$ 68,676,000
International Pharmaceuticals \| Revenue from Contract with Customer Benchmark \| Product Concentration Risk \| Maximum
Disaggregation of Revenue
Concentration risk, percentage			5.00%	5.00%

FAIR VALUE MEASUREMENTS - Restricted Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Restricted Cash and Cash Equivalents
Restricted cash and cash equivalents, current	$ 145,486	$ 124,114
Restricted cash and cash equivalents, noncurrent	85,000	0
Restricted cash and cash equivalents	230,486	124,114
Restricted Cash and Cash Equivalents, Insurance Coverage
Restricted Cash and Cash Equivalents
Restricted cash and cash equivalents, current	86,000	45,000
Opioid Related Cases and Mesh Related Cases
Restricted Cash and Cash Equivalents
Restricted cash and cash equivalents, current	$ 58,500	$ 78,400

FAIR VALUE MEASUREMENTS - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Acquisition-related contingent consideration \| Accounts Payable and Accrued Liabilities
Liabilities:
Fair value of financial liabilities measured on recurring basis		$ 5,700
Acquisition-related contingent consideration \| Other Liabilities
Liabilities:
Fair value of financial liabilities measured on recurring basis		14,300
Money Market Funds \| Restricted cash and cash equivalents
Assets:
Fair value of financial assets measured on recurring basis	$ 14,500	16,200
Fair value, measurements, recurring \| Acquisition-related contingent consideration
Liabilities:
Fair value of financial liabilities measured on recurring basis	15,812	20,076
Fair value, measurements, recurring \| Money Market Funds
Assets:
Fair value of financial assets measured on recurring basis	14,539	134,847
Fair value, measurements, recurring \| Level 1 Inputs \| Acquisition-related contingent consideration
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Fair value, measurements, recurring \| Level 1 Inputs \| Money Market Funds
Assets:
Fair value of financial assets measured on recurring basis	14,539	134,847
Fair value, measurements, recurring \| Level 2 Inputs \| Acquisition-related contingent consideration
Liabilities:
Fair value of financial liabilities measured on recurring basis	0	0
Fair value, measurements, recurring \| Level 2 Inputs \| Money Market Funds
Assets:
Fair value of financial assets measured on recurring basis	0	0
Fair value, measurements, recurring \| Level 3 Inputs \| Acquisition-related contingent consideration
Liabilities:
Fair value of financial liabilities measured on recurring basis	15,812	20,076
Fair value, measurements, recurring \| Level 3 Inputs \| Money Market Funds
Assets:
Fair value of financial assets measured on recurring basis	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Narrative (Details) - Discount rate	Sep. 30, 2022
Minimum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.100
Maximum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.150
Weighted average
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate applied	0.108

FAIR VALUE MEASUREMENTS - Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs (Details) - Acquisition-related contingent consideration - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period	$ 18,242	$ 27,447	$ 20,076	$ 36,249
Amounts settled	(286)	(2,612)	(2,445)	(6,302)
Changes in fair value recorded in earnings	(1,399)	(1,435)	(951)	(6,771)
Effect of currency translation	(745)	(188)	(868)	36
Changes in Fair Value Recorded in Earnings			(951)
Amounts Settled and Other			(3,313)
End of period	15,812	$ 23,212	15,812	$ 23,212
Auxilium acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			9,038
Changes in Fair Value Recorded in Earnings			422
Amounts Settled and Other			(536)
End of period	8,924		8,924
Lehigh Valley Technologies, Inc. acquisitions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			3,600
Changes in Fair Value Recorded in Earnings			(694)
Amounts Settled and Other			(506)
End of period	2,400		2,400
Other
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning of period			7,438
Changes in Fair Value Recorded in Earnings			(679)
Amounts Settled and Other			(2,271)
End of period	$ 4,488		$ 4,488

FAIR VALUE MEASUREMENTS - Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Assets:
Intangible assets, excluding goodwill	$ (53,200)		$ (103,153)	$ (7,800)
Total	$ (150,200)	$ (42,155)	(1,951,216)	$ (50,393)
Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill			(103,153)
Certain property, plant and equipment			(3,063)
Total			$ (106,216)
Fair value, measurements, nonrecurring \| Discount rate \| Minimum
Assets:
Discount rate applied	0.095		0.095
Fair value, measurements, nonrecurring \| Discount rate \| Maximum
Assets:
Discount rate applied	0.120		0.120
Fair value, measurements, nonrecurring \| Discount rate \| Weighted average
Assets:
Discount rate applied	0.117		0.117
Level 1 Inputs \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	$ 0		$ 0
Certain property, plant and equipment	0		0
Total	0		0
Level 2 Inputs \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	0		0
Certain property, plant and equipment	0		0
Total	0		0
Level 3 Inputs \| Fair value, measurements, nonrecurring
Assets:
Intangible assets, excluding goodwill	65,407		65,407
Certain property, plant and equipment	0		0
Total	$ 65,407		$ 65,407

INVENTORIES - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 101,407	$ 90,453
Work-in-process	59,630	82,728
Finished goods	127,877	110,371
Total	288,914	283,552
Long-term inventory	35,300	10,700
Inventories not yet available for sale	$ 11,300	$ 12,200

LEASES - Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Right-of-use assets:
Operating lease right-of-use assets	$ 31,342	$ 34,832
Finance lease right-of-use assets	28,819	38,365
Total right-of-use assets	$ 60,161	$ 73,197
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization	Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization
Operating lease liabilities
Current operating lease liabilities	$ 724	$ 10,992
Noncurrent operating lease liabilities	4,363	33,727
Total operating lease liabilities	$ 5,087	$ 44,719
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Current operating lease liabilities	Current operating lease liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Noncurrent operating lease liabilities	Noncurrent operating lease liabilities
Finance lease liabilities
Current finance lease liabilities	$ 0	$ 6,841
Noncurrent finance lease liabilities	1,415	18,374
Total finance lease liabilities	$ 1,415	$ 25,215
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accounts payable and accrued expenses	Accounts payable and accrued expenses
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent
Liabilities subject to compromise, operating lease	$ 33,600
Liabilities subject to compromise, finace lease	$ 18,800

LEASES - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Operating lease cost	$ 3,415	$ 3,612	$ 8,452	$ 10,869
Finance lease cost:
Amortization of right-of-use assets	2,024	2,311	6,455	6,933
Interest on lease liabilities	271	310	877	1,015
Other lease costs and income:
Variable lease costs	3,525	3,035	8,220	9,099
Finance lease right-of-use asset impairment charges	0	0	3,063	0
Sublease income	(1,560)	(957)	(4,810)	(2,837)
Cost of revenues
Lessee, Lease, Description
Lease, cost	1,539	2,988	4,668	9,032
Selling, general and administrative
Lessee, Lease, Description
Lease, cost	5,812	4,959	13,488	14,870
Research and development
Lessee, Lease, Description
Lease, cost	$ 53	$ 54	$ 161	$ 162

LEASES - Cash Flow and Supplemental Noncash Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash payments for operating leases	$ 9,746	$ 10,010
Operating cash payments for finance leases	1,439	1,791
Financing cash payments for finance leases	4,501	4,044
Operating lease	$ 1,296	$ 4,985

GOODWILL AND OTHER INTANGIBLES - Changes in the Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill
Goodwill, beginning balance	$ 3,197,011
Goodwill impairment charges	(1,845,000)
Goodwill, ending balance	1,352,011
Branded Pharmaceuticals
Goodwill
Goodwill, beginning balance	828,818
Goodwill impairment charges	0
Goodwill, ending balance	828,818
Sterile Injectables
Goodwill
Goodwill, beginning balance	2,368,193
Goodwill impairment charges	(1,845,000)
Goodwill, ending balance	523,193
Generic Pharmaceuticals
Goodwill
Goodwill, beginning balance	0
Goodwill impairment charges	0
Goodwill, ending balance	0
International Pharmaceuticals
Goodwill
Goodwill, beginning balance	0
Goodwill impairment charges	0
Goodwill, ending balance	$ 0

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

GOODWILL AND OTHER INTANGIBLES - Accumulated Impairment (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Goodwill [Line Items]
Accumulated impairment losses	$ 6,709,452	$ 4,911,822
Branded Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	855,810	855,810
Sterile Injectables
Goodwill [Line Items]
Accumulated impairment losses	2,208,000	363,000
Generic Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	3,142,657	3,142,657
International Pharmaceuticals
Goodwill [Line Items]
Accumulated impairment losses	$ 502,985	$ 550,355

GOODWILL AND OTHER INTANGIBLES - Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Intangible Assets, Gross [Roll Forward]
Beginning balance		$ 6,674,655
Acquisitions		0
Impairments	$ (53,200)	(103,153)	$ (7,800)
Effect of Currency Translation		(22,210)
Ending balance	6,549,292	6,549,292
Accumulated amortization:
Beginning Balance		(4,311,832)
Amortization		(261,844)
Impairments		0
Effect of Currency Translation		17,316
Ending Balance	(4,556,360)	(4,556,360)
Net other intangibles	1,992,932	1,992,932		$ 2,362,823
Licensing
Finite-lived intangibles:
Beginning Balance		442,107
Acquisitions		0
Impairments		0
Effect of Currency Translation		0
Ending Balance	442,107	442,107
Accumulated amortization:
Beginning Balance		(419,932)
Amortization		(3,432)
Impairments		0
Effect of Currency Translation		0
Ending Balance	(423,364)	(423,364)
Tradenames
Finite-lived intangibles:
Beginning Balance		6,409
Acquisitions		0
Impairments		0
Effect of Currency Translation		0
Ending Balance	6,409	6,409
Accumulated amortization:
Beginning Balance		(6,409)
Amortization		0
Impairments		0
Effect of Currency Translation		0
Ending Balance	(6,409)	(6,409)
Developed technology
Finite-lived intangibles:
Beginning Balance		6,226,139
Acquisitions		0
Impairments		(103,153)
Effect of Currency Translation		(22,210)
Ending Balance	6,100,776	6,100,776
Accumulated amortization:
Beginning Balance		(3,885,491)
Amortization		(258,412)
Impairments		0
Effect of Currency Translation		17,316
Ending Balance	$ (4,126,587)	$ (4,126,587)
Weighted average
Accumulated amortization:
Intangible life (years)		12 years
Weighted average \| Licensing
Accumulated amortization:
Intangible life (years)		14 years
Weighted average \| Developed technology
Accumulated amortization:
Intangible life (years)		12 years

GOODWILL AND OTHER INTANGIBLES - Other Intangibles (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Other Intangible Assets [Line Items]
Amortization of intangible assets			$ 261,844
Segment reconciling items
Other Intangible Assets [Line Items]
Amortization of intangible assets	$ 84,042	$ 91,901	$ 261,844	$ 281,101

GOODWILL AND OTHER INTANGIBLES - Impairments (Narrative) (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Goodwill [Line Items]
Goodwill impairment charges			$ 1,845,000
Impairment of intangible assets	$ 53,200		$ 103,153	$ 7,800
Sterile Injectables
Goodwill [Line Items]
Goodwill impairment charges	$ 97,000	$ 1,748,000
Discount rate \| Branded Pharmaceuticals
Goodwill [Line Items]
Goodwill impairment charges		$ 0
Intangible assets and goodwill, measurement input	0.150	0.135	0.150
Discount rate \| Sterile Injectables
Goodwill [Line Items]
Intangible assets and goodwill, measurement input	0.195	0.185	0.195

LICENSE, COLLABORATION AND ASSET ACQUISITION AGREEMENTS (Details) $ in Millions		1 Months Ended	3 Months Ended
	May 01, 2022 USD ($)	May 31, 2022 project	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Nevakar Injectables, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of in process research and development projects acquired \| project		6
Acquired in-process research and development	$ 35.0
TLC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development			$ 30.0
Investment in subsidiary			110.0
Payments of additional achievement certain development and regulatory milestones			30.0
Payments of additional achievement certain commercial milestones			$ 500.0
Cash into bank account				$ 85.0

CONTRACT ASSETS AND LIABILITIES - Contract Assets and Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Contract assets	$ 2,737	$ 13,005
Contract assets - $ change	$ (10,268)
Contract assets - % change	(79.00%)
Contract liabilities	$ 4,240	4,663
Contract liabilities - $ change	$ (423)
Contract liabilities - % change	(9.00%)
Contract with customer, asset, after allowance for credit loss, current	$ 1,200	2,800
Contract liability amounts classified as current	600	$ 600
Increase in contract liability	$ 400

CONTRACT ASSETS AND LIABILITIES - Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Performance obligation satisfied in previous period	$ 10.2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accounts Payable and Accrued Liabilities, Current [Abstract]
Trade accounts payable	$ 84,999	$ 123,129
Returns and allowances	159,215	183,116
Rebates	148,165	150,039
Chargebacks	834	2,617
Other sales deductions	6,551	2,500
Accrued interest	43	106,735
Accrued payroll and related benefits	39,465	90,029
Accrued royalties and other distribution partner payables	15,934	58,422
Acquisition-related contingent consideration—current	0	5,748
Other	83,524	114,563
Total	$ 538,730	$ 836,898

DEBT - Components of Total Indebtedness (Details) - USD ($)	3 Months Ended
	Sep. 30, 2022	Aug. 16, 2022	Jun. 30, 2022	Dec. 31, 2021	Oct. 31, 2021	Mar. 31, 2021
Debt Instrument
Principal amount	$ 8,147,826,000			$ 8,338,168,000
Carrying Amount	7,979,183,000			8,249,322,000
Interest expense, debt	77,000,000
Amortization of debt issuance cost	89,200,000
Current portion of long-term debt	$ 0			$ 200,342,000
Revolving Credit Facility
Debt Instrument
Interest rate (as a percent)	2.00%
Effective Interest Rate (as a percent)	9.75%			2.63%
Principal amount	$ 277,200,000			$ 277,200,000
Carrying Amount	$ 273,182,000			$ 277,200,000
7.25% Senior Notes due 2022
Debt Instrument
Interest rate (as a percent)	7.25%				7.25%
Effective Interest Rate (as a percent)				7.25%
Principal amount	$ 0			$ 8,294,000
Carrying Amount	$ 0			$ 8,294,000
5.75% Senior Notes due 2022
Debt Instrument
Interest rate (as a percent)	5.75%				5.75%
Effective Interest Rate (as a percent)				5.75%
Principal amount	$ 0			$ 172,048,000
Carrying Amount	$ 0			$ 172,048,000
5.375% Senior Notes due 2023
Debt Instrument
Interest rate (as a percent)			5.375%
Effective Interest Rate (as a percent)	5.38%			5.62%
Principal amount	$ 6,127,000			$ 6,127,000
Carrying Amount	$ 6,127,000			$ 6,111,000
6.00% Senior Notes due 2023
Debt Instrument
Interest rate (as a percent)			6.00%
Effective Interest Rate (as a percent)	6.00%			6.28%
Principal amount	$ 56,436,000			$ 56,436,000
Carrying Amount	$ 56,436,000			$ 56,203,000
5.875% Senior Secured Notes due 2024
Debt Instrument
Interest rate (as a percent)	5.875%
Effective Interest Rate (as a percent)	6.88%			6.14%
Principal amount	$ 300,000,000			$ 300,000,000
Carrying Amount	$ 291,531,000			$ 297,928,000
6.00% Senior Notes due 2025
Debt Instrument
Interest rate (as a percent)			6.00%
Effective Interest Rate (as a percent)	6.00%			6.27%
Principal amount	$ 21,578,000			$ 21,578,000
Carrying Amount	$ 21,578,000			$ 21,413,000
7.50% Senior Secured Notes due 2027
Debt Instrument
Interest rate (as a percent)	7.50%
Effective Interest Rate (as a percent)	8.50%			7.70%
Principal amount	$ 2,015,479,000			$ 2,015,479,000
Carrying Amount	$ 1,937,603,000			$ 1,997,777,000
9.50% Senior Secured Second Lien Notes due 2027
Debt Instrument
Interest rate (as a percent)	9.50%		9.50%
Effective Interest Rate (as a percent)	9.50%			9.68%
Principal amount	$ 940,590,000			$ 940,590,000
Carrying Amount	$ 940,590,000			$ 933,330,000
6.00% Senior Notes due 2028
Debt Instrument
Interest rate (as a percent)			6.00%
Effective Interest Rate (as a percent)	6.00%			6.11%
Principal amount	$ 1,260,416,000			$ 1,260,416,000
Carrying Amount	$ 1,260,416,000			$ 1,252,667,000
6.125% Senior Secured Notes due 2029
Debt Instrument
Interest rate (as a percent)	6.125%					6.125%
Effective Interest Rate (as a percent)	7.13%			6.34%
Principal amount	$ 1,295,000,000			$ 1,295,000,000		$ 1,295,000,000
Carrying Amount	$ 1,253,866,000			$ 1,278,718,000
Term Loan Facility
Debt Instrument
Interest rate (as a percent)	2.00%
Effective Interest Rate (as a percent)	12.25%			6.12%
Principal amount	$ 1,975,000,000			$ 1,985,000,000
Carrying Amount	$ 1,937,854,000			$ 1,947,633,000
9.75% Senior Secured Second Lien Notes due 2027
Debt Instrument
Interest rate (as a percent)		9.75%

DEBT - Narrative (Details) - USD ($) $ in Billions	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Mar. 31, 2021
Debt Instrument
Fair value of long term debt	$ 5.1		$ 8.0
5.875% Senior Secured Notes due 2024
Debt Instrument
Interest rate (as a percent)	5.875%
7.50% Senior Secured Notes due 2027
Debt Instrument
Interest rate (as a percent)	7.50%
6.125% Senior Secured Notes due 2029
Debt Instrument
Interest rate (as a percent)	6.125%			6.125%
9.50% Senior Secured Second Lien Notes due 2027
Debt Instrument
Interest rate (as a percent)	9.50%	9.50%

DEBT - Credit Facility (Details) - USD ($)	9 Months Ended
DEBT - Credit Facility (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Line of Credit Facility
Principal amount	$ 8,147,826,000	$ 8,338,168,000
Revolving Credit Facility
Line of Credit Facility
Principal amount	277,200,000	$ 277,200,000
2017 credit agreement \| Revolving Credit Facility
Line of Credit Facility
Principal amount	1,000,000,000
Commitments	76,000,000
Extinguishment of debt, amount	924,000,000
Term Loan Facility \| 2017 credit agreement
Line of Credit Facility
Principal amount	$ 2,000,000,000

DEBT - Covenants and Events of Default (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument, Redemption [Line Items]
Interest expense, debt	$ 77,000
Interest payments grace period		30 days
Adequate protection payments			$ 168,643	$ 0
Senior notes
Debt Instrument, Redemption [Line Items]
Interest rate (as a percent)	1.00%		1.00%
Adequate protection payments			$ 127,500
Revolving Credit Facility
Debt Instrument, Redemption [Line Items]
Interest rate (as a percent)	2.00%		2.00%
Adequate protection payments			$ 4,000
6.00% Senior Notes due 2028
Debt Instrument, Redemption [Line Items]
Debt interest payments		$ 38,000
Interest rate (as a percent)		6.00%
5.375% Senior Notes due 2023
Debt Instrument, Redemption [Line Items]
Debt interest payments		$ 2,000
Interest rate (as a percent)		5.375%
6.00% Senior Notes due 2023
Debt Instrument, Redemption [Line Items]
Debt interest payments		$ 2,000
Interest rate (as a percent)		6.00%
6.00% Senior Notes due 2025
Debt Instrument, Redemption [Line Items]
Debt interest payments		$ 1,000
Interest rate (as a percent)		6.00%
9.50% Senior Secured Second Lien Notes due 2027
Debt Instrument, Redemption [Line Items]
Debt interest payments		$ 45,000
Interest rate (as a percent)	9.50%	9.50%	9.50%
Term Loan Facility
Debt Instrument, Redemption [Line Items]
Interest rate (as a percent)	2.00%		2.00%
Adequate protection payments			$ 37,100

DEBT - Debt Financing Transactions (Details) - USD ($)	1 Months Ended		3 Months Ended			9 Months Ended
DEBT - Debt Financing Transactions (Details) - USD ($)	Oct. 31, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Feb. 28, 2021
Debt Instrument
Principal amount			$ 8,147,826,000			$ 8,147,826,000		$ 8,338,168,000
Loss on extinguishment of debt			0	$ 0		0	$ 13,753,000
Debt issuance costs, gross			56,700,000			56,700,000
6.125% Senior Secured Notes due 2029
Debt Instrument
Principal amount		$ 1,295,000,000	$ 1,295,000,000		$ 1,295,000,000	$ 1,295,000,000		1,295,000,000
Interest rate (as a percent)		6.125%	6.125%		6.125%	6.125%
Loss on extinguishment of debt					$ 6,000,000
Debt issuance costs, gross			$ 17,600,000			$ 17,600,000
6.125% Senior Secured Notes due 2029 \| Selling, general and administrative
Debt Instrument
Loss on extinguishment of debt					3,900,000
Term Loan Facility
Debt Instrument
Long-term debt, gross									$ 3,295,500,000
Proceeds from issuance of debt		$ 2,000,000,000
Principal amount			$ 1,975,000,000			$ 1,975,000,000		1,985,000,000
Interest rate (as a percent)			2.00%			2.00%
Extinguishment of debt, amount		1,295,000,000
Loss on extinguishment of debt					7,800,000
Debt Modification Expense		29,200,000
7.25% Senior Notes due 2022
Debt Instrument
Principal amount			$ 0			$ 0		8,294,000
Interest rate (as a percent)	7.25%		7.25%			7.25%
5.75% Senior Notes due 2022
Debt Instrument
Principal amount			$ 0			$ 0		172,048,000
Interest rate (as a percent)	5.75%		5.75%			5.75%
Senior notes
Debt Instrument
Interest rate (as a percent)			1.00%			1.00%
Long-term debt, maturity repayment deadline	91 days
Revolving Credit Facility
Debt Instrument
Principal amount			$ 277,200,000			$ 277,200,000		$ 277,200,000
Interest rate (as a percent)			2.00%			2.00%
Debt instrument, extended maturity modification, amount		$ 675,300,000			675,300,000
Deferred debt issuance costs					2,100,000
Unamortized discount (premium) and debt issuance costs, net					$ 2,100,000
Proceeds from long-term lines of credit	$ 76,000,000
Repayments of borrowings	$ 22,800,000

COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Thousands		1 Months Ended										3 Months Ended		9 Months Ended
	Aug. 16, 2022 USD ($)	Jul. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Feb. 28, 2022 USD ($)	Jan. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) county	Oct. 31, 2021 USD ($)	Sep. 30, 2021 USD ($) county	Aug. 31, 2021 USD ($) county municipality	Jan. 31, 2020 USD ($)	Sep. 30, 2019 USD ($) case	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($) case lawsuit	Nov. 01, 2022 case	Mar. 31, 2016 case
Loss Contingencies
Reserve for loss contingencies												$ 794,600		$ 794,600
Mesh related cases
Loss Contingencies
Payments to plaintiffs and qualified settlement funds														3,600,000
Settlement funds						$ 78,402						58,095		$ 58,095
Mesh related cases \| American Medical Systems
Loss Contingencies
Loss contingency, claims settled, number \| case														71,000
Opioid-related matters
Loss Contingencies
Reserve for loss contingencies												550,000		$ 550,000
Number of putative class actions \| lawsuit														3
Loss contingency, plaintiffs, number of counties									9		2
Settlement, amount awarded to other party								$ 50,000	$ 35,000	$ 8,750	$ 10,000
Loss contingency, number of municipalities \| municipality									18
Contingency charges												$ 419,000		$ 429,000
Opioid-related matters \| Subsequent event
Loss Contingencies
Number of cases filed by states \| case															15
Pending claims, number \| case															2,570
Number of cases filed by hospitals, health systems, unions, welfare funds or other third-party \| case															310
Number of cases alleging personal injury and/or wrongful death \| case															220
Opioid-related matters \| New York
Loss Contingencies
Loss contingency, plaintiffs, number of counties \| county								2
Opioid-related matters \| Texas
Loss Contingencies
Loss contingency, plaintiffs, number of counties \| county						4
Opioid-related matters \| San Francisco
Loss Contingencies
Initial settlement payments		$ 5,000
Subsequent settlement payments		$ 500
Accrual payment period (years)		10 years
Opioid-related matters \| VASOSTRICT and/or ADRENALIN
Loss Contingencies
Settlement, amount awarded to other party											$ 1,000
Opioid-related matters \| Endo International PLC
Loss Contingencies
Settlement, amount awarded to other party		$ 9,000	$ 26,000	$ 7,500	$ 65,000	$ 63,000	$ 25,000						$ 9,750
Opioid-related matters \| Ad Hoc First Lien Group
Loss Contingencies
Reserve for loss contingencies	$ 550,000
Accrual payment period (years)	10 years
District Court For The Eastern District of Pennsylvania
Loss Contingencies
Number of cases filed by states \| case																3
V A S O S T R I C T Related Matters \| Par Pharmaceutical Inc.
Loss Contingencies
Stay of approval period, Hatch-Waxman Act			30 months

COMMITMENTS AND CONTINGENCIES - Schedule of Loss Contingencies (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Mesh Liability Accrual
Ending balance	$ 794,600
Mesh related cases
Mesh Qualified Settlement Funds
Beginning balance	78,402
Cash received for reversionary interests, net of cash contributions to Qualified Settlement Funds	(367)
Cash distributions to settle disputes from Qualified Settlement Funds	(20,089)
Other	149
Ending balance	58,095
Mesh Liability Accrual
Other	149
Mesh related cases \| Mesh Liability Accrual
Mesh Qualified Settlement Funds
Other	(820)
Mesh Liability Accrual
Beginning balance	258,137
Cash distributions to settle disputes from Qualified Settlement Funds	(20,089)
Other cash distributions to settle disputes	(6,499)
Other	(820)
Ending balance	$ 230,729

OTHER COMPREHENSIVE (LOSS) INCOME (Details) - USD ($)	3 Months Ended		9 Months Ended
OTHER COMPREHENSIVE (LOSS) INCOME (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Equity [Abstract]
Other comprehensive income (loss), tax, portion attributable to parent	$ 0	$ 0	$ 0	$ 0
Reclassification from AOCI	$ 0	$ 0	$ 0	$ 0

SHAREHOLDERS' DEFICIT - Schedule of Stockholders Equity (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Increase (Decrease) in Stockholders' Equity
Shareholders' equity, beginning balance	$ (3,198,072)	$ (1,310,998)	$ (1,243,986)	$ (617,042)	$ (598,973)	$ (647,939)	$ (1,243,986)	$ (647,939)
Net Income (Loss)	(722,169)	(1,885,427)	(71,974)	(77,207)	(15,500)	41,524	(2,679,570)	(51,183)
Other comprehensive income (loss)	(10,649)	(4,334)	1,895	(3,293)	2,238	1,692	(13,088)	637
Compensation related to share-based awards	5,856	2,721	4,929	7,800	4,444	9,993
Exercise of options						622
Tax withholding for restricted shares	(4)	(31)	(1,863)	(574)	(9,251)	(4,863)
Other	(3)	(3)	1	(1)		(2)
Shareholders' equity, ending balance	(3,925,041)	(3,198,072)	(1,310,998)	(690,317)	(617,042)	(598,973)	(3,925,041)	(690,317)
Euro Deferred Shares
Increase (Decrease) in Stockholders' Equity
Shareholders' equity, beginning balance	42	44	45	47	47	49	45	49
Other	(3)	(2)	(1)	(1)		(2)
Shareholders' equity, ending balance	39	42	44	46	47	47	39	46
Ordinary Shares
Increase (Decrease) in Stockholders' Equity
Shareholders' equity, beginning balance	24	24	23	23	23	23	23	23
Other			1
Shareholders' equity, ending balance	24	24	24	23	23	23	24	23
Additional Paid-in Capital
Increase (Decrease) in Stockholders' Equity
Shareholders' equity, beginning balance	8,959,662	8,956,973	8,953,906	8,938,957	8,943,764	8,938,012	8,953,906	8,938,012
Compensation related to share-based awards	5,856	2,721	4,929	7,800	4,444	9,993
Exercise of options						622
Tax withholding for restricted shares	(4)	(31)	(1,863)	(574)	(9,251)	(4,863)
Other	0	(1)	1
Shareholders' equity, ending balance	8,965,514	8,959,662	8,956,973	8,946,183	8,938,957	8,943,764	8,965,514	8,946,183
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity
Shareholders' equity, beginning balance	(11,938,916)	(10,053,489)	(9,981,515)	(9,342,246)	(9,326,746)	(9,368,270)	(9,981,515)	(9,368,270)
Net Income (Loss)	(722,169)	(1,885,427)	(71,974)	(77,207)	(15,500)	41,524
Shareholders' equity, ending balance	(12,661,085)	(11,938,916)	(10,053,489)	(9,419,453)	(9,342,246)	(9,326,746)	(12,661,085)	(9,419,453)
Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity
Shareholders' equity, beginning balance	(218,884)	(214,550)	(216,445)	(213,823)	(216,061)	(217,753)	(216,445)	(217,753)
Other comprehensive income (loss)	(10,649)	(4,334)	1,895	(3,293)	2,238	1,692
Shareholders' equity, ending balance	$ (229,533)	$ (218,884)	$ (214,550)	$ (217,116)	$ (213,823)	$ (216,061)	$ (229,533)	$ (217,116)

SHAREHOLDERS' DEFICIT - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation related to share-based awards	$ 6.5	$ 7.8	$ 14.2	$ 22.2
Unrecognized compensation cost	$ 12.8		$ 12.8
Nonvested Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period			1 year

OTHER INCOME, NET - Schedule of Components of Other Expense, Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Component of Operating Income [Abstract]
Net loss (gain) on sale of business and other assets	$ (15)	$ 107	$ (11,760)	$ 198
Foreign currency (gain) loss, net	(3,984)	(754)	(4,552)	1,507
Net loss from our investments in the equity of other companies	71	89	297	399
Other miscellaneous, net	(70)	(5,397)	(6,132)	(6,775)
Other income, net	$ (3,998)	$ (5,955)	$ (22,147)	$ (4,671)

INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
(Loss) income from continuing operations before income tax	$ (707,592)	$ (47,741)	$ (2,648,439)	$ 958
Income tax expense	$ 10,680	$ 1,548	$ 16,016	$ 13,372
Effective tax rate (as a percent)	(1.50%)	(3.20%)	(0.60%)	1395.80%

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

INCOME TAXES - Narrative (Details) - Scenario, Plan $ in Millions	1 Months Ended
	Apr. 30, 2021 USD ($)
Minimum
Income Tax Examination [Line Items]
Net cash adjustments, excluding interest	$ 70
Maximum
Income Tax Examination [Line Items]
Net cash adjustments, excluding interest	$ 250

NET LOSS PER SHARE - Reconciliation of the Numerator and Denominator of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Income (loss) from continuing operations	$ (718,272)			$ (49,289)			$ (2,664,455)	$ (12,414)
Loss from discontinued operations, net of tax	(3,897)			(27,918)			(15,115)	(38,769)
Net loss	$ (722,169)	$ (1,885,427)	$ (71,974)	$ (77,207)	$ (15,500)	$ 41,524	$ (2,679,570)	$ (51,183)
Denominator:
For basic per share data—weighted average shares (in shares)	235,160			233,578			234,719	232,487
Dilutive effect of ordinary share equivalents (in shares)	0			0			0	0
For diluted per share data—weighted average shares (in shares)	235,160			233,578			234,719	232,487

- Definition

Amount after tax of income (loss) from continuing operations attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.13)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

+ Details

- Definition

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

NET LOSS PER SHARE - Computation of Diluted Income Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	5,274	6,532	5,558	6,626
Stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	5,151	8,668	6,066	9,570

CONDENSED COMBINED DEBTOR-IN-POSSESSION FINANCIAL INFORMATION- CONDENSED COMBINED BALANCE SHEETS (UNAUDITED) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 1,053,892			$ 1,507,196
Restricted cash and cash equivalents	145,486			124,114
Accounts receivable, net	423,460			592,019
Inventories, net	288,914			283,552
Prepaid expenses and other current assets	141,120			200,484
Income taxes receivable	1,290			7,221
Total current assets	2,054,162			2,714,586
PROPERTY, PLANT AND EQUIPMENT, NET	431,445			396,712
OPERATING LEASE ASSETS	31,342			34,832
GOODWILL	1,352,011			3,197,011
OTHER INTANGIBLES, NET	1,992,932			2,362,823
OTHER ASSETS	144,565			60,313
TOTAL ASSETS	6,006,457			8,767,415
CURRENT LIABILITIES:
Accounts payable and accrued expenses	538,730			836,898
Income taxes payable	3,599			736
Total current liabilities	543,053			1,629,962
DEFERRED INCOME TAXES	11,634			21,628
OTHER LIABILITIES	27,198			277,104
LIABILITIES SUBJECT TO COMPROMISE	9,345,250			0
Total shareholders’ deficit	(3,925,041)	$ (3,198,072)	$ (1,310,998)	(1,243,986)	$ (690,317)	$ (617,042)	$ (598,973)	$ (647,939)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	6,006,457			$ 8,767,415
Debtor-in-Possession
CURRENT ASSETS:
Cash and cash equivalents	990,107
Restricted cash and cash equivalents	59,486
Accounts receivable, net	409,333
Inventories, net	254,206
Prepaid expenses and other current assets	126,613
Income taxes receivable	1,290
Receivables from Non-Debtor Affiliates	102,162
Total current assets	1,943,197
PROPERTY, PLANT AND EQUIPMENT, NET	236,755
OPERATING LEASE ASSETS	26,240
GOODWILL	1,352,011
OTHER INTANGIBLES, NET	1,992,932
INVESTMENTS IN NON-DEBTOR AFFILIATES	53,887
RECEIVABLES FROM NON-DEBTOR AFFILIATES	241,860
OTHER ASSETS	139,659
TOTAL ASSETS	5,986,541
CURRENT LIABILITIES:
Accounts payable and accrued expenses	517,978
Income taxes payable	3,459
Payables to Non-Debtor Affiliates	2,614
Total current liabilities	524,051
DEFERRED INCOME TAXES	11,536
OTHER LIABILITIES	21,792
LIABILITIES SUBJECT TO COMPROMISE	9,345,250
Total shareholders’ deficit	(3,916,088)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	$ 5,986,541

CONDENSED COMBINED DEBTOR-IN-POSSESSION FINANCIAL INFORMATION - CONDENSED COMBINED STATEMENTS OF OPERATIONS (UNAUDITED) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
TOTAL REVENUES, NET	$ 541,690			$ 772,028			$ 1,763,063	$ 2,203,777
COSTS AND EXPENSES:
Cost of revenues	261,232			286,068			798,233	909,841
Selling, general and administrative	192,221			246,864			600,212	611,657
Research and development	31,885			25,616			97,803	85,024
Acquired in-process research and development charges	800			0			68,700	5,000
Litigation-related and other contingencies, net	419,376			83,495			444,738	119,327
Asset impairment charges	150,200			42,155			1,951,216	50,393
Acquisition-related and integration items, net	(1,399)			(1,432)			(951)	(6,357)
Interest expense, net	74,753			142,958			349,486	418,852
Reorganization items, net	124,212			0			124,212	0
Other income, net	(3,998)			(5,955)			(22,147)	(4,671)
(LOSS) INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAX	(707,592)			(47,741)			(2,648,439)	958
INCOME TAX EXPENSE	10,680			1,548			16,016	13,372
LOSS FROM CONTINUING OPERATIONS	(718,272)			(49,289)			(2,664,455)	(12,414)
Loss from discontinued operations, net of tax	(3,897)			(27,918)			(15,115)	(38,769)
EQUITY IN INCOME OF NON-DEBTOR AFFILIATES, NET OF TAX	(71)			(89)			(297)	(399)
Net loss	(722,169)	$ (1,885,427)	$ (71,974)	$ (77,207)	$ (15,500)	$ 41,524	(2,679,570)	$ (51,183)
Debtor-in-Possession
Income Statement [Abstract]
TOTAL REVENUES, NET	541,889						1,765,228
COSTS AND EXPENSES:
Cost of revenues	266,811						807,013
Selling, general and administrative	189,689						592,139
Research and development	34,519						102,942
Acquired in-process research and development charges	800						68,700
Litigation-related and other contingencies, net	419,377						444,738
Asset impairment charges	150,200						1,951,216
Acquisition-related and integration items, net	(1,399)						(951)
Interest expense, net	71,874						347,862
Reorganization items, net	124,212						124,212
Other income, net	9,052						(2,360)
(LOSS) INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAX	(723,246)						(2,670,283)
INCOME TAX EXPENSE	10,535						15,032
LOSS FROM CONTINUING OPERATIONS	(733,781)						(2,685,315)
Loss from discontinued operations, net of tax	(3,896)						(15,096)
Total loss from continuing operations before income tax	(737,677)						(2,700,411)
EQUITY IN INCOME OF NON-DEBTOR AFFILIATES, NET OF TAX	18,669						26,776
Net loss	$ (719,008)						$ (2,673,635)

CONDENSED COMBINED DEBTOR-IN-POSSESSION FINANCIAL INFORMATION-CONDENSED COMBINED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
NET LOSS	$ (722,169)	$ (1,885,427)	$ (71,974)	$ (77,207)	$ (15,500)	$ 41,524	$ (2,679,570)	$ (51,183)
OTHER COMPREHENSIVE (LOSS) INCOME:
Net unrealized (loss) gain on foreign currency	(10,649)			(3,293)			(13,088)	637
Total other comprehensive (loss) income	(10,649)	$ (4,334)	$ 1,895	(3,293)	$ 2,238	$ 1,692	(13,088)	637
COMPREHENSIVE LOSS	(732,818)			$ (80,500)			(2,692,658)	$ (50,546)
Debtor-in-Possession
Statement of Comprehensive Income [Abstract]
NET LOSS	(719,008)						(2,673,635)
OTHER COMPREHENSIVE (LOSS) INCOME:
Net unrealized (loss) gain on foreign currency	(10,649)						(13,088)
Total other comprehensive (loss) income	(10,649)						(13,088)
COMPREHENSIVE LOSS	$ (729,657)						$ (2,686,723)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

CONDENSED COMBINED DEBTOR-IN-POSSESSION FINANCIAL INFORMATION-CONDENSED COMBINED STATEMENTS OF CASH FLOWS (UNAUDITED) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
OPERATING ACTIVITIES:
Net cash provided by operating activities	$ 159,611	$ 460,914
INVESTING ACTIVITIES:
Capital expenditures, excluding capitalized interest	(77,865)	(61,496)
Proceeds from the U.S. Government Agreement	13,601	0
Acquisitions, including in-process research and development, net of cash and restricted cash acquired	(89,520)	(5,000)
Proceeds from sale of business and other assets, net	22,378	1,357
Net cash used in investing activities	(134,546)	(70,346)
FINANCING ACTIVITIES:
Repayments of notes	(180,342)	0
Repayments of term loans	(10,000)	(3,305,475)
Adequate protection payments	(168,643)	0
Repayments of other indebtedness	(4,501)	(4,044)
Payments for contingent consideration	(1,939)	(3,355)
Payments of tax withholding for restricted shares	(1,898)	(14,688)
Net cash used in financing activities	(367,323)	(75,536)
Effect of foreign exchange rate	(4,674)	238
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	(346,932)	315,270
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	1,631,310	1,385,000
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	1,284,378	$ 1,700,270
Debtor-in-Possession
OPERATING ACTIVITIES:
Net cash provided by operating activities	75,349
INVESTING ACTIVITIES:
Capital expenditures, excluding capitalized interest	(35,018)
Proceeds from the U.S. Government Agreement	13,601
Acquisitions, including in-process research and development, net of cash and restricted cash acquired	(89,520)
Proceeds from sale of business and other assets, net	22,378
Disbursements for loans made to Non-Debtor Affiliates	(51,180)
Net cash used in investing activities	(139,739)
FINANCING ACTIVITIES:
Repayments of notes	(180,342)
Repayments of term loans	(10,000)
Adequate protection payments	(168,643)
Repayments of other indebtedness	(4,500)
Payments for contingent consideration	(1,939)
Payments of tax withholding for restricted shares	(1,898)
Net cash used in financing activities	(367,322)
Effect of foreign exchange rate	(2,393)
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	(434,105)
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	1,568,698
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	$ 1,134,593